var title_f14_63_15344="RTT regression";
var content_f14_63_15344=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rett syndrome, regression",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    From ages one to four year, many girls with RTT experience periods of inconsolable irritability. Hand stereotypes may consist of repetitious finger-rubbing movements.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Glaze DG, Schultz RJ. Rett syndrome: Meeting the challenge of this gender-specific neurodevelopmental disorder. Medscape Women's Health 1997; 2. Copyright &copy; 1997 Medscape.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15344=[""].join("\n");
var outline_f14_63_15344=null;
var title_f14_63_15345="Lumbar plexus";
var content_f14_63_15345=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lumbar plexus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lumbar plexus is formed by the ventral rami of the lumbar nerve roots and supplies the muscular and cutaneous innervation to the lower extremity",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15345=[""].join("\n");
var outline_f14_63_15345=null;
var title_f14_63_15346="Congenital tracheal stenosis";
var content_f14_63_15346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital tracheal stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 344px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFYAcIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDW1PWb0ylFvZWb7pwRgCuaubq+Kl1nkKg43bqn1WIRs6IxAxznt61jef5MJAAyTkswyB06UAXoby6lXe13IpBH8R+9mqGrXtzC4InlPQn5/wBahmuNhzgn5uaq6lJ5mxY3bIGCcdB9aAGzeIL1Vz9ol+U4BWQ5Aql/wnOqWjOyX0xVfuhjnFUyJcSbGDDPUnNZl7bFnHmHkjIXPWgD0Pw/8V9StWTznVwrZ+auy0/4tWE0uNRBUycDd7188XNtL8xBG88ZHQDv+NRwCWPlMMQcjjtQB9T/ANv6HqhUR3PLcYzt4qtq1pZqgdCZvTvj8q+cbe5mjPmJcSKAe3AH4V1GkeMr+0liS6YSwAZ3ZycUAejmWBo3QF17ruGDVS0fzXkiebcvfpmix1rS9bt8JIiOyg9cNn+tc5reg6nAr3FkX2ryME9PU0AdRJbpJbNk7gp6HoR9azLyyjutPZCqBgcAA8Ae9YVh4rNn5dresQG4OR1rb1F0FuLiBshuTg8GgDzjxHp0thMhdyq5yAvQfXNQWZ8lw6sHhYHeec10U2rBr5oLyLzEYnAZT/OuhbwjZazoqDTGWOTOSBxigDJh1y6n0eOONwrKuFwOq1r2d7cyeFroSxurKMrt4zXQaF8P/smnwuVLKv3jmtGTTRGJonAEBjwqHvQB5T4e8VXCarboGlUlgvfpXtXiOc3ehRl2MhBztrnovDGlWlzbyLHEj5BLHtVjxJqSM7W1sy7FyODn8aANX4RoVh1m5RnIBC9eB7VvWt7cfaysbMSWydx6CqfwggMPhTUpOX3z4HGK6BLeONy2CfUUAZPiC4Y2jklxgduleM+JNZubeYpFO2wjJOa9o1/5rGUqF+6cDuK8Rns1mnuJZyM46etAHN6l4nuoHXNy+w9Tmung1W6/4V3q+pR3DglQgO7rXn+q2Ed9qDxowxnBOelekXehHT/hF5fnD9/cKtAHlUWs3tvFGy3co3rkHOefQ0w63qgXfK8gYjJJY810CeH4Y7Z2nYEtjHOTVabT41GySQMvQZoAXw5rmoTB8+YcjGSSRWlqep3VvZxmSTLMeADzVjSrSIRTpEdu1c59fpWTrdncQvGQhkGM8896AJ7TVr25mAX5eOxPNdNpRleeDfIySEjOeTmubsdyWhlQCN2PArqfDcZa8hubiVgSc7VFAHqPiTVJdD8MRNaZWV05IHUmvN21Ka0tkhZz9qmzJyeSD616tNbR61YQwnEiodzKewFeY/8ACPXL+KJLsRloFJA3c4A9KAL1xNJaWkLBg8jKGcLzzWd4HhW98RXE7kqyZYZ/lW1DpxSO6urtzHE42J7Gs3w1pc9ja3N1JkkE7cdxnigDkfG11PPqk4j+ZN52huSf8KwpID5cLBiJCQCldLq9nIs7zyxv83zbcck1lacBe3oRlfMfO08YoA6/wmHi06SJUG4DcS3Y+1as0TCxcoWyPm+9waqaZp804XykaIg5Kg8N/hWxY6FdXU5AfETnjPA96AKsRae13wHDrgEZ4x3qezDAkIrnd1FdANHsdLjYSSYlwBgnOfrTPtkVrLuxFGpHJJwKAKNvpfmODISOMqSMjNTRaU7MkqjEnIYDpWZq/i3T7YyZukDf3Qa5XV/iUqwtHbElyMKy9jQB6jpmnqXZZn+XhuW71Le28MCL59yFUZICHmvn+Xxtq0kpEEj7T65p0fiHVLkMbifH+FAHt8a6XlZXcBRxyeoNaC3ukuwi2rxwDng1833GuXcRb/SWbkY9qp/8JBfH/l6cEE5IPX6UAfUcT6RtypAYnnnNbFrBYSLtQYJw2Fr5SXxJqaxr5V0/XqSK1rHxtrlsVYXjbh75oA+oPs1uwCgqobHI4I+tNu9MIG1CpJ4ya+ftO+I+qxHdIwZsjhhwRXW6N8V3aQ/bYgNvdM9KAPSH065t1BjY5Bzu2/nWlYX01lIEu2WRDwrEdK53SfiDpd7Jj7RsZucPXSwappt4gCywt+XNAFnZpd3MJPmhf+8BwavRaUwUNbShhjK81Qs47aV9uQoUkqEOfwrW0yOWSUJGSrDn2oAeonCgG3yR7UV0CwS7Rllz9KKAPA28K3d/p0Ui2rea74eRhwR/+qsPWvC8ltfRWjF3iTLE46Dua+lZ7ZIbWQJ9xVJC+lfOPi3VNVu9TuW0+3lMe4xsxHFAHMa1orW42RvmSZgygngDHAPvUH/CKzb5TLKEcD5QO9S6Wt//AGqTcZle3G4g881Qa6vbvW5bvUbqSGNDgAD5TQBi30vkSyRHbvQhcYxmqOqRSRQ287f8tASpxwenFaXiBIDdia1ZpFbnkdSRUnh/TJvEmYjOkVvY5faR19sd+aAOXMdx9neQwkIMkg1DFJnjhGUZ6ZyK9curiztvBzrqcIieQMBtHzEf0rzO+sjY3rzTqYrbZuAb7wGOKAKKyKQZDkn+Ef8A1qZLcYBG5RxuJC44qS0SbUblY7S3d1cYBA4471nXbFbhoWBwCRkDjigC2jPbPHNayMHI6L3+tel+CPHUckYstS4YfI30ryPz3RGZ5eV5+tWbW/gubcqVKyoQ+/p/+ugD0/xv4etGkGo2oLQ/7J9axtM1CV91vKSUVeAfT6Va8I+J0nh/szVJPkbowHU9qo65ZHT5/PtjlCSMgjpQBQ8RXW64UY3K38qfp+v3ekTRm2uCqt0XPArJ1aU5Vk5bHIIIK1XEe6EqxyXzg+lAH0v4J8aRahpSxsV3YwynBOazNYvbxJfNaMG3BOT3ArxLwZqsuka7aq8n7h8BjnNfRMKw3mlzGb95EyZAAHSgDiNQuGvrFZ0ckA5ITrWVJPttyp2Ju6FjitANBHd+TDuRORtbj6Vj+JpZLQRrtUk9gOhoA9s+FdmYPASPKOZ5SwIPWtyWzCsWPGPep/DVp9i8D6REow3khjn1PNROjCTLsSD6jNAHPeIdqWxWNcvJkDivF9T0+8UXkzgqgJwAa9r1kE5dQ3yg44rzvVUDQPAzBWYncG4yKAPGbaJ3u52kjyCv516N4seX/hVmkW4VxI824hetc0tlFbXzeYeGbA54610Xxc1UaXZ+HrKKMN+48wkds+tAHMQ2Ye0DOG3rwRms+bTJJPLmLhgGxjNbVjqUd3ZqskADOv3gaxNTSSK4traFjGrNng8mgDW0e3lldRsKFTjce9XLyP5jIZAyjgA96oadHOZJWe5/dQ/eAPJPtUWqXMk+XtlLbDsMbDBPvQBqRadBeKhY7UQZCqcc062RheRG1k2Ih5RuazYElt7dpmcq2MBPSr2lTeZIsc5KsRkNQB6BousmylMilipj+ck8Vr6frdhPjfIqvkgD1Brk7ptmjC2VVSSUgCQmsJNEuxqke2YCHAyQaAPX7nTrK801VlwyeaGAOOTWo+m2K6cOYkVevQc1yVtMbiGGKPbsiwMg9feuH+J/jCVb+DSNPk2qgy2OdxoAn+Iet27QuLBfPCtg7Bxmue8DywXWqTSNGuETPXv6ViaZqNwP3flgsz9Diur8M2nkeYqIoeUks+DgUAdnb3DTOkcMG0tztTv9a6O7mstE0oSajLHFxu681xWseLNM8FaYXdklvXHyY5INeGeKfFuqeLLzzLyV47YnIRegoA9E8Y/Faya4K6cGdl/i9TXA6l4p1bWZiZLl44z/AAgYrnYbVDLuQjHvWr5QMJIwGIwGPIoAjaFptzSszDru3d8+tWYYESNiyKz8/nUtvthiHmH92BnHeqN9eI+VChY89fUUAWnu9qbTFiVRlsHoaoSXksjg7zjFURdEzMFOd3cdafM4LSbcHGCP8KALgY7gGb5W9DTAxJIJAIPSoLaRHLbsrjt71BdTqZcKwBH60AbUUgC4LDnqx5qVHLbVwDzwfWsW3uExxgs3qK0oY95wWZFPIw2KANiKVXGG/P8ApWhac5CLlSOWz7VixSKCpAOTxjt+NXorgIGQZDLyxHegDZtlZX3kkHpjHtWnZ6zNbygI7BweNprCtLmS7dYolzjAyB/Ou28L+GgriS8Xdg7vr/n+tAHS+EtV1qaXdLMwtzghmHNe8+GdQjNuivhZOM5615TpiQwwoGVRg5AAyQfpXY6XfLKVWPDFDj3oA9JEyEAgjFFcsty4UAmigDZD4QQgGTecOSa8i+LF1LpdnJ9igjjgXPQZJb1r2E8OvloBu9axfHHhyPXNL+yxx4mc4EgH3PU0AfN0N/bW9mJriZ3nlVWZQSCeaNYe2uobWVoUiiZeWHQZrrv+FfTm8ihWzZYXH72V+ny+lc7qvhW4jeOOZW+zxuSWUcYH86AOKvbYrFKId2wE4J53fSn+GLHUIIJdR01WYqwV1PUe9dNqllMLSSOKJzEF4OOQcVU8Ovr89nLHpmnvDDGNrsf4j60AaemT2tz4hfS9V4ilgEjPLyATziuZ+KEFu2pOsSlkRcRbP4h6fSs3xW11Y6qI7oSyuQCxTgr7ZrQOo3+safA+l2Ctcp8jySc7BjrQBg6LrqaZp8UFshS9lY72xkKCOlVvsVqkQa4cSySSYH9TXQ3GgJFZrcTTRbtpDv2BPUCuAa9hs78wzbgik7SR0FAFfVYVivHjiyyA5PPaq0KKWL7wy9h0qfXJoDJGLc5zz9BVK1+fJZjgdsUAXZWJRHiZg3PT0rT0jXpfKFtqDmSPqhesZQzkLGuQTkt0qtegwod38J/hNAHU3CxzyblONw6YqWBEJAYjJGAzcg1g6IrTJtDEg85zyK1PLkhbaoDgnknpQBelhVHJXaPTBr1vw/q8/wDYlmY0LHG0k85+tePWgRXXz5Nq52qTzmvTPDFyumaF5bv/AK1vlY9v8KANbWZbKS+iwm255JxwPesm6Cahq0EU0nDSqij2zVfUQ0+oeacvs4yOPxqbTbc3+uWEdtgTCdevfmgD6kvLVYrC1gj+VY41UAegFZUiD7pHSt66XEMIZctsAPtxWbLGCuec49aAOW1iJEglLAk4zXl3isAsHjRhIOePSvV9bXqMZ7YPeuN1KxEyM6gjggADrQB5I+mXF1qsEShcHBINS/GmcP4iislwxtrJFIHY1saXGlx47tYkjf5ZArDsa4/4i6iLrx5rckZJ2N5SqOcACgDP0i83aaI3QIycKo6mjXLKVru1uP8AZ4xRom94jhDuUg421tSRvej7RGS/kHBXFAE+mwl4iu3BRcn3OKbEI0YSTqCApwD60zRVuZpLkbjgN0HepdTtpIrDLZUYyAPWgDIu9SLuI4oA2SM47Vf0e1nbUd90+IVwSAe1Mtoj9mZ0gzcHJBYcYqTQLR5Zs3kxUnII6D6CgDU8Q3g86LZuEAxtqMM0VzEqM0qudzHP3faqPimyntNPVjKFYNiMHvUGmXgtGUXDOZAoLMeRn60AekvdwadYPK2Q2zCA9zXkV1amW8lvZjlyTnPoa6jxXrcsuiRSMowpGSK464tpbmNJJZnG9t57fKOgoALN1kvcqxVQetXtT8SPZwExSYYjaAK4555hLIoG3DEgj0rLvrhz8xY5bpxQAapfXOqXe+5cvIOQWOeKW0+UEPgADG71qkNzuGVtuP5VbjXEJUEEnoD0H4UATZC4KLnBz+FX7eVFibfjf1rPjfy0ZjtPG0+1Upp3YhyQOOgoA0Lq780FmZt2eBjqKoTyCVBg8k9+1G8uu7Cg49KpsxVvagCQO0bBkyD0qwpLjJIHqaps5zngDtT0bBHO4Y5oAs7lQnceWHWqs7Lv4xxzQz7gO20GonGD1oAkjYbxnNakU2NpcMcDk55rFzzVyOdcKApZhgAZ/pQB0kE6KVXKqDjjNbOl2b3jPuX5DxkdxXOaFbvIQ0v3Sc4zXo+g2++IscBF6DuaALOh2C2o/cjDnnB7V3WmyfbY1d2wVA4AwAayNKtLcM7TnDsBke1atsgmV0hUwWyjh8/eA68UAdNab5gu1TzjPAPBz/hXS2skKmKK0UHoGOOlcro8yRQBV5wcbgev1rc0yVo2JKZYenSgDofOb+4x/Gisxp2ycn8mooA9Y2LkHHSlJC9TS1HMQAM0Ac94puGgCuBuQjaAPWuXXyWn+0aihFrGBkj1rvb2zW+hCNwuazdV063WzaKZQYcUAedXNkNTnlksoj5B5AxjdXRaNpB0rTX+0RqkHUhe3tVvR7eK3gcWeI89A3Srl/JPHpxiXEjuMEdeaAPLvEnh+2vmnlQb3mJMSqucCs86amhaO2niIoZ1Cyv6E13scEun6ra/bABCg54qbxLpiazcQmB1EatuGf4jQB434s8B3dr4e/0G5wZCCVY54ryDxP4cuVSPbDI0gGGKjIr6c1C2ubnUJdOu3Z5NnyKuQB9azNR8JXEFrEttatIioNzNzyaAPku4sL3zlIhdOCBu4Ax611Gm+Fbu40wXG1o4jgruB6V6Pd+H7xjLJNbDbG+GAUcc16drVpFP4YgCxR+YsYUgDbgUAfM97a28cflJlJlYBjnqK53VGEJaIEnHp6V7f4i8BWK6e2o27Fiy4KdcGvHfEdjHDfgXDmFBxnHWgBnhuVhHIVUkE5JxXT2sgeBtyEopyc9ea5/REA0+R4lIi3EAnqfpWhovnNKsbSn5j91iOB9OvNAFqG2S9u41ExXawOMZ4969HZBDZRwNGshjUGNuxrnYbG2tg4gy8vd8cEntXQWiSP5GcjC8k8igB8TyXM0btHsYdWz1A9q2/Ddlu8TaVI0oLNPwAO1YUMvktNiQ7s4wR1FbPgWSU+NNFjK/KZwSaAPpu9UKqjvjFZsgC5yMjFa+oDpWPcY2MT0oA57VofNlGMKx5rldYRorGV5XCsmdp6V1l1A8lwjqTgVznjG1ins/JdmG7qAaAOG8IW8b+IJtTD48lGkOe/FeSK51DUdTZVAmlmdgx6kE9K9XtIW0Pw/r0gXnyiiMevNeQeG7Zo76SZtww+eSaAOi0bSrkAB2XaVxurW8F2SWkl9bzyFnkO7aTkkVUd5luBKHBgYZVe1O8I+bdeKWZ3+4pGxeqj1oA0baOe3kupfsx8pjwVqhrOoNBbxGe3UhhjrjFbuq3o055reDJAbJY15v4r1ppwIQzEE53HsaAN221A+W3l7M4IxnpVTSo724vllAzEjcp29q4P8AtO7a52h2GOADkBq9F0Fp7CwQEgtIM9OB65oAr+O5Z3NsrjCxSAtjuaoWVybyC5TbhAPvHsaXVbsTRoJkJ3S8ZNUYP9Gtzbq4Adt3PpQBtTlr7w/JFLtLr93HbFYUczGwUFWDgYYZxVzzWi1CM4/0Y4HA71NeQPcT3EloFAA5x0NAHK3sJuXUx7QuMEZxzWbcxBM+ZkLjAAPpWyZ0ikKvHhhy2eMfSsPXJQ0iEMCg4BHNAFeGAEZDFRjO3NOYxugJO0DsRzmorcmRsIOQeMcZq+bB5NuVYMeMD/GgDOcFt2CCCfWmTQnYMIc/nXRwadu2+Wu0g/MPSnR2onco8ZUL/Fjr+FAHKqrlcYIHrUcgxjPWu1bQ0EWWYqcg/WmroNpJKqM59MgdM0AcTwR16U4OQpUd+tdwPCMEMwWQl1xkEd6fe6LYW8YVFMbbgxyo5A6igDhE3HPBbNPW2ndcrE5+grrVa1hY7IPlYfKNvf0NLZ6owu/LjtgCCE6d6AOSS0uHYKsEhbpgKa6HRvC1/IyyyQkDGQO4rttMh3MblYlLdMY6Gup0mcpal3j3g/KcjAHvQBy+k+G7tnBkgbPYgYxW8I5LI7GjO7gNxzmuv0XU4ERGZCNvQEZ31t2EOn3Nys95HG0kpxhhx35xQB5lZXDPceZcs4iB5z39q6yGQSwRqh2RAdCeld1/wg+lXx81TwwzwMc1Vu/h9NCjGzl+WQcjHJ+tAGNpwitWJIyRyAP51uWN4vltLIQoIJyf5YrKvPD+q2zyKhBPRSPasqcXtvahXjfzVyCcnpQB0X9pMOBMSPXNFceb2UHHltRQB9ZU1l3EZ6CnUUAIFwKq6pB59lJGBuJHFW+tNPyigDz5bO4tZ1TcS7H5h6V1NnAk0IbcNw61buLNXm81fvY5rJkaSCRhBnBbBxQA/WoILxjGiI0iADce1V7iy8v7MIwqvEd3TipFt52l3IGUE5Oa1rm2VrYA4L460AZE2l+cgnCgXDcNJjoKe1nNHpbW7yqI84LY5q2JpIowu3IHbtWNq+oybFRAWPovQUAcF4hWC11cqsckkTkDkcEisvxEbwReSqhd68L356Gu7vjb39isxhy8RPA7e9cZql+l5cmGBCRgAEdQBQBi6ZpV8o8q9YG1LAvnk471W1jwt4T1WYtdw+ayZKg8D8a6W/1QxWssECFpGAVWI71w+sC4+zhssjDIJHf1oA47xNomnCVbbTZFhWPlR0H51Y8LaJp0t3HHM6GU/wAQ6df8aoAwGWZZSXYfcJ7c1saZex2s63aQjbEwQHHBI70Ab8OiWsEskTklW+7x1NaE1hHBcoIkMgC4zimrdR6pOs4YRgKD1xV4X8cO0OykMMcUAVIdIkFrcN5e126EjJxTPh/Zyw+K7ITNuKz5VxXf6NPZXkUcBlRyy496ItHisfElmySD5m3AUAer33OPpWPdD5SOMn1Nas/zIp9qzZ0Jb+VAGNcB0hJBHAwK4LxNqiwW001wPlyB06V3uqN5UZBGSfSuC8RW8N5bvbuQXdgFUfWgDmfGN3Z23gOJ5DmW+mAGc5KivPFtZra1kuY48xEYOOcA1p/H+5VdV0jQbHzPJsIg0kg6ZPauX8L6vd2sM9pdRySW8mAMj8qAOjspwEhjbBB65GMCrGk3VlY3V9qETL9oClFz0Wsye4k+1ArARtHYZwKyNTuWEk0LREZGSwHU0AWBeyXbv5rZBfcx9fpXO67HHNcEh28tG4yetasF1H5CbITGccseST9axtQ3uV2Rs4DZK9c0AZ0VvI2pl4LZp9rhiqnHFeqFI7G0XzASWA3Z6/hVH4d+H53YzyxnLnPI6V2mp6OL64igkXasbADjk0Aef6nbNNJAyg7OSBiqkulm7ibzMq4+bHSvb7vwxpWkaUJbw5dRkM3TNcBqU2n3KOIpNhLYBQUAc1PZSrpaCPkRrkt3Jo0SynSIoqNJvG5sDJFb5tpZrNEj+YOduc9av6feQaZEyPh5PujHWgDlbrwzFPdKXQJI3JPrSWnw50+8mWGa6Cq5yAD3q9qt5JPLNzt64waz9Hacy7pJWXYeG3dqANS4+GkOmW4a0kSYngdMgVhy6BNZ7zsLODjB7V2FvNKTl3Z92O/b6VfvbkwJ5LDdu+6xoA89XTAjBkYqRycjgGpEsTAGkYxrvODmuoMKFQQNzHhiegrLvlZLtg8SsjkYI5oAzhZwyW2Syt7VWn01DIhJ2bTyQeta1ysEaCPLIRyAAcGobG1jnnJkYlGHRiBigDOvpzAgEbMSOpI7VjXM/nmSO4YswHy8da6PW7LzoDGpIKDj5ax9L0O71S5Ty96gc5Ax6UAYdpaST4igOcHuM12Xhvw6UcTPhzjJyOldfoXhFYokJVlfkE4xmtSHTZY7h7YRhR06dqAMSOw+yxFIgH5zgDBFRW9ldJ+9wrRgElfb3rsJdEf7K0juX2jJbpj2rCuVukkMUA2RlckHq3pQAyO/LxrlcPj5fStnRbxZplaRW85OETrism306coTEmR02nGVq1o9u9oCSr7m4LdSpFAHdWN1NYHzC+cHJQmtm38YJc5t2zHK3APb8+1cBf6jGbffKW342KR0z71hNqSWwVix83qcHJPtQB6zd6k6MhniBhxjd16ehrm9Z1uzv2ZYEHzDaxPXiuOm8VXF3b+VgrsG1QzYzVG1mZSxcMdxzwfWgDpV053UN56fMM0VkhxjrJ+dFAH1pRTUORz1p1AEbsQ4A6GopHO4DNPlycYzx1qvI3JJzknFADWulDlCD7Gs+ab7Ndecf9SOTV0KjNll79agmg8wPnGzrg96AMR/HemSagbWMksp2knjk9KvXWoSMpeBgV9Ca5PXPCVnIHu7bMdwzFixPcdqzGS/tmQRvJ5EZw2Od3FAHZHUXmUxGRQ4Gcg4o0vVLApNHLtyONxPevNdQvp/tE7gOJDH+7TuffFYSa1fR2ZikgZJWcZPTj/GgD0zUb6K3hmSzxtckHFZXh/TFmhluYZF8wnoevvXEXHiJo5thjbyzwTn9a7TQJVl08XFpJtwOVFAGTqaTaffRJIhwxOGx0rF1sR3KiLyyg5wenPrXQ+J5L94N7KrKnJPfFcXrFzerArmIyLxyB900AZFp4QYXNzLI6eQBuCk8mqclxDtS3WHaivjca1V1O4gjeSD95OeCrciqlnqAvJ7hbqBEZkO0KO9AHSeHbWxv9KuJIuGixlQewrAJS8vWPKKGwqA8YqXwPbXH+kwF/L3jhPWqlxBc2uqncrFUOSRwTzQBq6VJJpV8tyzMojP3c9RXrOlXqa1aW17bgHawzntXkWqyu9vLLImOwPr711Xws1JltZoQP3WcrmgD3Z2LQoevANVZV3KcdakgYSWUTf7Paql1LshYjrQByviyWeKDEGPNIOMmvOtEGppqU89wPMaONnGRxkV6HeS+bIXkAIHrWfqkttYeGL+8x5bOPLQY6k0AfMfiLxJrN1ez3NxYo8pkJzjJxnvXPz+NNUSVS9sqt7DFeuxWdh5TtLFuJ+8SKyrmz0BJQ3kgsvYjigDhtP8Xa7O5KW6ADrxjio9R8RX84AeJFcty5Ga9AS70xY5FhgBY9gv9e1Yj2dvO7S/ZSFB44oAp+HrW7vLYC4VGVz2Wu60HQLOKcz3Mae2RUvhlUTTd0cTRsp7/wCear6xeSCX5eEI4HSgDZ1LXoLFZIdPRVdRjIHFaHw2uv7Y1YC74KknpxXnstwzeYluA8pxketelfCyxNu/m3iiOQoT1oAp/HHVNlk1im7acAleOK8hsI2FlNxhVHGe9dB8ZNRuX8QyJbp+5VwCxz0rOeOW50lmt8KQvcdaAG+FdQeTUvKMjFI0ORnvVm2nZr+VGIaPd3rJ8CwPuuXYZZ2I47V0s9nBp8Radh5pOQw7g0AO1eFDZo6Iu72Pas6xtFluI4hIxhU5LqeB7UzWdQcwIkXzLjnjtT7WZVijtodwaQZOB/OgDqI41S9t4IPmT+Ij0qXV3R59gQ4H3SRVfw4JVlRUG8Jycjk1a1QSA+YkbB2Jx8pJzQBm+ZtVIoIgNzYJ9PrVa7Ehwsfy45+XpnNaNpYXcsbOy9eSenFaNvpsRhBJMj57DnFAHHsZt37wKWB681btLRppmEMZaXGOnFdUvhpvJLTARxlsqT1xV77bpuklTCyGTjnjJFAEeh+FwwD6hGnmFc4PPHr9a6PSdL0WGDGBDIpx8uK5PU/GjIrJbxtuA5Nef3vi69aaQZYqGJJHrQB7xfy6ZaOhVmOOCvr9KdG1jPMZGbZkZ2kjP0r58m8U3bg+Wxd8g/MTxU0OvalLcfLM43j5gPw70AfRNy9ubLagUKeMEZH1qlBo9ndrI8rqWA5z1x6V5B/wkurxIkXnfuhkgHqcVTj8e31tcMsTEA9cnj3zQB7QdMtlIkjIG8dO4+tZE9qLVmedyy9Tx0Aryg/Ey4t0cyH5gMgk81iXHxUuZvMiZ2aNwByOnNAHp2u6hbzqI7VN5OTjGK5KWwleYvL1POPSsrT/ABZbzOrqQjdeec+tdjpniTTJmX7b5bKByBgHPagDCiXymQDBAPIzjH41cid1kV/MwM4+la1xDp11Mr27CN89M5Bqz/wjklyP9HIOcMcH3oAp/ax3Lk+oNFdAPBd8AMRtj60UAfTMciuSB1p+eKyftDpLHhMbutXGuNoHBOaAJmfnFRCMbs8E09SS3zcCoJZMMAnOfSgBlyARj+VVmjdRhnO09AKdO75VQvHcnrRLEdjMGPSgB8tnBLDtbGOmawNXSKx02dLCMSTBSwB5zipXu54xghsdKhsJUe9kEnUrigDzy4V4IodQvQftEoGE29B3q14jhgvtBNxawmNYE3OTwM+9drq0NtNaHMa+ZEDgAV57qetW7QX1rKNoOAyDsPpQB5pFqVreXYiUkzbSCO1Vb7xrc6aDFZscRnBQHGas6locVheSXlgf3ewuuR3Ncy0VnKZJp8G52lmz09qAPVfAvj+z8QK0V98kgGCD3rVtJLRdTa0mMYilB2hvf0r53Opy6O6y6eq/a84J6ZFdxbazLq9jFMvy3SABvUUAdTr+nDTb1wnzR7jtYc8GuPstShtNYVLhAEZuCRWnpPiSaWWS0vgH2D5T3qnqGhW2pmS6tpirJkuM4x70Ad1o1nFeX0F5Ylgo+8ccGrur+GrqbUQUjbbL0auK0bVbnSLWNoJFljjGevavc/Cniyw1DQ4bi5j2SjA2t1+tAHm03h69B+zTqTIOc9iOldrpWlR6TZiMRKjlc5960fFd3EksM0KYJGQK5y6upr2JWjmCAAjJ7UAeoaJL5ujRMDk4xVe4/eEpjisrwFctJpkkMj7nRuMdwa0bslCR3PSgDn79g1wIExgnnFYHxPnS2sbHT0XsZWHauiiiEmoxqT8xbNcH461A3viie3AwkShASeaAOXkBWMsqjawAK+nvUZtLSdDstw6rwT6mrrJHEuzfvYjkGtPT7W3jjA2hi43cHofpQBylxGkEGYrYJzg8Viyz3P2sRpGMhunbFd7rFqpjj3nbGxJAHBrlEtkmmkeIshCkBj6+9AGzZXpTS5wI8SxnBUd/pVHUZlmSItGo6E4NO0qJxu3BnKDLnsKs3JjEeSg2noKAKWkWlrc3waNAJD0UDjNeh+GQlgsZuWEkjHa3PT2rhNJZY5mljO2QcHA4regkuGv4cgqjfOSfWgDoviB4TsNZsN0SokhGd1ctpPgl7a3gG5HXo+a2ddj1BLSSRrg7PvLj+QrEvNeuo9IsoUZhcytlyPQUATf8I5o/hexmuZHiRmJO08c1w2qLbX5jlnuP3W47QvQD3rmPFuvXmva/PbrK3k23G0HqantJlish5ilx6Y70Aazra3cyQRFRtHHfP1Nben6EXi8yNgZQRwO1c5o1upnaUhlTGeT0rvdFE0FqpHJk5zjoKANPw/o8lqzySScBcZI6CtOaKziBJnRZR33Vy3iXXf7Os1DvuHQj3rhv7QuL8yHe6ofu4agD0O9v7C2lKxTq+4ZJzwT6U+DxFBHZ7LOCJJAOST1PtXncFtKqr8zFQCWHXipLaAg7kldoiM5JxQB1N/rGpSu21vLjKkEkZxmsC2th5hknYsMYye/09KluJ2FmVUvkAAnrxS2jvLIsKkHIwc+uKAKVxueGfAUvuxnPaufvreNXIX5S4yRWvqySWbnCBcnGDWTFm5uts5U7etAGdZwzTTeXEdoBy59q1lYW5CrjHdqZIscG8wDAJwcnmsrVdQESFFbBA5xxigDenv1liCo4JQd/WuV1jUord2yCx3DcBwCPSs6DVgd6eYN7fKCe1ZWtRBZA3mF3P3j2oAbqd2925OwJGTkDOcVatIoHgQPkPkcVmJIgjAOT6jtUqTlsZbBHIIoA2o7JDCrLxtyM+1USZku2CM6qOQBWjpk/mRGB+f5YqO9jxcE87jzx/n2oA1dLutRWULFLISuMHd1r0bw94gv7fO475o8eZz0H+RXn2mh0jiY4A9BXT2d+yEhBkAc+pzQB6jH8UpljVW8vcAAflNFcAHkIB5GfaigD7MK71LN29KjhmzGdwAYdBTPMbDYyQAcD1qrbMHXezEOOoNAFiG4ZyfMPIbaBnrRLI2cJg4PNZ3zwXAB6OTg1PFK6TFdoyTkD1oAkvLgonK+1V47wsBHJkBuhovJc8Eg+3oagUGaMeThmU8nNAF2SMG1VXGOetUHtljkLRA5HOanN8YQBOucHB4qXzEm3SRkEkYAoA5Oa/YzMsP8Art2eemK868e+Grqef7fbEgyEGVR3xXoV/pVy92WiBBBycelWIoWO6OYDGzo1AHjN06RaYIrllDsNoX0HvXnmoWJjeWNZOSc8ema77xfpbx6lMVH7sEkHr+FclLE3zEHLn7ox0oA5ZrN2lL/wqcgHmtbT7wWd0vlYCSDDA96dd28rQmVR5YVsMSKrqiyRttU7uScmgCU3bQ3xdSPmOTWvpTu100nmYt2U7kFZf2KLUb6JYAwaJN8hzxwK1vDc48+e38sfOvBPXPSgCSy0+IRPLNK6RlvlU8CtHQdZ8vxQtpBIXgwBn0rq9EsLPU9Lu7W5jXzY4+T6ntWR4R8NJYa2zyxFlZcBiOhoA73ULp54E2MWZeN2elZFrJtJBdgGbsOKsm0ktklSR9yElt39KgjjX7GGjXLA9T2oA7XwAQb6ZRISQMbcd/Wuv1EIhBbGRxivK/hzdyxeLfIYkq64zXo2uSsrsOTz2oArIYY71p8ACNSxrxjXrwT6xPckEeYSc/yNetWpJgvnkO1PKI5HtXlbWylXleMsAcLz1FAEAgjP2diSuFDHPet3SUgkEkic+XzmsuOBZYSu4mMcjPGKs2BAikihBO/gYoAoa3eRyhITkPIxxWdHbfZo5GRcs3y81LqZW3lH2nb5kTfLkc1ZkRbi2/dv82N3SgBNPhPlNBApaWQ/P7U3xNB5YgtVx5nBPHX2rV8NWTwS75XO8jcTjin6hC00zS7lJPTI7UAYUOmsluxBbI5JB6mtywkHmqMFkCjAPb6Gmonk225Twx24NXtItv8AS+CPLA6YoAZ4uupP7MiSLKr6ZritbtnS2N0GIaNMgZ4rvNdt0uYmWPG4LjHqa4vWIhLZSxbjvK42ZzkigDyfKiS5uh8skrYLGr9hN5EaIcNjqM9aU6c0lp5ZXd854PUVcGmsLu25BGRkHjFAHQ6TCpfDriLq2O9aWp68LBCIslQuBntWLeP9kuWIJ5HQGsW+FzqSpHGeA+GBHQetAE/+ka/dgOSuDnB5FbgsktkRWhZ3TGStWfD9nbaVCsshDtjLZ5q79oR5TtUneckk4AoAy0OblfKXcr/Kc9RUq2qS3DKVwo6jPNaEapjMaAlTz3BPtT3hUIs5I3L2xz+NAGKyyRxSLt/dHOGPf2pun7rObOwncMqfer0gzayF1PGflbrWXYzOlwFZf3QPINAD9S824uhNNjA7dazXiVhJKqKidQSOtdHftCsKyPhUk+Y47Vx3iHURCh8sssYAKkHrQBj69fraWrgZD7uua4i/1B7ksBkKTmtDWbw3UjJxtxnNYFAEtuMtnOCO3rWksf2i3O9iBjpWXHj8amguGV9rMdp460AROhTcD64oVu2BUt7y4wOKhRAVJJwR0FAGjY3DRoevHOBW1H/pEasSvmHkY6j2rC0dfMugjEY54Peus0/TwkybADu+bk0Ablpp8UsCqu4OEyDnoaNJBik/egE9OvfsRXVR2qw6HI/lBZQACR3GK5pUO4Fm5AGMdvrQBt/2hIOGjUkdeKK5GTXIEkZPs1220kZC8H3ooA+9njliIdRxnpSW9oksrSv69K0JGXaQx7VTgmCyEAdelADLq3UsoUdO9ZtykiDzIhkjrWxI65wTyRWe5YTYA+U96AKDwyyp5h4bHTpUFnBOsoBPyk8gVovexxyFJOGHGKlEkLrhTgnnOelADZ7USRyBcHI61FYWwgj2nrnrViJmZR5bhlBwRU0+FUFcUAV0hfz8ggKRzVXVLeKJ1OPmcYHFXk2q4YN17Gmzxqz/ALw54xQB5vq3hgTM0mFaIsSc96811rw41vqm+I5SQ4xjpX0NfWiLbkKCVUdq4fxRpRmt1e2wgH3sjmgDxnWLKafzIYIiqoMg44z3Nc6umT2qeY+TgHjHWvUrqCa10+WN0B3n5TjJNcfesjlo34kOQF/pQBh6PIkF2DIgCsMPg8mus0XTLFd93gZyfLB7+1clcxqJnyCAMZHQ5rT03UmV7aKJdwVv0oA6WP7Rp1zby3JxFMwZtoxnnpXpNtbROpubdF3SLkDrXnckEl0iyXTk7eUU9K6DQb2/jmRd/wC524XjjFAGnqSnKISGB++B61nSW/kwMIwxUtnnvUNvNO2uOzAtGpPatmG2M0cjSHAB3DHSgCn4OZ4PF0OI8qTjI+lekaq2JyCeprlPCFqra8jtn5VLCt3WGd5GYkcN60AQalKV0q88pATsrgbm0W5WPysKwXoDXosEZm0y6UgfcNeZXXmeb5gYgqSpAP5UAVTaPFLJESQpG0GrNlE9mAYlA9D71e0+N3dnlGOAeau3K4tnVVHy88daAOM8QwPcapDlfTcxHWpjELa6cBM4AAUHt7VrNtmUSyLuYdPaqUoaSYzr8xHFAGr4YYzGVZnAG7CDHQVNqdqI+CCFB4I7VF4YjAuyq5KsN3TpXSahB5qqFO0Y5zQBzOn2rtcPJMNqY+Uetba2fl27tGoMq/nVD7T5uo/Zj0QZOO1b2nbXhzGfmxkg0AYk0AaB/M+VtuR6n2rz+dGNyzDI2nAr1C4UFwjxkcZJNcjqNlho4ooSQ7klqAOQ1HSBG63EQJjc8DHQ1PaWqbdjgb85ya6yaxVVCyD9z2HTBqtLpJIE4UhRwKAOH1ezLS7lBxuwD0qcWkVlG+0AMwB5PWm+IGeNmCMxweKms3OpWwDAh0/WgB6sk0OEHLdRngVSvf3LDDEY9KsW6PM2Cm0rwdp61dn00P8A6w7TwMZoApWl/tdYsYUfMxzV2K+R3KjCxsevtSW+jxH/AFjZJB4HpSzaOjxRRRFg2d2BQBU1idLe5dYRvTuar20Ekwd9oUeg6Guii0D7WiRXAKk9v71Gt2Fro1nHAkmZsEjnP4UAefeKdWSwh8gZJx8w61541++oStHlipGEjAzXRa5pk99M0sjNnkEH0rFh0CeJ0MEu2RTkY7ZoAxryEksyjD9weorNIwcHrXWah4Y1BACql94ABB4rnb6wubNyLiNl98cUAVaKKSgCcgmIMSDVzw/p0mrarFZxEBpDgZqnCV8twx57VNpN4+napb3UTYaKQNmgDf8AEnhrUPCl5ELpeJOjZ61NoupSxToN6kMehHQe1dr8X7g6poWm3O0EgDDZ9RXntn5bTWrr3cACgD2vUYrqHRI2uUIhuUVo39eK5hoQqsz4G3v3Y9q9c8d3dj/wq/QDtVZ40C4A6jArxg3bSrJ8rGLnHHvQBODYEZZZMnrgUUqTfIv3ulFAH3K8bbTjg1XjAWUFiKsPnPJ5qrLHuYn9KAI9RVeGVupwAKhkmby+MZFLcxlo0d88HimlVKAr19KAMe4DSSAnBYHHNTWuUm+YZToSOtWLleVaMAEc596gjkCOWOc9OaANCz2xyOVPBPSprjhwoOd3eoYmVctkcdAKli/fEHncKACSHIBXqPSqyi4MpaUHaO1aEY2k7uMVDeSkKAOh4oAzLu+OWjQ8d8Vz2uyO8pjg+YFSSBW3qcYhPmxAYAwapW9kJZDOuc9DmgDjnK3MRiljwFBwe+a4vxB4ebYZYgxz8xI616peackd0X3Lz2FI+n2zQ85zjnNAHgWtWW2BVIO9ACWHerWhaasEXmybi3VQa9guPCWl3iuzkbjg81z+o+GWhfbCxKZz9AKAINOEV1GpnUZAxgVs21tGCVRCqgcYrnLC6jsboLIDkNzmuvt54rpQ0JGR1zQBkpC0d8vDLk/NkcGti9kENkRGQM8fSrEcBkYucbTyB6VQvoDKHJcbT60AT+FbtE8Rwpu++pUV0GqTIksikfPnArnPCOitLrMV2SSkWTmuiv1WW+kbtzQA+1PlaXesp5EZ5I6V5u8O8xyE8nPHSu6nmePR70LnhK5C0miuY4g7LkHkigCeytmd0LthUUkinSMHDDcWZ84xW2loi6c0sbA7hjJrFjQxzBuCy5AoArQwqkZ8zaJG7E1nWpTLLsOSxUj1qe9V2u2y2Dxz71oyWy2YgM2PnG4mgCTRYvssjSZB3cAVe1CZ4m2nac9Aaybe4hNydkuWzjHpTL+WWacopB4zgDkUANtCou5p1wxY4yD0qxY6oF1IRZIQe3BqKws1jZVLhQx+7VyPRomvVdGLc/hQB0EgjuoEZVHTmshrFN4Ysciuh0+BSgVSMA4PtTri3tUUgsuf60AcxJaMrsJFVkxnmsa+uwj+Up+XutdBql0uWVeAeM1z7Wiys0shDEdCDzQBw/iSxk2GRgyx9RjsapaIdl/GIz14cY7V6BLbw3arDsbpg7uaji8DyvdRy2/yr0PHagCA2dvARLHHtWUg5HSrj6X9sjyqgFuSxFdZZ+GmSHZMwYDp7U+XSvkEccgA7+1AHG/YbaCJVwWlB602OBlZC21MHuByK6WXT0hhLBwXU8jHWs+a1VLkTsfu847UAGpXNrpGmi5mKmd1wgryHV9Ue+1Z5lfdsbP09QK73xw3211WFTtUYX61wn9mPb3ZZ12yEYx60AZus2zPFuiJ2sPlz6+tY1tazwb2xuboTXaiyMo27juQZwR0qrLbFHKMnzOASR3oAo/bS9ogZQpVdvHQ47n61ymvsLqyLMV8xOmeQxzXVajZi2tXYdOwribyKVEIUDbgkGgDDspbcS7Z4VB5zx1q5NpdjcBWjBjOMnB4NZ8jCOYLKg29veoLx3hQBWPXjntQBrWvh+OUjZIPei78I37Hdax7+M47kU3SZZigl37mXmutsPGgtdqXKAKDgtQB0fiHw/q8XwoxeWjkRorI2znjrXj+hSut9DGeNrA/N2Ga+2bvxNaaz8LFEFvHLugUAepryC48D6bqaRahb25Ry4EqKOV9/wBKALnjy7jPg3TFXG5VGCenSvM7W7ZQQcEMOh6fhX0D8QfBNtP4Jt1jdsoqtgV4RdeHL2AmOFWIQ5APcUAIpiKg5cZHTNFQjSdQwOG/KigD77kTI681XZMMetW5ASOKz7mUpnIOKAIZg2Cg6E1B5e1gFPFRTagCnTOKsQW7tBuPDEZFADTFtA3YqndQl9xQ8gdaddzNHErtkYODVB9QAyd2B6CgC5ZYE53HB6Yp63Dpd4VTgnHFZi3O+ZRG+T2rasYsyeYykEcUAS+bvDDBqJt0uFYYx0q60Sod2OnNZ8zs84XoCeRQBT1VXESxKc4OSaprcskYWPOemK3Lza1s3HzYwKxJICcYHbNAFFpQ0mVGGBx8xptxGUwQu4n8qnktduHwcjnPpRIAYM/MewPvQBiT+eko2vhgM8DtVK6uZ0mUOeG/zk1sXkT5VEH74jJIqhqFi/moWOQRjrg5oAxrvTra5RnIy5GMjpVqKz+w6TgfK2c5Jq1eWAtrND3J5xV9rWT+ylfbuPr6UAZdlNLE0cgkzET8w61oalpzTW6ywyDytvSmRW6mDAAUevvW3oMaz23knnHrQBd8JW32bRQTndJzmqt5FtlLZxW+kaw26xoQABWdeRA8gHnmgCjb2az6feA5AZCM9jXmMFjBHOwW5ClW6GvXLTAsLlBnG018/wAolhv7gSliRIefbNAHq1oiHTY4/tCEGm/YIMO5uAcdvWvOtP1WQrjcRjJAJ4WtK21CVty7y4AznPWgDrjp9s0iyyTptHSszxJCl7NFDBcoNq9M9a5ubVJord1I3yM2EHoKzx9omkDpIfOHbpj2FAHRaJpohuX8yTfkda1WsZpbxTBtwfvHdggVi+HoLia62vvJYc47V3mnaX5VpnaSxPrQBgW1i0DySSMWc8L61u6ZbFgNzZbFQ/ZXN38yFUJzXSxRxw2wIA3FaAKd1PHaQhVAMh9K5pzJeX4GWCqeR61v3MQbbMAdxHA9Kr2tuquzhMDuaAOf1CFWuzE52Dt9arSxBI1WJc8881oThpJnJPLEgGqgj81iCCGBwRQA7Sigm3OjBCc81uPqDgMtsvQ+tZTQNE0caLnu1XrZMT5YcDg49KAL0F7OVUSDDHrTzJGpO7ndUMo/eDrsHIqC5kiDjvgdO+aAHX8apE2DhWPJArC1F3GYgysuOPWtC7MzqAVyM9M1TWydpS0qcEYoAy7iCN0KSZV9uckVh6nYfINibpFTcrV3i6d5qnzVypXAJPWmx6Su4tIuFHAHtQB5SEmS1Mi4AyQ3r7UhtZ3iE0yFgB29PevQ5tDhV5EKIIy27Bpl7p8SRs8Ua5XqD0NAHlWpWs6pKu5WjUE+/vXG6pb/ACjKgY5Fex67bItoR5a5bvjhc1xV7pRwwcZRckN68UAeR6rBKJhIGwhPcfSu10vwbp3iHRlFleFNRQZMTfxdarajbgW0mVG0EckcLnp/KsJr6a3nW4tJWjmQ7gU7H6dxQAy40u40i8mtpY2jlQYwe/vWZqNrcMOQTnkivWvteneLvDkV06rHr0I2yAf8tAPX9a5C6hEsghnjKkZHzDHP1oA9p+H9tNa/Dm1uiCyxp8wPpisXw744MXiWW3SIC0mIHHTdXr+iaTH/AMKYlW2iGfsZI+uO1fLPhGaSbxRawS5CmYAjHPHvQB9LeMtbjPhtAx2hzgYNeeW99HJKrb1cE4wRzmtH4m+Z5NvY2QaWJF3nA6cV51ZyyxzIRnKtjmgDu9hbnyIeefv0VmxXsnlpk84FFAH1us48tDJwx7U90V1O4Ag02aASR46HsaqG4NsQk2SOgNAEU+mQyHKjBHap4Q0a7D24qdCpGU701yAeaAMjWbYysipwG4+lJZaDDEjGU7mPFW9WX/RN65JU5FTWru8CORjcKAOLubaTT9UWNQSGPy+ldjFiG13yEfKuTTby1jkkSZlyy9Kw9c1TdbvAoKjocjrQBLLqjTbgowO2ay5dVaCQvJkjt7VRN7sCbAPc+tVLm6SfKFDk9M96ANZvECXJHO0A45q3HdK5GGGO4JrkDAJGzGBnPrVm0klQAKpBJ5z2oA6vyWJJI+U1GI1KlMHOe9Z9nqzjaHXrW3HJHcjdGfmoAyp42QqFAJHX6VR1OQLKGKk4PIA7YrfeHBwayrwb7gowIXGM0AZyhJ7YKxbjkFq0ILfGjspJCqQRUbwtHiIJ8p+Ymtqyg32rocYPagDFtyht5MLlh0Ard0C1MNv50q7Sw4UinaZpaxSs7fd7VqS4x6UAZ102c47VUZyxxk7cZ/8ArVbuFzk56dKoFircjjtQBasFAWRSeDXJXfhW0a4lLN8xz+tdNbyfvPT2pmrqVZZUAwRtoA5GTwXZSHKjDHrSJ4NRYyInwM4yfSuhhm2sxYcVZjn4IHGRn60Acn/whcZwXOe/Wrtr4Us4juY5b1rW+0kJnHPSnxy8liPvcUALYaNaWzK8YIb1FXpiqpiLrUFsT5n7xiPaluMlyMcAdc0AQRoZHDE9DzmptU3LHGqAcnpSRgvtwMjParl1GZodoxkUAU7VC6Z7e9NuoAkW0HBPpThHIpjUcDPOKmu42ABGT2zQByOo2qxsd4J3cmorWIPcJuZsA/KTW5eIJJNmMMOjGqptnivlcgYNADbgEuduQOhBq1FF8hKL1HWo/LWeRAeAD071qymC3gAxgDpQBUjhYFcqQfemSaeqyl2YFzzRcX7EYiAzjv2rMub6RYxI+AQDnmgC5O0UeSevas+5vIXfaWXHpnpWDqWoPhiSQCeDWLNcbi0hkK7cH60AdmupxpIYo2y4GRzUceuCWU7slF43VwMd4321pCxDV02gajZh2S6RQsnBPp70AX9W1NIysnBB6E1kXmtYZghG5yCR2OKva/psXlsqlnjzvVh6dq4h/lnjjXDLznjpQBq32uWtwTEAvHVq5/XdXtooDGCpAHHOKxdZgMPmsAck8YNcdqRmZVkk3HnHXgCgCTWLyGVnThPlAz2OM1zAu4IXdZAN/wDAag1m5Oxl65PX09qwmYk5JJoA66x1OOzZZbclJF5IzjNemeGbrSfGmni2uJIob0jrwCK8FLEnkmp9PvbjT7qO5tJGjmQ5BFAH354ejbTPhxJYiXzWt7ZgeevFfP3w80qG+8Ty3ojKlGJAPY5611vw4+IUer+GJBdOscrxlZF9+hAqHwxPY6BZTXPmAB2bCnqT2oA7I3Wm6Q9xNqu15JV2nPp6AV5HfiD7a7QhvIZjt47Zpmoa+NY1J5ZZAIEY7FY1PHBFdRqYG+6OP8KALAs4SAQzAfWir66fcFRw3T1ooA+rzdqrgMMZ6EU64hS4TDDIpsVsFJL8mmz3AhO0DJoAjEZh4RsrVbU5NkBYHpyavq6uD24qpf23mr8p5oAZaMZrIO/3WzgVaCkREjHynGKitohHGFxTiOfrQBS1W9+zCMf3j+lZ+rWsV7YebGD5g6YrQ1KyF0oGdrL0qHTI/KheE5J6UAcfLD5SENncP4R1+tVXVVjJwWIPP9K7C609InkkxvZht2+nvXPPYbQ56YPFAFGzhVWEpyWxkYq1hGG3aRu7nt7VpaRawzRlZWwRwOaq6jGtvOyRBiueo9aAKzWzYDDke1PsrmW2lHUrnjFODMF2nG4nApl7kQ5BIbuM9KAOgaUNEZFwe1ZTyszndzjgU2wcrbkF8oBTGOW+Vs570APmusoHUfKeM+gqXQbx7rUxFHu24+b2rPeQRxFWBYjgjtXSeFrEWlqZ3X99Nz9BQBstgdO1RycrTy4zxz9aYTxQBVlj3YHc1Uki2hgOT/Krd5OIIyx+8fu1lWkjPdEucluvNACAETLnoKmuRmzY+nIpsmN7H8KdKN1sygdqAMyGMNGSTkmntk7VTg96ltowsZbpxjFNjUDcSRwPzoAqtEzS/JjHualbjbgH5TyKhZyJFHap0dmPIBUjGaAHrIfNQc8HqKsynIIAPNUDneFAIOeMVcMxRTjlgOT6UAR25ZCQeVHvV2GcBiMcY61QY5iLA8E80JOy5UDjbzQBtweUQWPUCqeoXKBPk/CoLVmaOT86x7p3c5JwqnqDQBXe7ZpyrIT6GrduHdQzsSMVnyyfOPLYemKkN191UBI3YOO1AF55lgkYhRvPrVC7v9p3SsAvUBqddHzYpJCeMcE9yK4yW+e/uXTGFBIJx2FAF281pnl8uMjI/Wqd5cyupRX+/wAbu4qJoEDbweD2xTVXDMNxKnnAHNAGXdXXl5U5fB65qq0ilhIoY84x7VfvIS0vzDaCM9Ky2QhXK5zzyKAHSTNG6DYR0yTWlDceahLRYXvgd6qonmyguSHGOPUVpQwhF3RZdSeR6jFAHp2l6Raaj4VRrmfZcOpCkHvXjniLTrrRdQ2zE7D91sYGPWu1uLhk0qyEUrpt5CA1pMbTxfo0unXBVb2JPldutAHk+o20U1uJD93rzyDXFa7beXbuwI2YJwe5r2/StGEXhbVLO+tv9It8+XkfyrybV4hIBHIm1Rnv060AeUalFvgJ6e+KwiMHBrs9ZjUzlUyqEgY7Vzt9aZAeJSWJORigDNopSCOtJQB9B/swaCNfN2jr+6i3Z46nAxUPxgP9mKtpYqS4k8slfrXrH7H2kLb/AA+k1Fl2vcTOuSOoB618/fFnxNLH8RNWht1EkKSlWRumfagDlfEJk069hjR2GEDdehq5pPiu5sY0LEbT1HX6VkzXMl/JvuCPlUkZ64NZkxwMEEdOvY0AenJ8STsXLHOP7tFeZCAYHIooA/TlbhmjYjtVSa5TcowCx5FSRRuqNkAcVBcRIm18ZkoASe6EMYf+JjjFWbe6SYAZ+YDNY92jTuvynC4q1awbYWZPvYAyaANU9DimnJxioLKRmUhxjHrU/uKAEK+tVX2pLgnFXOvNZ2qKQFdRz0zQA6fJJZeSeKzLmDKnjqMcdzV+He1r1BOKrn5tpb7o/nQBh2irBctyflPOf6U7UGVmdiBnHSpJWCXMm4fLmo7pFdMjvwaAKKNtfay8FeoqJ/nLhshV5yfX0qdoismOTn0pkuACmMbuueaAJLeQFVGAAeDVsRgkDAGOhFU4RtbnAU8YFaacRggfLnn6UAV7a0a5vAoGB1fjrXUH5FCr0AwBVbS4BFFuOCx71YZc+vWgBrE4xjFOU8jmolZ2B3JgA4+tKg5FAGdq5DSKvoMmqVsQLxOSM8Vb1df9JQj05qllUuQ6/wAJzg0Aak0AB4HXnmnJH8j9M4p00u5FYYORnikicZ56YoAyIs7jG+RilKHAHHH61O6BLtgBxnIprYB5GPegClcEopA557UeYQm3bjBGc1M43nPQ+tQfMQQcHPU0AIW3Tr1GKsOcFnyR2x61BDKCWBAFPlI2LkE9xigCK7YEiNeO9TNGqxAZJOOBUcqnfknr7VKRwhJwCOmaAH20hQf7R61WvUXJVAMH9KkizLKc/dHSklAB5OM0AZDxPFdBeNpPBxSSxrGxcqeGrUWPcoOCG9arXsWQP7vvQBk6hMYI2jjJKk9PTNcsbeSO4dN5B+8D0yK6PUEBDPkg9MHvWJrC7RDLG33VxgdaAIP3qxEZUjqciofNKHdjPG0VYRgYt7bgQcio2AWT5gPmOcCgBmQ4AkZsMPSoZIl8sqqjHfjmtGFV4QYLqcjPentIrMSihz0NAGOlu6RliCT0z6VctmkQCPgDr61K8EQRyGbcOMDmorJBNKyOQOPWgC/vMlqXYNgcbfbFZhvH06/S8tVOUPIHHHvV4o8ZEYycjO3PSob3S7r7Orsudwxx9KAPU9Jey8Q6IbiBQXlXbJjnB7182+O9Nk0jX7iwbdsjJKe4zxXqXw5vZtD1EW1wzCKXgDsM9KofHzTI4r201KFCfOXaxC5we1AHz/rMPm3BI5XOcY6VlatDiNPJyABg12U1iZJN7ehJ44/GsXU44wGO3B5x9KAPP7mEox4xntVYgjgjBroZohIhDZaVeRgdPSsGUFp2B67sUAfZfwX8SDwr8O7DTLiIktamdGA7nJr5O8VXa6h4w1G4bcBLOx56g19tTWum+F/g7Y6rqMKyS2FguGA65HSvhjW9RXUdbur+OIRLNIXCDtQBH56idAMhfumreoWTGITREtGeCay13F8qDnOeBmun0uN20m8jUbX6qp70Ac/5E/ZHx24oq2H1BAFHmADjGOlFAH6ZySrjpn6VTaYMeBjHrVl0wc9jVPy8zgHgGgCOVipyQCKW3cnO7hat3EIaPAFVXxsKAZIoAmDhhtTqakjO07W61TtWKyKD61ZkyWJ4oAmPse9RzIHUgioo5ADjrmpgwboc0AVQvkW7ACqsqGRFPQ+nrWhMhYcHj0qu6lVx7UAZb22YmHUg/pVSReCoACj9K1x8vUckfnVGaN1Y5HFAFQJ+7yQAOxJqlLEFG5hlx0GeK0jHkhTiorhVPyrjHf60AZ6jYBg7iT+VbGlwmZlOSVXrms6K3lmkCRqck9fSumsLUWsIXq3c0AWuBx29KY3UHFKc8HFBzgZoAj65HalQBfmJpTkd+P5VVupgqlVPPrQBn3r+ZcNxkDiqshAc8dqmbPmkeozmo5dpJxyaAL9owlthnqvGKcrBTjqarWDN5jKTjint8rZBzmgAuhlww79ahk2soBHy/wA6ssubck9c1XcYHTAFAFOUZfAOAO1RMcknBXaePepiQQTx14qGX7uGbjPTFADJNg3FeSetLHEQyuuckc5PGKRUWOMljkn1qwsmI15B459qAGsS0gGMqOlPlUbST1A6imuWEQY9Sc4qXO9CDkAUAQQvg/IDn0pJCwwfvEnv2p/RVA9ae0SsrMDzQBDITn5TxjnFR3OCoBPA706MHknoO9V7+bCNg+30FAHP6ju83eJMjPFV/swuLaQDDkDI4wc1PMu9gQclcn61Ys43IcnrtwBjANAHOqu5RhWx0I9amSMB2Yr8mMZ9TWmYEiJ456HHakkt0MZ8vj8aAMjyl3M4zuY8560+G1dnLZPI64wQavpbhsZJJHU4q0LaQuMc+uDQBkLYS7mK8hhy3pTbHSJba4WRcnnrXRxxNFlOCSM4NXdPhaa/jjIIHUg0AMg02GONrmXqy5247+tVp9QnIKvCropGFA5rS1i4RZzEOCnFVraRvMV2QbRx9aAJLyztNUggZAsUyc8djUnj3RpdT8EOx+/CoYfh3FWo/KkZTtCEHqBXQWdzFPZy2coyCuMdqAPlaW28syZf5JB0B6VzGr2wluW8naoHJH0r6L1vwdafaphGqL0IwBXBal8PpJGlaOQF3bA56E0AeHS2zKzNHtO/jjtWTpWknVvF2m6eAM3U6Rt24J5/HFeraj4C1G0aY+VkA5BANQfBrwrf3Pxl0x7q3Y29sTMTjgcUAe4/tNONG+CRs0fkmKADPUdK+H1AJwa+tv21L2SLQtEsgcJLcFiPUBf8a+SQM8igCwk7Rfdzk4B96fHe3Ky+bE7AjqB6VEUXYMhgT3rb0VLfyCH2+aQGGfSgCRNaYopaEkkc8UVqraWrKCqtgjIxRQB+irxhlx0qq9uRJnt2q3vAOCcfWhumT0oAqysVX1NUpYsZI+8e1aDjPNRlQO1AGf5LtjHSpghUjceKs8DNNZh6ZoAgMOWyDxTBuQ8Z4q0MZGOKRgPTigBoORnbQcdcUpGKTNAEbxK2CRmoJoN/1xVknimnp70AUH08N944qP8AsxM/NzWix+bpTWYDqaAEhiSFQqgDFPOT60zeMZzUE12i96ALWT78U0sFPzHis17x2Y7elRTTSFh6CgC9PdcHyz7Vn7suQxyTUsThxtIqu4ZJCOKAElRT8+77vaoQTvJHJqKeZo1JAGOppkFysrfN8pI496AL1k5E/PHarUyjcc1TUBQGU5xV6TDAMp4xQAsf3SuaoXJwSDzV1WXOQahuVVZiGwAwoAoDIwR07VXP7tmZgSM9KtSgbwFYYoeIfeL4NAGZcmaVF2LjPPPpVq2iyqkjHY06QrGudw6Y5pto5aMtIQB6CgCWYMQmw/LnBJ7UsUpUAHBHSoZdrFT6/pToyW6AsB6UAWnQYL9h2poUIh77uajMxBG7AAPelWRZGbZ0oAjlkGwBRkk1nXURbJzj6VIzMs58s/XNPYhhtxwe5oAx7a32Ph+UA5NWyxR8DkVoJbZH3ATmrK2GZNzY+lAGPLaq7F1GGYYwO9J9k3DB+7/eI5re+zx264U5GeDUEsXm5Gcc/jQBlfZlX7oyOxpqjDZX5l9zjFX5oNyFSSAOeKrCMqV3cY7gUAK4O9W9B0rX0KJBHLPLyVPWqsMHmlWbJPQgdq0rSWIWUkR4yccUAc9qUQmkZkz8zGpIUVYVwDx71YdFxsycgkg+lVyriTllwDkL60AKZQg2sSMd6v6fJuvVUcdiKz1KNIS4Ksexq9boq3ELI3y54I7/AFoAwvFeqAXgSNW3Ln2/WsWCPUb8F7b/AFatnnqa6HxDpAlmba4yWyDXS+F1tbHRGEyoZV5JxQB5v/aUm+SK6iOcEnPt0rp/hClpNrF7PFGFmjQKfUZrlvEc2+/lKoEV3LDA7V23wpthbw3N0wA8zj3wKAOS/as8Nw+IdE0pTN5VzBIzI3YAjvXyLceGry0uWhO1j0Bxj8a+qfixf3uveL3tbKIzW1smwgeprxrxJoOt2t+xe2lBGNpK54oA8uvtKuLYEk7gOc03RrC8vr2OK0idmLY47V7p4Z+HF9fxi91FALY4yp4JrtpvCNnoOjLeaRaxz3SON7KM7B9KAOEsvhjdGzgLRYYxrkbj6UV7HBZ+IWgjYabLgqCMN7UUAexyxvLKGGcA1OVwOealpkhCqSTxQBC459qjPueKjluRk7egGayrm/kY/IvegDXY4IHWmleeOlZpknNtuB+8PSqx1J4yA568Y9TQBtD1yKUkDnNVLSQSRbmyD3FSFgT149KAJgQetNY88CmIefXFI/PtQA7OenIprcc5xUL5Geeaaj7lIzQBMR75pj4CnNMJIX7w60yYkqcHmgCGeXjg4ArOcnoPrWgQfLIYDBNVimPpmgCOJgCAO3epmGep5PPSogmCcDNWIxuQD0oAYjbWB7dKfcDdgkZpGXHQipioMYz6dKAMyeLzEOMceveseeIoTyQR0ArpduQwwOnWs65tCWyG5PagCrA7hMMSPetfT2MluwOMqazzCFUEnpV3TfkBB70ATMpJptypeLdj5lqeReKI05wTxQBiPkN3BqG4kY4ERya0L+ECcgHANUGtxnJY9e1AGFc/aGm5LMenXpWpaQyLAAc89RVxLPLZGOTVxYdhwf0oAqNAxULzgdxUxUQwjb948H1q4iYB4qneZPC8UAU5G3jPXP51Yto9ikgduAajjjIVtvrVtRshBPUjFAFIqN7ZXrxSKiRgknvwKcwLEkkg0dWBdR+dAFgS+WFxgk09pmOeQKiZRuGRQGwzEjjpmgBS4bnOT6ZpuNzMoGO+c0hO7Gwc1IiblUknJ60AQyhiDtPQ5xSQksCNvHXFW/J2qS3SnKEB5GD60ARAHOeRnnilIJwQBT/lAJJyOlNEyIemGoAgdRIcHaDn86jFqFJZeSfXtTZJQ0x59x7U1brp6ZxQBIbMFWLEbeCKsxxKiBRnr8uaZDcI2VPIPQGn3BwwY/cx0AoAtvai9hXABdR+YqtJa/umTBDA1oaCwN2ydttWdZhVAWXgsO3rigDhtQ0kSySPt3EnA9vWu38N6f8AZtMRBgMy84FY+nqZLhUyGO7oa7COPYOOOlAGNpXh22sry5uHRWeQ5yRmq/iafR4YP38UTMnfHIq7r1+8aCK3xuPUiuF1i1LOTcAkP2NAGL4x1K3v7aKDS7xYAeMg4A+tZ+lafq2nxPNb3YuoHALRA8k4/wDrVz3ivwxLG7vbs0aEZXB4zXC6f4n1bRtSAS6kcKdrBvSgD6htfHvl2sKSW671QBvm74or53/te5l/efP83zfe9aKAPskkDqao3gkkbavSp7pWfGCQBzRG5KYb7woAy50ZVIbP4VTeE5G08dcVt3SbwDVQnacYznvQA5F/0ZRjnFUhYq772AO05rQ3loyOcg1GjFQy+tADYVCcdqdIBtz3pOveo3YhWPYUAORzg9zSscjNV4Txx1JzmrOMEfSgCJ1yaQKFGPepWAxjNQybgDzQBBK+Tgcc0bsnjn1qOZSen1602R9qrt4oAJslsDt2qtIGUnJ4J6VLI/zBgcnFMLliAaAJEX5RlfxqSIYb5uopInAOCeasBQWyCKAK75YlVH41LjbGB3p5ABPNMduDQBG5wDnoajZd2MilfheuKaSemfyoAYbdTkfjSQR7JBg04ZxwRn0pI2/ejPIoAtyLkg5waYMrjn61I/A6dqjJ4BAbjjFAFe/hLuGz+NV0g24LZ/Kr9wwVNxYKF7mq4w65B+WgBuxVyRTkx9496Ye/OaB90AUAWFyFb5h7e1VCAMjqTVqLIGCaa8fBxjJoApnCsoxxnmm3angKTntVpYxu+bqKiuEO7PbHrQBV8tgmSPr/APWqNAZXC++easFsrtHPFRRKQ+T1oAfLksFx0oWPGdxJFSHax5PA6+1MlLsoCOFBPUjtQBJGqKfY+tNlkCMFXGM9RUUrxquGYZPQZqk0wOSrd6AL7XPBDHiq7XStHkMR64qqJVyPmBx7c0+RNuCoxk5+lACyXWUIXdgDg471nTTTu6lGJA5Aq0zLjdk+/FM4G7aQccYoAhZpXnGWC55OaiYsM4JHOauyIjNlOmDg5qGRVIGQVPTHtQARPKgXlmC9qkN47nbtLc9AcVEqs5749amSHcTgkY6YoA0NFvPK1GLk8nB5rsdRiNxb/KQG6iuEeJkYEbVIIPWu10q6FxZxk8sBg4oApaTYsmos7DAA/Wt6aQRRM5xxTEUb92MEVk69ckIYk+hoAyJrkz3rN/D2pszROuJMH3qtcRBIXIPIB6Vx+oX9xl/KGeccntQBoeKYYfskkUR+8Cef6GvBPEuiTxXv2pVwj/eAXJ616DrWvT2G6CcMzHorciqMWr297BLHcKv3T1HQUAc1FbSiJBnoooq8dX01TtCEgcUUAfZBGRg1Cy4YYqamN9aAIX5GDURUZBqdu9RnNAETE/TNN2ALTzjqT1oB+X1oAr7doLZ5pr48slu9TOoY/WqjnJI7CgB8YUJwBmlJ3MPao0G1cDv0qLzcOVYcD1oAtMcHPSo5TnrVWS9XcVXnHWm3E4QKxBwe3pQASybATwe1Q43R5zk561DeXAkTEeMdc+lEEmY8EjbnNADtpCZ6+w706Pg89cUE5OQMZBFNDngEZx1NACKxLjjkVajbCtzzUBGO1PU5+melADy2eCfwppJAINKwA6ACmO2ADjigBdw4zUZzuzjrSswXHFITzk9frQArcAE4z7UsCEtuIpo+bgdTVlMJH70AK7A8A0wcnk/jTCckZ4zS5AyO4oAlOCmDz2qtIpR8DGD2qeMjB5zRIFcY70AVRhWPGB3ppBPXAFK67G5Jpgbnjp6UASA84B5qQSDvUXGRnkmoH3CQ4IHbFAFwOME1Tnk3OSehoaQ5Ax/9eq8bfvCvc/pQBIY2VVKn3qFySw5yAe1WCxA2g9Peq8qjjafc5oARpBkYIwfWoZ7kqoUEZzjilbhWLAEY61QI+YMTk5xQBHcb92Ac5GcUJvO3f0J6VOIwRgjD9cA09412nb8pGMUARspIOBx69qepITnI9c85oI4TA4xTWG1hwSOp4oAimYuxVgRg54pURRkn6g1JtDNnoD1qVFjGB0XGBQBBGCpwoJOct7VK6jk9804IUJJbg1MV3DgADPXNAEOwhscsKliQAlQcEd89ak+66ZIZCOPXNIkeQxPU+lAE0aiVBvUbgK3NAUCNhjGDWJENjLuB56n1rotHXFsGPfmgDRXA3Hn1rlL5nku7hgCQTxXSXUgjt3fOMCudtreS4IKsAWJ5FAGffTFImywGB09a5d1aaTAwHIJyB2rpNX0i8RnkHzKBXNWsxDM03DBjHgcYz3oA5LxTA11Mf3P+rHJ9TXHXEHmCRI/lP1xg16ldWM1zC5BEm4dR2rmF0rzmn2oA4XBJ7mgDzl9PuA7Dyuh9aK7J7aQOw2jr60UAfW8r7BmojKDTmTKkEcDpVaVf3RK9aAJGmXIXikdhjOayTPtfJzxxj3q1BOpUo3UetAEfn75SrfdFWY+2OlQxxRliAefapUQoTzxQA/rkVC0YIOal3UwncMkUAZ1y5hAboM1XeUySbuo/nVye2EgJOTUDxhNuMDFAFRSAXPcc0szI8a8Dk1Hgea/zZJ5qALyQce1AD5wEwEHH06mkiUgjk4A+6O9N3MV2sD7GpI2O4FwM46Z6UAWlT5R2z2p2wBaIzkHNPGOhPOKAGgLgetIAetOK8cntSg549BQAxz8uTjrSZzwcnH5Up5zke1AUnIH50AMcZBznOaa/tz71YEB6k04QKOetAEMCD7xyDT5GG088U52CgAVXc5GMc0AJk7qV2IbnkdzSLyvHJpzYKfd6UACscGlRyD9aQY75JoAx9aAJwwbsKrXERByo4p27BPrTvNB68GgCsDk85zSMASTn5qnmj/iWonAyM8GgCuVyCRx2qPyzuDD0qyygdKbwAf8APNAEDEZ+YDkcVFuyVOOnerLhSKqt8obnjOBQBHeESYwQD3A71UXqR+QxTy4WRiTlqdsU5kjbGO3WgBoTEg2njpTzuzjJ55zUOWwxGcZ5FPRNwGM8d6AJ9u4Z4ziq7K5ZtxGegzxU4IXkkmkYI/I4bP3SOtADI+xbB9fapV+VyAoB7VHGAduBwfXjNTKmxzxnIPU0ADoWxzgenSnKpzzwM9qi3kswHapd5DYPJA4FADyoOMKSRzmplVVwzDk9qau0heWz+gpWx/Fzk0APUdsg5PNdLZpst4xxnFYWnxCWVSRwvXIroBhcAduKAM7xBIUtGUdWrF0a7eG5EUnCEYB960dZV52ZIzzjFVtIs90u2bsOPrQB0cDq6YcBgR3rzzXtI/4n0gjGFbkYHAxXdGEw52ngngjtWRrEDNIJYx860AYnhW08t71pfuqD79q45U8y4nZScbjgY5rvpYp7bSL6VVy8gyoH0rk9Hs5JrspgouzBJGPfrQBy9wIVnlXcvDEdPeitS802b7ZP+5X/AFjdveigD6E6jiqhDKxH8NWN4AOKa5yucUAZ01sSSRzzkZqqLVy+48GtTJxzVWZwp5OKAFjjCcinlvXpUPmEjI7VHJMVcA9DzQBK+QeD0pEkGDk4phuEHB/Gk3Rv0x+dAEgZSCR/Oq8oVgcmnmNdpAYj8arvwOKAIjaRuS2cGo3sNqNsY81MpIJ57dKesvygNzigDCn86AMGUMp7kU6zlUn5c89cituWKOaMhgOe1UV04I2V4FAEispHHB9qkyG6GmLasCCDip0h20ANHB55pEUl8chTUwUA805BjOehoAj8v1pcbRjAoZsZqB26daAJ/MGOOoqJ5OxB6+tREn16UwNk8Z4oAe3L8009sYpcE8UbOMdqAEQgkggcd6Ru56CpPlAppGFwelAEZyGG44Bo8xscjac96c2OvOcUu0Ec9RQAwngj9abkjqM1MVB+tMdTnigBY5dpAPAPenmPecgnIqA4CAYyacsu0AsT6GgBGhINMYMpxgVaWQMvOR70MgboeTQBUIBBz0qjc9SB0rSmiIHydayrwmOT5lxigCAxNu38E4xSocfdPQ4x609fmwRjjoc08INgbAyDQBH5fG9QMk8gD9KQKAvfJ9PSrKKAfvEe3rTmTPzKADmgCqU+bufSmqGB+YEEdOatCM5+9wetGzaPlAxjvQBAxLIDxux6UA8Hgk47mpwN4G4nBHSnCJDHnHXtQBWRdoO7H4GpVY5PHB56UnksB8pyO49KCCMZOOMUASoSMHAqTksVTrUKRykErnORjPWtWxttvzuT75oAt6enlRAt1NXC6hc57dzVORWYgIcAUXaMkKkc4/lQBWH72fcPX1qZFEMhzwcdfrVBWVM4JyO1Oup99vuDYOcUAa8VwssW1iAwqBQXu/LPQDn0rCEsquCjEv1rodNkPlGaYfNjvQA0lJf3RHy8qRiuN8RyPpupAQgglcg9M12M0sIcSBuCTwK5jxhKkk6OiMSAMlulAHJ3Gu5nkJWPO49T70Vx2qQz/wBp3e2UBfOfAx0+Y0UAfTm4g9eKlU/JuH40UUAMfOSQeKglVWxxzRRQBWdSh4HyiocAyepFFFAFZoWc/MSBSfcyCcn1xRRQAkNwQfX0qdZVYfN69KKKAFZRyQajwQcY5oooAUk4wB0705HOPUUUUASbunI/wppbPSiigA96Y7YHHPPaiigCNieeRUfmHPv2oooAReaftA69KKKAA4HemlvQ/WiigCPd8/3s0pHJGeT70UUAQsHEi4OEHUY6/wCFOLN9aKKAFDYPXHvTg3qefWiigBxUEelRsnAzRRQBGTt654p3mlV9OfyoooAdHMG4Yj1ps0UUo5wTRRQBALCPOV4FOe1YKdvP4UUUAQrAyY3YzQo5IOTjrRRQAYBJ4z34pNhAJHGOwoooAkTDbcqoI54FL5bMvy59aKKAJhGdgDDPGcikS13sDRRQBoRRoExge9PHBwBRRQBMnrT2+fgnrRRQBlz2rKxK4IJqJbd/JOVNFFABY2x+0HPRexqzrNx9ntQqHBPGPWiigCC1CmJA7YwAT6VJf2scqSKQMYyBRRQB5jqWnL/aN1ndnzX/AJmiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast tracheobronchogram from a seven-year-old boy with congenital tracheal stenosis. The lower trachea and both mainstem bronchi are narrow. A tracheal bronchus connecting the trachea directly with the right upper lobe is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15346=[""].join("\n");
var outline_f14_63_15346=null;
var title_f14_63_15347="Tracheal occlusion for CDH";
var content_f14_63_15347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74750&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Schematic representation of tracheal occlusion (TO) for severe CDH",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 539px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    TO occludes trachea preventing normal egress of lung fluid, resulting in increased lung stretch and accelerated lung growth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Holly L Hedrick, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15347=[""].join("\n");
var outline_f14_63_15347=null;
var title_f14_63_15348="Diclofenac (ophthalmic): Drug information";
var content_f14_63_15348=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diclofenac (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?9/51/10036?source=see_link\">",
"    see \"Diclofenac (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/1/32787?source=see_link\">",
"    see \"Diclofenac (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8016890\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Voltaren Ophthalmic&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8016891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Voltaren Ophtha&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8017288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID);",
"     </li>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8017005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cataract surgery:",
"     </b>",
"     Ophthalmic: Instill 1 drop into affected eye 4 times/day beginning 24 hours after cataract surgery and continuing for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Corneal refractive surgery:",
"     </b>",
"     Ophthalmic: Instill 1-2 drops into affected eye within the hour prior to surgery, within 15 minutes following surgery, and then continue for 4 times/day, up to 3 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8017022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No specific dosing recommendations.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8017237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as sodium [drops]: 0.1% (2.5 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Voltaren Ophthalmic&reg;: 0.1% (5 mL [DSC]) [contains sorbic acid]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8016893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8017024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     For ophthalmic use only; avoid contact of bottle tip with skin or eye. Wait at least 5 minutes before administering other types of eye drops.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8016894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of postoperative inflammation following cataract extraction; temporary relief of pain and photophobia in patients undergoing corneal refractive surgery",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8016888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Diclofenac may be confused with Diflucan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International Issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diclofenac may be confused with Duphalac brand name for lactulose [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin: Brand name for diclofenac [Argentina], but also the brand name for cyclobenzaprine [Chile] and orphenadrine [Israel]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin [Argentina] may be confused with Floxin brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [U.S., Canada], and pefloxacin [Philippines]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8016902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Ocular: Lacrimation (30%), keratitis (28%), intraocular pressure increased (15%), transient burning/stinging (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Facial edema (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: &le;3%: Chills, dizziness, fever, headache, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: &le;3%: Abdominal pain, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: &le;3%: Pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: &le;10%: Abnormal vision, blurred vision, conjunctivitis, corneal deposits, corneal edema, corneal lesions, corneal opacity, discharge, eyelid swelling, eye pain, injection, iritis, irritation, itching, lacrimation disorder, ocular allergy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Corneal erosion, corneal infiltrates, corneal perforation, corneal thinning, corneal ulceration, epithelial breakdown",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9550444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diclofenac or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8016899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin/NSAID sensitivity: Use with caution in patients with previous sensitivity to acetylsalicylic acid and phenylacetic acid derivatives, including patients who experience bronchospasm, asthma, rhinitis, or urticaria following NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding and/or healing delay: May slow/delay healing or prolong bleeding time following surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Keratitis: Use of topical ophthalmic NSAIDs may be associated with keratitis. Continued use may be associated with sight-threatening complications, including corneal perforation. Discontinue use of topical NSAIDs in any patient with evidence of corneal epithelial breakdown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may be at risk of corneal adverse events, potentially resulting in loss of vision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, ocular surface disease, or repeat ocular surgeries (within a short timeframe); may be at risk of corneal adverse events, potentially resulting in loss of vision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Rheumatoid arthritis: Use with caution in patients with rheumatoid arthritis; may be at risk of corneal adverse events, potentially resulting in loss of vision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Post-surgical patients: To minimize the risk of infection following surgery of both eyes, two separate bottles of eye drops (one for each eye) should be used; instruct patients not to use the same bottle for both eyes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warning/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Follow up/monitoring: Monitor patients for 1 year following application of ophthalmic drops for corneal refractive procedures. Patients using ophthalmic drops should not wear soft contact lenses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged use: Use of topical ophthalmic NSAIDs for more than 24 hours prior to surgery and greater than 14 days after ocular surgery has been associated with an increased risk of more frequent and severe corneal adverse events.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9811041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Latanoprost: NSAID (Ophthalmic) may diminish the therapeutic effect of Latanoprost.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8017290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8017291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal studies; therefore, the manufacturer classifies diclofenac ophthalmic as pregnancy category C. When administered orally, diclofenac crosses the placenta. Refer to the Diclofenac (Systemic) monograph for details. The amount of diclofenac available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral doses; however, because it may cause prenatal constriction of the ductus arteriosus, the manufacturer recommends that the use of diclofenac ophthalmic drops late in pregnancy be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9771812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     When administered orally, low concentrations of diclofenac can be found in breast milk. Refer to the Diclofenac (Systemic) monograph for details. The amount of diclofenac available systemically following topical application of the ophthalmic drops is significantly less in comparison to oral doses.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8017264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Diclofenac Sodium Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1% (2.5 mL): $44.77",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13276702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      3-A Ofteno (CN, CR, DO, GT, HN, NI, PA, SV, VE);",
"     </li>",
"     <li>",
"      Cataflam (SG);",
"     </li>",
"     <li>",
"      Chen Jing (CL);",
"     </li>",
"     <li>",
"      Dicloabak (BE);",
"     </li>",
"     <li>",
"      Dicloced (FR);",
"     </li>",
"     <li>",
"      Dicloftil (IL);",
"     </li>",
"     <li>",
"      Flamar Eye Drops (ID);",
"     </li>",
"     <li>",
"      Optanac (KP);",
"     </li>",
"     <li>",
"      Voltaren Colirio (BR, PY);",
"     </li>",
"     <li>",
"      Voltaren Ofta (IT);",
"     </li>",
"     <li>",
"      Voltaren Oftalmico (CN, UY);",
"     </li>",
"     <li>",
"      Voltaren Ophtha (AT, AU, CH, CO, CZ, DE, DK, EE, FI, HK, ID, IL, MY, NO, NZ, PE, PH, PT, SE, SG, TH, TW);",
"     </li>",
"     <li>",
"      Voltarene (FR);",
"     </li>",
"     <li>",
"      Voltarol Ophtha (GB);",
"     </li>",
"     <li>",
"      Voveran (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F12818264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity, inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F12818266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Negligible",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9101 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15348=[""].join("\n");
var outline_f14_63_15348=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016890\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016891\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017288\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017005\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017022\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017237\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016893\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017024\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016894\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016888\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016902\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9550444\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8016899\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299184\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9811041\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017290\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017291\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9771812\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8017264\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276702\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12818264\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12818266\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9101\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9101|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?9/51/10036?source=related_link\">",
"      Diclofenac (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/1/32787?source=related_link\">",
"      Diclofenac (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/43/8890?source=related_link\">",
"      Diclofenac (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/32/20998?source=related_link\">",
"      Diclofenac (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/52/31560?source=related_link\">",
"      Diclofenac (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/21/24920?source=related_link\">",
"      Diclofenac (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/29/2518?source=related_link\">",
"      Diclofenac (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/43/1720?source=related_link\">",
"      Diclofenac (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_63_15349="Pelvic organ prolapse";
var content_f14_63_15349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62745&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 510px\">",
"   <div class=\"ttl\">",
"    Anatomic sites of pelvic organ prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 490px; height: 478px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pelvic support disorders.",
"    <br>",
"     (A) Cystocele.",
"     <br>",
"      (B) Rectocele.",
"      <br>",
"       (C) Enterocele.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"        Modified with permission from: Smeltzer, S, Bare, B. Brunner and Suddarth's Textbook of Medical-Surgical Nursing, Ninth Edition. Philadelphia: Lippincott Williams &amp; Wilkins. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15349=[""].join("\n");
var outline_f14_63_15349=null;
var title_f14_63_15350="Use of thiazide diuretics in patients with primary hypertension";
var content_f14_63_15350=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Use of thiazide diuretics in patients with primary hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/63/15350/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15350/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/63/15350/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15350/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/63/15350/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15350/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/63/15350/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazide diuretics have been a mainstay of the therapy of primary hypertension. The most popular agent in this class,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    , was traditionally used in doses of 50 to 100 mg per day. These doses were associated with metabolic and electrolyte complications. Low dose therapy has since been demonstrated to be efficacious and to have a much lower incidence of side effects.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     Chlorthalidone",
"    </a>",
"    has been shown to provide a greater antihypertensive effect than hydrochlorothiazide and, more importantly, to reduce mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/1\">",
"     1",
"    </a>",
"    ]. No trial has documented a mortality benefit from hydrochlorothiazide.",
"   </p>",
"   <p>",
"    This topic will review the antihypertensive mechanisms of thiazide therapy, the common side effects of high dose thiazide diuretics, and the benefits of low dose therapy. The role of thiazides in the treatment of primary hypertension is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIHYPERTENSIVE MECHANISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms responsible for the decline in blood pressure (BP) are incompletely understood. The BP response appears to require initial volume loss (averaging about 1.5 kg), since it is not seen in patients who are resistant to the diuretic or who are ingesting a high-salt diet [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/2\">",
"     2",
"    </a>",
"    ]. The BP in responders begins to fall within the first week, but a slow decline can continue for as long as 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/3\">",
"     3",
"    </a>",
"    ]. Longer-acting thiazide diuretics are more effective than short-acting loop diuretics in patients with mild to moderate primary hypertension because they maintain the decline in intravascular volume. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13027?source=see_link\">",
"     \"Thiazides versus loop diuretics in treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial hypotensive response is mediated by a modest reduction in plasma volume and cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, the fall in BP is blunted by hypovolemia-induced activation of the renin-angiotensin system [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Thus, nonresponders to a thiazide diuretic may have a diuresis that is equivalent to that in responders, but little or no reduction in BP due to a rise in systemic vascular resistance (",
"    <a class=\"graphic graphic_figure graphicRef76363 \" href=\"UTD.htm?29/26/30125\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/3\">",
"     3",
"    </a>",
"    ] . This relationship explains the synergistic response between a diuretic and an angiotensin converting enzyme (ACE) inhibitor or an angiotensin II-receptor blocker. These agents block either the generation or the effects of angiotensin II, thereby allowing the full antihypertensive effect of the thiazide to be expressed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=see_link\">",
"     \"Renin-angiotensin system inhibition in the treatment of hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term maintenance of the decrease in BP is associated with partial reversal of the initial hemodynamic changes: the plasma volume and cardiac output partially rise toward the baseline level, while the systemic vascular resistance falls [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Despite near normalization of the plasma volume, it is likely that the plasma volume remains low in relation to the vasodilatation-induced increase in the vascular capacity. Two observations are consistent with this hypothesis: (1) the plasma renin activity is persistently elevated; and (2) discontinuation of the diuretic leads to rapid fluid retention before any reversal of the fall in systemic vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism of vasodilatation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factors responsible for the secondary vasodilatation remain unclear. One hypothesis has proposed a central role for a circulating endogenous digitalis-like natriuretic hormone (distinct from atrial natriuretic peptide) that inhibits the cellular Na-K-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/7\">",
"     7",
"    </a>",
"    ]. By inducing volume depletion, diuretics would diminish the secretion of this hormone, leading sequentially to a rise in Na-K-ATPase activity, a fall in cell sodium concentration (since more sodium is pumped out of the cell), and increased calcium efflux from the cells. The ensuing decline in the cell calcium concentration then leads to vasodilatation and a fall in systemic vascular resistance. This theory, however, has yet to be confirmed.",
"   </p>",
"   <p>",
"    Another possibility is a direct effect upon potassium channels. Modest vasodilation of the forearm in response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    can be abolished with the concurrent administration of tetraethylammonium, a calcium-activated potassium channel blocker [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/8\">",
"     8",
"    </a>",
"    ]. Since this is only observed with high doses of hydrochlorothiazide, it is unclear whether a similar effect occurs in patients undergoing chronic low-dose thiazide therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential adverse metabolic effects of thiazide therapy include hypokalemia, hyponatremia [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/9\">",
"     9",
"    </a>",
"    ], hyperuricemia, elevations in the plasma glucose and cholesterol concentrations, and magnesium depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidence and magnitude of these side effects is much lower with low dose therapy (eg, 12.5 to 25 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    ) as commonly used in the treatment of primary hypertension (",
"    <a class=\"graphic graphic_figure graphicRef69912 \" href=\"UTD.htm?37/49/38685\">",
"     figure 2",
"    </a>",
"    ). In contrast, hypertensive patients treated with high doses of a thiazide diuretic without a potassium-sparing agent have an increased incidence of sudden cardiac death (",
"    <a class=\"graphic graphic_figure graphicRef68346 \" href=\"UTD.htm?10/23/10621\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Low dose therapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=see_link&amp;anchor=H27627359#H27627359\">",
"     \"Causes of hypokalemia\", section on 'Diuretics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/31/502?source=see_link\">",
"     \"Diuretic-induced hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=see_link\">",
"     \"Diuretic-induced hyperuricemia and gout\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44659?source=see_link\">",
"     \"Antihypertensive drugs and lipids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"     \"Diuretics and calcium balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/41/43668?source=see_link\">",
"     \"Diuretics and magnesium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LOW DOSE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with primary hypertension and normal renal function, thiazide diuretics are used at low doses (eg, 12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ) to minimize the metabolic complications, while maintaining the antihypertensive response [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/10,12-16\">",
"     10,12-16",
"    </a>",
"    ]. At the equivalent of 12.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of hydrochlorothiazide, for example, the fall in BP is similar to that at higher doses (",
"    <a class=\"graphic graphic_figure graphicRef61248 \" href=\"UTD.htm?18/24/18829\">",
"     figure 4",
"    </a>",
"    ) with a minimal rise in the plasma urate concentration and little or no change in plasma potassium, glucose, or cholesterol levels (",
"    <a class=\"graphic graphic_figure graphicRef69912 \" href=\"UTD.htm?37/49/38685\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/10,16\">",
"     10,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although higher diuretic doses tend to produce more fluid loss, there may be little or no greater antihypertensive effect because of greater activation of the renin-angiotensin system [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     ALLHAT trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits and side effects of low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    were illustrated in the ALLHAT trial, in which the effectiveness of therapy that began with 12.5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and then increased to a maximum of 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was compared with that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    (with this last arm prematurely terminated because of an increased risk of heart failure due to doxazosin) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. At study end at a mean follow-up of almost five years, each of the continued antihypertensive agents (usually with the addition of other drugs) successfully lowered blood pressure (with the goal of less than",
"    <span class=\"nowrap\">",
"     140/90",
"    </span>",
"    mmHg achieved in approximately 75 percent of patients). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=see_link&amp;anchor=H9#H9\">",
"     \"Choice of therapy in essential hypertension: Clinical trials\", section on 'ALLHAT trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    therapy was associated with the same frequency of the primary end point of cardiovascular death or nonfatal myocardial infarction (",
"    <a class=\"graphic graphic_figure graphicRef82432 \" href=\"UTD.htm?6/63/7166\">",
"     figure 5",
"    </a>",
"    ) but was associated with a significantly lower rate of heart failure (",
"    <a class=\"graphic graphic_figure graphicRef68780 \" href=\"UTD.htm?39/59/40893\">",
"     figure 6",
"    </a>",
"    ) and, compared with lisinopril, stroke (",
"    <a class=\"graphic graphic_figure graphicRef61612 \" href=\"UTD.htm?39/18/40237\">",
"     figure 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In terms of side effects,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    was associated with a mean reduction in plasma potassium of only 0.2",
"    <span class=\"nowrap\">",
"     meq/L,",
"    </span>",
"    8.5 percent required potassium supplements and, compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/58/937?source=see_link\">",
"     lisinopril",
"    </a>",
"    , a slightly more frequent elevation (11.6 versus 9.8 and 8.1 percent, respectively) in fasting blood glucose to values &ge;126",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    which is a diagnostic criterion for type 2 diabetes. An increase in risk for new onset diabetes with diuretics versus placebo was also noted in a subsequent meta-analysis of trials of antihypertensive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although low-dose therapy seems to minimize the metabolic complications induced by a thiazide diuretic, it may not necessarily eliminate other side effects. As an example, as many as 25 percent of men treated with 25 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    per day develop a decline in sexual function [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/21\">",
"     21",
"    </a>",
"    ]. Sleep disturbances also can occur, particularly if the patient is also on a low-sodium diet [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/21\">",
"     21",
"    </a>",
"    ]. How these problems occur is not known.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"     Chlorthalidone",
"    </a>",
"    is 1.5 to 2 times as potent as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    at the same dose and is longer acting [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Thus, although some guidelines recommend 12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of either drug, one cannot assume that the benefits of chlorthalidone in ALLHAT would have replicated with similar doses of hydrochlorothiazide. There is no evidence that hydrochlorothiazide alone in a dose of 12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    reduces cardiovascular events. As a result, some experts suggest that chlorthalidone (12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    is the low-dose thiazide diuretic of choice. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H5#H5\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Chlorthalidone versus hydrochlorothiazide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Caveat",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consideration of low-dose thiazide monotherapy applies primarily to uncomplicated patients with primary hypertension and normal renal function. As an example, the mean baseline serum creatinine in ALLHAT was 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (88.4",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15350/abstract/17\">",
"     17",
"    </a>",
"    ]. Higher doses, including the use of loop diuretics, may be required in patients with resistant hypertension, and loop diuretics are the drugs of choice in patients with fluid overload due to heart failure or chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35256?source=see_link\">",
"     \"Treatment of resistant hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7337?source=see_link\">",
"     \"Overview of hypertension in acute and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20103260\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mechanisms responsible for the thiazide induced blood pressure decline are incompletely understood (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Antihypertensive mechanism'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The potential adverse metabolic effects of thiazide therapy include hypokalemia, hyponatremia, hyperuricemia, elevations in the plasma glucose and cholesterol concentrations, and magnesium depletion. The incidence and magnitude of these side effects are much lower with low dose therapy (eg, 12.5 to 25 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      ) as commonly used in the treatment of primary hypertension (",
"      <a class=\"graphic graphic_figure graphicRef69912 \" href=\"UTD.htm?37/49/38685\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the current treatment of patients with primary hypertension and normal renal function, thiazide diuretics are used at low doses (eg, 12.5 to 25",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       chlorthalidone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      ) to minimize the metabolic complications, while maintaining the antihypertensive response (",
"      <a class=\"graphic graphic_figure graphicRef61248 \" href=\"UTD.htm?18/24/18829\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Low dose therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/14/26854?source=see_link\">",
"       Chlorthalidone",
"      </a>",
"      is 1.5 to 2 times as potent as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      at the same dose and is longer acting. Thus, although some guidelines recommend 12.5 to 25",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of either drug, one cannot assume that the benefits of chlorthalidone in ALLHAT would have replicated with similar doses of hydrochlorothiazide. There is no evidence that hydrochlorothiazide alone in a dose of 12.5 to 25",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      reduces cardiovascular events. As a result, some experts suggest that chlorthalidone (12.5 to 25",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is the low-dose thiazide diuretic of choice. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'ALLHAT trial'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H5#H5\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Chlorthalidone versus hydrochlorothiazide'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/1\">",
"      Kaplan NM. Chlorthalidone versus hydrochlorothiazide: a tale of tortoises and a hare. Hypertension 2011; 58:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/2\">",
"      Freis ED, Reda DJ, Materson BJ. Volume (weight) loss and blood pressure response following thiazide diuretics. Hypertension 1988; 12:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/3\">",
"      van Brummelen P, Man in 't Veld AJ, Schalekamp MA. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther 1980; 27:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/4\">",
"      Shah S, Khatri I, Freis ED. Mechanism of antihypertensive effect of thiazide diuretics. Am Heart J 1978; 95:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/5\">",
"      Vaughan ED Jr, Carey RM, Peach MJ, et al. The renin response to diuretic therapyl A limitation of antihypertensive potential. Circ Res 1978; 42:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/6\">",
"      Tarazi RC, Dustan HP, Frohlich ED. Long-term thiazide therapy in essential hypertension. Evidence for persistent alteration in plasma volume and renin activity. Circulation 1970; 41:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/7\">",
"      Blaustein MP. Endogenous ouabain: role in the pathogenesis of hypertension. Kidney Int 1996; 49:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/8\">",
"      Pickkers P, Hughes AD, Russel FG, et al. Thiazide-induced vasodilation in humans is mediated by potassium channel activation. Hypertension 1998; 32:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/9\">",
"      Leung AA, Wright A, Pazo V, et al. Risk of thiazide-induced hyponatremia in patients with hypertension. Am J Med 2011; 124:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/10\">",
"      Carlsen JE, K&oslash;ber L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/11\">",
"      Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/12\">",
"      Materson BJ, Cushman WC, Goldstein G, et al. Treatment of hypertension in the elderly: I. Blood pressure and clinical changes. Results of a Department of Veterans Affairs Cooperative Study. Hypertension 1990; 15:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/13\">",
"      Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289:2534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/14\">",
"      Harper R, Ennis CN, Sheridan B, et al. Effects of low dose versus conventional dose thiazide diuretic on insulin action in essential hypertension. BMJ 1994; 309:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/15\">",
"      Freis ED, Thomas JR, Fisher SG, et al. Effects of reduction in drugs or dosage after long-term control of systemic hypertension. Am J Cardiol 1989; 63:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/16\">",
"      Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998; 158:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/17\">",
"      ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/18\">",
"      Wright JT Jr, Probstfield JL, Cushman WC, et al. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med 2009; 169:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/19\">",
"      Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/20\">",
"      Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007; 369:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/21\">",
"      Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med 1991; 114:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/22\">",
"      Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006; 47:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15350/abstract/23\">",
"      Ernst ME, Moser M. Use of diuretics in patients with hypertension. N Engl J Med 2009; 361:2153.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3860 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15350=[""].join("\n");
var outline_f14_63_15350=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20103260\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIHYPERTENSIVE MECHANISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism of vasodilatation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LOW DOSE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ALLHAT trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Caveat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20103260\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3860\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3860|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/26/30125\" title=\"figure 1\">",
"      BP response to TZ diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/49/38685\" title=\"figure 2\">",
"      Thiazide side effects and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/23/10621\" title=\"figure 3\">",
"      Thiazides and cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/24/18829\" title=\"figure 4\">",
"      Antihypertensive dose-response to thiazide therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7166\" title=\"figure 5\">",
"      AHT drug and outcome ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/59/40893\" title=\"figure 6\">",
"      AHT drug and HF ALLHAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/18/40237\" title=\"figure 7\">",
"      AHT drug and stroke ALLHAT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44659?source=related_link\">",
"      Antihypertensive drugs and lipids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20218?source=related_link\">",
"      Choice of therapy in essential hypertension: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/26/29094?source=related_link\">",
"      Diuretic-induced hyperuricemia and gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/31/502?source=related_link\">",
"      Diuretic-induced hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/41/43668?source=related_link\">",
"      Diuretics and magnesium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/10/7337?source=related_link\">",
"      Overview of hypertension in acute and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/40/25224?source=related_link\">",
"      Renin-angiotensin system inhibition in the treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/46/13027?source=related_link\">",
"      Thiazides versus loop diuretics in treatment of hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35256?source=related_link\">",
"      Treatment of resistant hypertension",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_63_15351="EtCO2 monitor photo";
var content_f14_63_15351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62543&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    End tidal CO2 (EtCO2) monitor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 578px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The photo shows a child being monitored with capnography: 29 is the end tidal CO",
"    <sub>",
"     2",
"    </sub>",
"    . The capnographic waveform appears in the screen adjacent to the number. The nasal prongs and the bladder that extends from the front of the mouth detect exhaled CO",
"    <sub>",
"     2",
"    </sub>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Mark Waltzman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15351=[""].join("\n");
var outline_f14_63_15351=null;
var title_f14_63_15352="Hepatic adenoma";
var content_f14_63_15352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatic adenoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/63/15352/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15352/contributors\">",
"     Michael P Curry, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15352/contributors\">",
"     Nezam H Afdhal, MD, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/63/15352/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15352/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/63/15352/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15352/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/63/15352/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic adenomas are uncommon benign epithelial liver tumors that develop in an otherwise normal appearing liver. They are seen predominantly in young women (20 to 44 years-old), are frequently located in the right hepatic lobe, and are typically solitary (70 to 80 percent), although multiple adenomas have been described in patients with prolonged contraceptive use, glycogen storage diseases (GSD), and hepatic adenomatosis. Adenomas range in size from 1 to 30 cm. Symptoms, such as abdominal pain, are more likely with larger lesions (",
"    <a class=\"graphic graphic_figure graphicRef58773 \" href=\"UTD.htm?4/4/4173\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis of hepatic adenomas is not well established. However, they have been associated with malignant transformation, spontaneous hemorrhage, and rupture. As a result, their distinction from other types of benign liver tumors is important. This can most often be accomplished using a combination of imaging techniques, although rarely a definitive diagnosis may only be achieved following resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic adenomas are strongly associated with use of oral contraceptives, anabolic androgens, and glycogen storage disease. They are less commonly associated with pregnancy and diabetes mellitus.",
"   </p>",
"   <p>",
"    The incidence of hepatic adenomas has increased in the last several decades, a trend that coincided with the introduction of oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. In addition, adenomas are increasingly encountered as incidental findings in patients undergoing ultrasound, computed tomography, or magnetic resonance imaging for unrelated or non-specific symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Contraceptive use and estrogen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic adenomas were rarely reported before the advent of oral contraceptives (OCPs) in the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/6\">",
"     6",
"    </a>",
"    ]. The association between OCPs and the development of liver tumors was first described in 1973 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/4\">",
"     4",
"    </a>",
"    ]. Multiple subsequent studies have confirmed this association and have also demonstrated that the development of hepatic adenomas correlated with the dose and duration of hormonal therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/5,7-10\">",
"     5,7-10",
"    </a>",
"    ]. The annual incidence is approximately 1 per 1,000,000 in women who have never used OCPs, compared to 30 to 40 per million in long-term users [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]. In a study comparing OCP use in 79 women with hepatic adenomas to 220 controls, the largest risk of development of hepatic adenoma occurred in women over the age of 30 years who had used OCPs for longer than 25 months, particularly those who had used OCPs with a high estrogenic component [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar conclusions were reached in another report in which the duration of OCP use was significantly longer in women with adenomas compared to controls (73 versus 36 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the duration of use was as short as 6 to 12 months in approximately 10 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/12\">",
"     12",
"    </a>",
"    ]. The introduction of low dose estrogen contraceptives in recent years may have reduced the incidence of hepatic adenomas, although there have been no large epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    OCPs also affect the natural history of hepatic adenomas. Adenomas are more numerous, larger, and more likely to bleed in patients who take OCPs [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/3,10,14,15\">",
"     3,10,14,15",
"    </a>",
"    ]. In addition, regression of adenomas has been observed after discontinuation of OCPs with recurrence during readministration or pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/7,16-19\">",
"     7,16-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which estrogen therapy contributes to the development of hepatic adenomas is incompletely understood. One hypothesis is that estrogens directly cause the transformation of hepatocytes via steroid receptors. However, immunohistochemical studies of adenomatous and normal liver tissue for steroid receptors have been small and inconclusive. One study described positive staining for estrogen, progesterone, and androgen receptors in approximately one-third of patients while another showed no receptor staining of adenomatous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anabolic androgen use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of hepatic adenomas has been associated with the use of anabolic steroids for the treatment of impotence, Fanconi's syndrome, and muscle mass development in body builders and in transsexuals [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. Most cases are associated with the use of 17-alpha-alkylated steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/19\">",
"     19",
"    </a>",
"    ]. Similar to OCPs, androgens appear to predispose to multiple adenomas and frequently regress following discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/23,26\">",
"     23,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Glycogen storage diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenomas occur in patients with type I and III glycogen storage diseases (GSD) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The incidence is up to 51 percent with type I and 25 percent with type III GSD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. They usually occur before the age of 20 years, are more common in males, and are typically multiple. Resolution has been reported in some patients after dietary therapy and correction of insulin, glucose, and glucagon levels [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/14\">",
"     14",
"    </a>",
"    ]. The mechanism by which GSD promotes the development of hepatic adenoma is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;One group described germline mutations in the APC genes and p53 genes in an infant with a hepatic adenoma and a family history of adenomatous polyposis coli [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between pregnancy and hepatic adenomas may be related to the increased endogenous levels of steroid hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/33\">",
"     33",
"    </a>",
"    ]. Several cases of ruptured hepatic adenoma during gestation have been described with a reported 59 percent maternal and 62 percent fetal mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/34\">",
"     34",
"    </a>",
"    ]. The high mortality may be related to delays in diagnosis because of confusion with other conditions such as preeclampsia or pulmonary embolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic adenomas are typically solitary lesions (70 to 80 percent), which vary in size from a few millimeters to several centimeters. The lesions are often in the right lobe of the liver. Approximately 10 percent are pedunculated. They are soft and smooth with a tan appearance, large prominent blood vessels on the surface and within the tumor with areas of hemorrhage and necrosis. There is usually no fibrous capsule; as a result, hemorrhage from an adenoma can freely extend into the liver (",
"    <a class=\"graphic graphic_picture graphicRef72131 \" href=\"UTD.htm?6/5/6227\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Microscopically, adenomas are composed of large plates of adenoma cells, which are typically larger than normal hepatocytes and contain glycogen and lipid (",
"    <a class=\"graphic graphic_picture graphicRef51149 \" href=\"UTD.htm?13/12/13508\">",
"     picture 2",
"    </a>",
"    ). The nuclei are small and regular and mitoses are almost never seen. There is notable absence of normal hepatic architecture and the cells are arranged in normal or thickened trabeculae interspersed with prominent arteries and thin walled blood vessels and sinusoids. Regular septa, portal tracts, and bile ductules are absent, a feature that helps distinguish it from non-neoplastic liver tissue and focal nodular hyperplasia. Kupffer cells may be present, but only in small numbers. Furthermore, they are non-functional, explaining the inability of most adenomas to take up technetium-99m labeled sulfur colloid. The distinction from hepatocellular carcinoma is occasionally difficult but can usually be made on the basis of the trabecular pattern and appearance of the tumor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A classification of hepatic adenomas according to genotype and phenotype characteristics has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/36\">",
"     36",
"    </a>",
"    ]. Of 96 cases of hepatic adenoma, three major groupings were identified: those with mutations in hepatocyte nuclear factor 1 alpha (HNF1alpha), those with mutations in beta-catenin, and those with neither mutation. The most common mutation was in HNF1alpha, which was seen in 46 percent of adenomas. These were characterized by the presence of marked steatosis, and lack of cytologic abnormalities or inflammatory infiltrates. By contrast, adenomas with mutations in beta-catenin (14 percent of cases) had frequent cytologic abnormalities and pseudo-glandular formation.",
"   </p>",
"   <p>",
"    The third group (lacking these mutations) could be subdivided into two groups: those with and without inflammatory infiltrates. The authors noted that adenomas associated with hepatocellular carcinoma (or having histologic features bordering on hepatocellular carcinoma) were observed almost exclusively in the beta-catenin group, rarely in the HNF1alpha group, and never in inflammatory lesions. These observations suggest that adenomas with mutations in beta-catenin may be at increased risk for malignant transformation. Interestingly, certain radiologic features on MRI correlate with the histologic subtypes, suggesting it may be possible to classify them by MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Further studies are needed to validate these findings and determine whether they may change the management of patients suspected to have a hepatic adenoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, the majority of hepatic adenomas are seen in young women who have a history of prolonged OCP use. They are typically diagnosed because of abdominal pain localized to the epigastrium or right upper quadrant, during an imaging study done for unrelated reasons, and less commonly because of detection of a mass on clinical examination or as a sudden life threatening collapse associated with rupture and intraabdominal bleeding (",
"    <a class=\"graphic graphic_figure graphicRef58773 \" href=\"UTD.htm?4/4/4173\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Episodic abdominal pain localized to the epigastrium or right upper quadrant may reflect an enlarged liver, bleeding into the tumor, or tumor necrosis. The development of sudden severe pain associated with hypotension reflects rupture into the peritoneum, an event associated with a mortality of up to 20 percent if not identified and appropriately treated [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/3,30,39,40\">",
"     3,30,39,40",
"    </a>",
"    ]. The actual risk of bleeding is difficult to establish since estimates have been derived mostly from studies of symptomatic patients in whom the risk of bleeding may be as high as 25 to 41 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/40\">",
"     40",
"    </a>",
"    ]. The presence of abdominal pain, a history of long duration of contraceptive use, and sub-capsular location are features associated with an increased risk of bleeding.",
"   </p>",
"   <p>",
"    An abdominal mass can be identified in up to 30 percent of patients while hepatomegaly is present in approximately 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/41\">",
"     41",
"    </a>",
"    ]. Jaundice has been described and presumably reflects compression of the intrahepatic bile ducts by an enlarging tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Liver function test abnormalities are rare but may be more frequent in patients with a hepatic adenoma compared to those with focal nodular hyperplasia (FNH), a diagnosis that may have similar clinical and radiologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22791?source=see_link\">",
"     \"Focal nodular hyperplasia\"",
"    </a>",
"    .) Elevation of alkaline phosphatase and gamma glutamyl transpeptidase (gGT) may be present, particularly in patients with intratumoral bleeding or multiple adenomas. Alpha fetoprotein (AFP) is normal except in patients in whom malignant transformation has occurred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Risk of malignant transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of malignant transformation to hepatocellular carcinoma is difficult to ascertain from the literature. Two small studies reported the development of malignant transformation in 8 to 13 percent of patients, suggesting that it is not a rare occurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. An increase in size on sequential imaging studies or a rise in serum AFP levels should raise concern that malignant transformation has developed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adenomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenomatosis has been classified as a distinct pathological entity from isolated hepatic adenoma. First described in 1985, it is characterized by the presence of more than 10 adenomas, lack of correlation with steroid medication or lack of resolution with steroid withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/46\">",
"     46",
"    </a>",
"    ], lack of association with GSD, involvement in both men and women, and abnormal increases in serum alkaline phosphatase and gGT levels [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distinction of hepatic adenoma(s) from adenomatosis may seem arbitrary since more than 10 adenomas have been documented in patients with GSD and those who use oral contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. However, these cases do not fit the classification proposed above [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/47\">",
"     47",
"    </a>",
"    ]. There is no correlation between estrogen receptor status and hepatic adenomatosis since estrogen receptor positive and negative tumors have been isolated from the same liver [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The conditions that predispose to adenomatosis are poorly understood. One theory is that the development of adenomatosis is associated with congenital or acquired abnormalities of hepatic vasculature. This hypothesis was supported in a study in which 5 of 15 patients with adenomatosis had evidence of abnormal vasculature: two had congenital absence of portal vein, one had portal venous thrombosis with cavernous transformation, and two had intrahepatic portosystemic shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The natural history of adenomatosis is not well understood since the available information is derived from individual reports and small case series [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/46,47,50-52\">",
"     46,47,50-52",
"    </a>",
"    ]. Hemorrhage appears to be common, particularly in patients who have adenomas larger than 4 cm that are in a subcapsular location. Bleeding occurred in five of eight patients (62 percent) in a series of patients seen at the Mayo Clinic during an 11-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/46\">",
"     46",
"    </a>",
"    ]. This compared to a bleeding rate of 26 percent in patients with hepatic adenomas seen during the same period. Malignant transformation has been documented in several case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/30,53,54\">",
"     30,53,54",
"    </a>",
"    ]; it occurred in 2 of 15 patients in a series from the University of Pittsburgh [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis should be made based upon the clinical setting, a combination of imaging studies,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical resection. Percutaneous liver biopsy or fine needle aspiration are usually",
"    <strong>",
"     not",
"    </strong>",
"    indicated because adenomas have a tendency to bleed following biopsy and because the amount of tissue obtained using these methods is frequently insufficient for establishing a diagnosis.",
"   </p>",
"   <p>",
"    The diagnosis of a hepatic adenoma is frequently considered in the broader context of patients presenting with a focal liver lesion. An approach to such patients is presented separately. A common dilemma is the differentiation of an adenoma from focal nodular hyperplasia (FNH). Although the distinction can often be made based upon imaging characteristics, surgical resection may be required for definitive diagnosis and is at the same time curative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multiple imaging modalities are usually required since similar radiologic features can be seen with any vascular tumor of the liver and because imaging characteristics are variable depending upon the presence of intratumoral hemorrhage, necrosis, and fat in the surrounding liver. However, the diagnosis may remain uncertain even after multiple imaging modalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenomas are often first detected by ultrasound (US). However, sonographic characteristics are often non-specific and may mimic other benign or malignant liver lesions. Adenomas may appear well-demarcated and hyperechoic because of the high lipid content of hepatocytes but can also be heterogeneous because of intratumoral bleeding. Bleeding may also appear as calcifications. Necrosis may appear as hyperechoic areas with acoustic shadows [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/55\">",
"     55",
"    </a>",
"    ]. Color Doppler US can assist in making the distinction from FNH because of the appearance of intratumoral and peritumoral vessels in the absence of a central arterial signal [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) has the advantage of acquiring images during non-contrast and contrast enhanced (arterial and venous) phases providing a dynamic sequence for evaluating focal liver lesions. Adenomas are typically well-demarcated and have low attenuation or are isodense on non-contrast images of the liver. Contrast-enhanced scans may show peripheral enhancement during the early phase with subsequent centripetal flow during the portal venous phase, which is characteristic of adenoma [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/1\">",
"     1",
"    </a>",
"    ]. During the late phase of the contrast-enhanced scans, the lesion may become isodense and then hypodense (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68931 \" href=\"UTD.htm?16/0/16384\">",
"     image 1",
"    </a>",
"    ). Adenomas often have areas of hemorrhage, necrosis, or fibrosis, giving them a heterogeneous appearance. The presence of fresh blood within the adenoma gives the appearance of a high attenuating lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenomas are usually well- demarcated on magnetic resonance imaging (MRI) because of the fat or glycogen content of the hepatocytes. However, MRI characteristics are highly variable [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/57\">",
"     57",
"    </a>",
"    ]. Most adenomas are hyperintense on T1 weighted images (because of the presence of fat or glycogen) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/58,59\">",
"     58,59",
"    </a>",
"    ] and on T2 images. The presence of enhanced T2 weight images that enhance further with gadolinium administration is highly suggestive of the diagnosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79542 \" href=\"UTD.htm?14/10/14496\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/57\">",
"     57",
"    </a>",
"    ]. Gadolinium enhancement is early, after which the lesion becomes isodense [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A relatively new MR contrast agent has been introduced into clinical use. Unlike currently used gadolinium-based contrast agents for MRI, this agent, a Gd-BOPTA chelate of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/45/25301?source=see_link\">",
"     Gadobenate Dimeglumine",
"    </a>",
"    , has a dual route of elimination, through both renal and hepatobiliary excretion. Thus, it can be useful for distinguishing hepatic adenomas from focal nodular hyperplasia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Technetium-99m (99mTc) sulfur colloid scanning",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, Kupffer cells may be present in adenomas but only in small numbers. Furthermore, they are generally non-functional. Kupffer cells may be present histologically in adenomas with and without uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most adenomas do not take up the sulfur colloid; thus the scintigram shows a \"cold\" spot in the liver. However, a minority (as many as 25 percent in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/61\">",
"     61",
"    </a>",
"    ]) take up the sulfur colloid, thus rendering them indistinguishable from FNH [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Focal nodular hyperplasia, on the other hand, shows equal or greater uptake of the radiolabeled agent compared to surrounding liver. Thus, sulfur colloid scanning is generally not useful for establishing the diagnosis of an adenoma, but may be helpful when the clinical setting and results of other radiologic testing point to a diagnosis of FNH. In many centers, nuclear imaging has been largely replaced by Gd-BOPTA-enhanced MRI or dynamic multi-phase CT angiography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"     \"Approach to the patient with a focal liver lesion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiography is rarely used for the diagnosis of hepatic adenomas. Approximately one-half of adenomas have the typical features of a hypervascular well-circumscribed tumor with increased peripheral vascularity, in contrast to the central vessel seen in FNH. Unfortunately, these features may not be as apparent in adenomas with necrosis or hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history and prognosis of hepatic adenomas is not well established. As a result, decisions regarding management of these tumors depend upon symptoms, size, number, location, and certainty of the diagnosis.",
"   </p>",
"   <p>",
"    The following discussions will present common clinical scenarios in which the clinical setting and radiologic findings suggest the diagnosis of an adenoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Asymptomatic woman on OCPs with a small adenoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of asymptomatic patients who are taking OCPs is controversial. Some authors have advocated a conservative approach in patients with small lesions (&lt;5 cm) with discontinuation of contraceptive medication, and close observation of the lesion with repeated imaging and AFP determinations [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/63\">",
"     63",
"    </a>",
"    ]. Complete regression of tumor has been documented after discontinuing steroid medications [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/16,64,65\">",
"     16,64,65",
"    </a>",
"    ]. However, even after discontinuation of steroid medications, growth, rupture, and malignant transformation (despite a decrease in size of the adenoma) have been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/14,66\">",
"     14,66",
"    </a>",
"    ]. As a result, other authors recommend resection of all adenomas regardless of size if technically feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend resection of all symptomatic hepatic adenomas. Adenomas that do not resolve or enlarge after discontinuation of steroid medication should also be considered for surgical resection after discussion with the patient. We suggest repeating the imaging study six months after stopping OCPs.&nbsp;If there is no change, or if the presumed adenoma has grown in size, we suggest surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     A woman contemplating pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should generally be advised against pregnancy since the behavior of a liver adenoma during pregnancy is unpredictable [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Resection of the lesion prior to pregnancy may be the best option for such patients. A ruptured adenoma during pregnancy should be managed with appropriate resuscitation and surgical resection. The optimal management of an incidentally identified adenoma during pregnancy is unclear. Because of the unpredictable behavior and risk of rupture, surgical resection should be recommended for patients with large or symptomatic adenomas. Resection should ideally be performed during the second trimester, during which the risks to the mother and the fetus are minimized [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Symptomatic patients and those with large adenomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection should be recommended for patients with symptoms attributable to the adenoma and those with large lesions (&gt;5 cm) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/70\">",
"     70",
"    </a>",
"    ]. Surgical options include enucleation, resection, and rarely liver transplantation. Liver transplantation should be reserved for patients in whom surgical resection is not possible due to tumor",
"    <span class=\"nowrap\">",
"     size/location",
"    </span>",
"    and those with adenomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/71-74\">",
"     71-74",
"    </a>",
"    ]. Mortality from elective surgical resection is &lt;1 percent and resection of some peripherally located adenomas can even be accomplished laparoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who present with abdominal pain and hypotension as a result of intraperitoneal bleeding from a ruptured adenoma have a mortality of up to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/7\">",
"     7",
"    </a>",
"    ]. Such patients should undergo surgery for definitive resection and control of hemorrhage. Emergency surgery is associated with a mortality of 5 to 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/76\">",
"     76",
"    </a>",
"    ]. Preoperative selective arterial embolization using coils and particulate matter may control bleeding and reduce mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15352/abstract/65,77,78\">",
"     65,77,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23173051\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hepatic adenomas are uncommon benign epithelial liver tumors that develop in an otherwise normal appearing liver. They are seen predominantly in young women (20 to 44 years old), are frequently located in the right hepatic lobe, and are typically solitary (70 to 80 percent), although multiple adenomas have been described in patients with prolonged contraceptive use, glycogen storage diseases, and hepatic adenomatosis. Adenomas range in size from 1 to 30 cm. Symptoms such as abdominal pain are more likely with larger lesions (",
"      <a class=\"graphic graphic_figure graphicRef58773 \" href=\"UTD.htm?4/4/4173\">",
"       figure 1",
"      </a>",
"      ). Adenomas are typically diagnosed because of abdominal pain localized to the epigastrium or right upper quadrant, during an imaging study done for unrelated reasons, and (less commonly) because of detection of a mass on clinical examination or as a sudden life-threatening hemodynamic collapse associated with rupture and intra-abdominal bleeding. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hepatic adenomas are strongly associated with the use of oral contraceptives, anabolic androgens, and glycogen storage disease. They are less commonly associated with pregnancy and diabetes mellitus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and incidence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis should be made based upon the clinical setting, a combination of imaging studies,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      surgical resection. Percutaneous liver biopsy or fine needle aspiration is usually",
"      <strong>",
"       not",
"      </strong>",
"      indicated because adenomas have a tendency to bleed following biopsy and because the amount of tissue obtained using these methods is frequently insufficient for establishing a diagnosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.) The diagnosis of a hepatic adenoma is frequently considered in the broader context of patients presenting with a focal liver lesion. An approach to such patients is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=see_link\">",
"       \"Approach to the patient with a focal liver lesion\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The natural history and prognosis of hepatic adenomas is not well established. As a result, decisions regarding management of these tumors depend upon symptoms, size, number, location, and certainty of the diagnosis. An approach to common clinical scenarios is presented above. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend resection of all symptomatic hepatic adenomas and adenomas &gt;5 cm (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Adenomas that do not resolve or enlarge after discontinuation of steroid medication should also be considered for surgical resection after discussion with the patient. In women taking oral contraceptives, we suggest repeating the imaging study six months after stopping oral contraceptives.&nbsp;If there is no change, or if the presumed adenoma has grown in size, we suggest surgery.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/1\">",
"      Grazioli L, Federle MP, Brancatelli G, et al. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001; 21:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/2\">",
"      Sherlock S. Hepatic adenomas and oral contraceptives. Gut 1975; 16:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/3\">",
"      Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology 1977; 73:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/4\">",
"      Baum JK, Bookstein JJ, Holtz F, Klein EW. Possible association between benign hepatomas and oral contraceptives. Lancet 1973; 2:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/5\">",
"      Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976; 294:470.",
"     </a>",
"    </li>",
"    <li>",
"     Edmondson H. Tumors of the liver and intrahepatic bile ducts. Vol. Fascicle 25 Washington, DC: Armed Forces Institute of Pathology, 1958 Atlas of tumorpathology.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/7\">",
"      Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979; 242:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/8\">",
"      Nime F, Pickren JW, Vana J, et al. The histology of liver tumors in oral contraceptive users observed during a national survey by the American College of Surgeons Commission on Cancer. Cancer 1979; 44:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/9\">",
"      Rosenberg L. The risk of liver neoplasia in relation to combined oral contraceptive use. Contraception 1991; 43:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/10\">",
"      S&oslash;e KL, S&oslash;e M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992; 12:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/11\">",
"      Reddy KR, Schiff ER. Approach to a liver mass. Semin Liver Dis 1993; 13:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/12\">",
"      Cherqui D, Rahmouni A, Charlotte F, et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 1995; 22:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/13\">",
"      Benhamou JP. Diagnostic approach to a liver mass: diagnosis of an asymptomatic liver tumor in a young woman. J Hepatol 1996; 25 Suppl 1:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/14\">",
"      Shortell CK, Schwartz SI. Hepatic adenoma and focal nodular hyperplasia. Surg Gynecol Obstet 1991; 173:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/15\">",
"      Meissner K. Hemorrhage caused by ruptured liver cell adenoma following long-term oral contraceptives: a case report. Hepatogastroenterology 1998; 45:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/16\">",
"      Edmondson HA, Reynolds TB, Henderson B, Benton B. Regression of liver cell adenomas associated with oral contraceptives. Ann Intern Med 1977; 86:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/17\">",
"      Kawakatsu M, Vilgrain V, Erlinger S, Nahum H. Disappearance of liver cell adenoma: CT and MR imaging. Abdom Imaging 1997; 22:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/18\">",
"      Aseni P, Sansalone CV, Sammartino C, et al. Rapid disappearance of hepatic adenoma after contraceptive withdrawal. J Clin Gastroenterol 2001; 33:234.",
"     </a>",
"    </li>",
"    <li>",
"     Norris S. Drug- and Toxin-Induced Liver Injury. In: Comprehensive Clinical Hepatology, O'Grady J, Lake J, Howdle P (Eds), Harcourt Publishers Limited, London 2000. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/20\">",
"      Cohen C, Lawson D, DeRose PB. Sex and androgenic steroid receptor expression in hepatic adenomas. Hum Pathol 1998; 29:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/21\">",
"      Masood S, West AB, Barwick KW. Expression of steroid hormone receptors in benign hepatic tumors. An immunocytochemical study. Arch Pathol Lab Med 1992; 116:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/22\">",
"      Nakao A, Sakagami K, Nakata Y, et al. Multiple hepatic adenomas caused by long-term administration of androgenic steroids for aplastic anemia in association with familial adenomatous polyposis. J Gastroenterol 2000; 35:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/23\">",
"      Resnick MB, Kozakewich HP, Perez-Atayde AR. Hepatic adenoma in the pediatric age group. Clinicopathological observations and assessment of cell proliferative activity. Am J Surg Pathol 1995; 19:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/24\">",
"      Touraine RL, Bertrand Y, Foray P, et al. Hepatic tumours during androgen therapy in Fanconi anaemia. Eur J Pediatr 1993; 152:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/25\">",
"      Coombes GB, Reiser J, Paradinas FJ, Burn I. An androgen-associated hepatic adenoma in a trans-sexual. Br J Surg 1978; 65:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/26\">",
"      Carrasco D, Prieto M, Pallard&oacute; L, et al. Multiple hepatic adenomas after long-term therapy with testosterone enanthate. Review of the literature. J Hepatol 1985; 1:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/27\">",
"      Fujiyama S, Sato K, Sakai M, et al. A case of type Ia glycogen storage disease complicated by hepatic adenoma. Hepatogastroenterology 1990; 37:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/28\">",
"      Alshak NS, Cocjin J, Podesta L, et al. Hepatocellular adenoma in glycogen storage disease type IV. Arch Pathol Lab Med 1994; 118:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/29\">",
"      Labrune P, Trioche P, Duvaltier I, et al. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 1997; 24:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/30\">",
"      Leese T, Farges O, Bismuth H. Liver cell adenomas. A 12-year surgical experience from a specialist hepato-biliary unit. Ann Surg 1988; 208:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/31\">",
"      Talente GM, Coleman RA, Alter C, et al. Glycogen storage disease in adults. Ann Intern Med 1994; 120:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/32\">",
"      Bala S, W&uuml;nsch PH, Ballhausen WG. Childhood hepatocellular adenoma in familial adenomatous polyposis: mutations in adenomatous polyposis coli gene and p53. Gastroenterology 1997; 112:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/33\">",
"      Kent DR, Nissen ED, Nissen SE, Ziehm DJ. Effect of pregnancy on liver tumor associated with oral contraceptives. Obstet Gynecol 1978; 51:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/34\">",
"      Bis KA, Waxman B. Rupture of the liver associated with pregnancy: a review of the literature and report of 2 cases. Obstet Gynecol Surv 1976; 31:763.",
"     </a>",
"    </li>",
"    <li>",
"     Scheuer, P, Lefkowitch, J. Neoplasms and Nodules. In: Liver Biopsy Interpretation, 6th edition, WB Saunders, London 2000. p.191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/36\">",
"      Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006; 43:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/37\">",
"      Laumonier H, Bioulac-Sage P, Laurent C, et al. Hepatocellular adenomas: magnetic resonance imaging features as a function of molecular pathological classification. Hepatology 2008; 48:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/38\">",
"      Ronot M, Bahrami S, Calderaro J, et al. Hepatocellular adenomas: accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology 2011; 53:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/39\">",
"      Nagorney DM. Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World J Surg 1995; 19:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/40\">",
"      Rubin RA, Mitchell DG. Evaluation of the solid hepatic mass. Med Clin North Am 1996; 80:907.",
"     </a>",
"    </li>",
"    <li>",
"     Molina, E, Schiff, E. Benign solid lesions of the liver. In: Schiff's Diseases of the Liver, 8th edition, Schiff, E, Sorrell, M, Maddrey, W (Eds), Lippincott-Raven, Philadelphia 1999. p.1245.",
"    </li>",
"    <li>",
"     Sturvetant, F. Oral contraceptives and liver tumors. In: Controversies in contraception, Moghissi, K (Eds), Williams and Wilkins, Baltimore 1979. p.93.",
"    </li>",
"    <li>",
"     Neuberger, J, Davis, M, Williams, R. Clinical aspects of oral contraceptive-associated liver tumors. In: Drug reactions and the liver, Davis, M, Tredger, J, Williams, R (Eds), Pittman Medical, Bath, UK 1981. p.271.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/44\">",
"      Kerlin P, Davis GL, McGill DB, et al. Hepatic adenoma and focal nodular hyperplasia: clinical, pathologic, and radiologic features. Gastroenterology 1983; 84:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/45\">",
"      Foster JH, Berman MM. The malignant transformation of liver cell adenomas. Arch Surg 1994; 129:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/46\">",
"      Ribeiro A, Burgart LJ, Nagorney DM, Gores GJ. Management of liver adenomatosis: results with a conservative surgical approach. Liver Transpl Surg 1998; 4:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/47\">",
"      Flejou JF, Barge J, Menu Y, et al. Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology 1985; 89:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/48\">",
"      Howell RR, Stevenson RE, Ben-Menachem Y, et al. Hepatic adenomata with type 1 glycogen storage disease. JAMA 1976; 236:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/49\">",
"      Chen KT, Bocian JJ. Multiple hepatic adenomas. Arch Pathol Lab Med 1983; 107:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/50\">",
"      Grazioli L, Federle MP, Ichikawa T, et al. Liver adenomatosis: clinical, histopathologic, and imaging findings in 15 patients. Radiology 2000; 216:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/51\">",
"      Khan SS, Fink M, King S. Case report: liver adenomatosis presenting as multiple calcified masses. Clin Radiol 1992; 45:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/52\">",
"      Choi BI, Han JK, Kim SH, Han MC. MR findings in liver adenomatosis. Gastrointest Radiol 1991; 16:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/53\">",
"      Neuberger J, Portmann B, Nunnerley HB, et al. Oral-contraceptive-associated liver tumours: occurrence of malignancy and difficulties in diagnosis. Lancet 1980; 1:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/54\">",
"      Ferrell LD. Hepatocellular carcinoma arising in a focus of multilobular adenoma. A case report. Am J Surg Pathol 1993; 17:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/55\">",
"      Sandler MA, Petrocelli RD, Marks DS, Lopez R. Ultrasonic features and radionuclide correlation in liver cell adenoma and focal nodular hyperlasia. Radiology 1980; 135:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/56\">",
"      Golli M, Van Nhieu JT, Mathieu D, et al. Hepatocellular adenoma: color Doppler US and pathologic correlations. Radiology 1994; 190:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/57\">",
"      Chung KY, Mayo-Smith WW, Saini S, et al. Hepatocellular adenoma: MR imaging features with pathologic correlation. AJR Am J Roentgenol 1995; 165:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/58\">",
"      Paulson EK, McClellan JS, Washington K, et al. Hepatic adenoma: MR characteristics and correlation with pathologic findings. AJR Am J Roentgenol 1994; 163:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/59\">",
"      Arriv&eacute; L, Fl&eacute;jou JF, Vilgrain V, et al. Hepatic adenoma: MR findings in 51 pathologically proved lesions. Radiology 1994; 193:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/60\">",
"      Lubbers PR, Ros PR, Goodman ZD, Ishak KG. Accumulation of technetium-99m sulfur colloid by hepatocellular adenoma: scintigraphic-pathologic correlation. AJR Am J Roentgenol 1987; 148:1105.",
"     </a>",
"    </li>",
"    <li>",
"     Henderson, J, Vogt, D. Non-transplant Surgery and the Liver. In: Comprehensive Clinical Hepatology, Volume 1, O'Grady, J, Lake, J, Howdel, P (Eds), Harcourt Publishers Limited, London 2000. p.31.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/62\">",
"      Rubin RA, Lichtenstein GR. Hepatic scintigraphy in the evaluation of solitary solid liver masses. J Nucl Med 1993; 34:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/63\">",
"      Sherlock S. Hepatic reactions to drugs. Gut 1979; 20:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/64\">",
"      Malt RA. Surgery for hepatic neoplasms. N Engl J Med 1985; 313:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/65\">",
"      Ault GT, Wren SM, Ralls PW, et al. Selective management of hepatic adenomas. Am Surg 1996; 62:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/66\">",
"      Knowles DM 2nd, Casarella WJ, Johnson PM, Wolff M. The clinical, radiologic, and pathologic characterization of benign hepatic neoplasms. Alleged association with oral contraceptives. Medicine (Baltimore) 1978; 57:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/67\">",
"      Monks PL, Fryar BG, Biggs WW. Spontaneous rupture of an hepatic adenoma in pregnancy with survival of mother and fetus. Aust N Z J Obstet Gynaecol 1986; 26:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/68\">",
"      Estebe JP, Malledant Y, Guillou YM, et al. [Spontaneous rupture of an adenoma of the liver during pregnancy]. J Chir (Paris) 1988; 125:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/69\">",
"      Terkivatan T, de Wilt JH, de Man RA, Ijzermans JN. Management of hepatocellular adenoma during pregnancy. Liver 2000; 20:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/70\">",
"      Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009; 137:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/71\">",
"      Belghiti J, Pateron D, Panis Y, et al. Resection of presumed benign liver tumours. Br J Surg 1993; 80:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/72\">",
"      Mueller J, Keeffe EB, Esquivel CO. Liver transplantation for treatment of giant hepatocellular adenomas. Liver Transpl Surg 1995; 1:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/73\">",
"      Tepetes K, Selby R, Webb M, et al. Orthotopic liver transplantation for benign hepatic neoplasms. Arch Surg 1995; 130:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/74\">",
"      Yoshidome H, McMasters KM, Edwards MJ. Management issues regarding hepatic adenomatosis. Am Surg 1999; 65:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/75\">",
"      Azagra JS, Goergen M, Gilbart E, Jacobs D. Laparoscopic anatomical (hepatic) left lateral segmentectomy-technical aspects. Surg Endosc 1996; 10:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/76\">",
"      Eckhauser FE, Knol JA, Raper SE, Thompson NW. Enucleation combined with hepatic vascular exclusion is a safe and effective alternative to hepatic resection for liver cell adenoma. Am Surg 1994; 60:466.",
"     </a>",
"    </li>",
"    <li>",
"     Karani, J. Benign Tumors and Cystic Disease of the Liver. In: Comprehensive Clinical Hepatology, Volume 1, O'Grady, J, Lake, J, Howdel, P (Eds), Harcourt Publisher Limited, London 2000. p.24.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15352/abstract/78\">",
"      Wheeler PG, Melia W, Dubbins P, et al. Non-operative arterial embolisation in primary liver tumours. Br Med J 1979; 2:242.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3590 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.131.240.2-B6AD6E7C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15352=[""].join("\n");
var outline_f14_63_15352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23173051\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Contraceptive use and estrogen therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anabolic androgen use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Glycogen storage diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Risk of malignant transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adenomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Technetium-99m (99mTc) sulfur colloid scanning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Asymptomatic woman on OCPs with a small adenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      A woman contemplating pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Symptomatic patients and those with large adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23173051\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3590\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3590|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/0/16384\" title=\"diagnostic image 1\">",
"      Large adenoma CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?14/10/14496\" title=\"diagnostic image 2\">",
"      Two hepatic adenomas MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3590|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/4/4173\" title=\"figure 1\">",
"      Hepatic adenoma symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3590|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/5/6227\" title=\"picture 1\">",
"      Hepatic adenoma gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/12/13508\" title=\"picture 2\">",
"      Hepatic adenoma Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/1/36888?source=related_link\">",
"      Approach to the patient with a focal liver lesion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22791?source=related_link\">",
"      Focal nodular hyperplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_63_15353="Inhaled insulin therapy in diabetes mellitus";
var content_f14_63_15353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Inhaled insulin therapy in diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/63/15353/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15353/contributors\">",
"     Anastassios G Pittas, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/63/15353/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15353/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/63/15353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15353/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/63/15353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy with insulin is effective at lowering blood glucose in patients with diabetes, but there is resistance to its use by patients and health care providers because of its need to be injected subcutaneously, and by patients primarily because of concern regarding interference with their lifestyle, risk of hypoglycemia, and perception that people treated with insulin are \"sicker\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Specifically, patients with type 2 diabetes may defer initiating insulin therapy for prolonged periods of time, resulting in inadequate glycemic control and increased risk for short- and long-term complications. Therefore, alternative, less invasive options for insulin therapy are desirable.",
"   </p>",
"   <p>",
"    An inhaled form of rapid-acting insulin (Exubera) was available for a short time (August 2006 to October 2007) before it was discontinued by the manufacturer as the new technology failed to gain acceptance by patients or clinicians [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/4\">",
"     4",
"    </a>",
"    ]. Within a short period of time, most other companies abandoned their development programs on inhaled insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/5\">",
"     5",
"    </a>",
"    ]. Currently, there is one formulation of inhaled insulin in phase III clinical trials that uses a different technology for insulin delivery (Technosphere) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhaled insulin represents a paradigm shift for insulin delivery, as it differs not only in route of administration, but also dosing units, patient eligibility (precautions and exclusions related to lung disease and smoking), and required periodic testing for safety. This topic will review the efficacy, safety, and patient acceptability of inhaled insulin therapy. Since most of the publicly available data on inhaled insulin are for Exubera, the topic primarily reflects the experience with this formulation. An overview of pharmacologic therapy for type 1 and type 2 diabetes including insulin therapy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=see_link\">",
"     \"General principles of insulin therapy in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"     \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"     \"Insulin therapy in type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most polypeptides used for therapy require injection for delivery, as oral administration results in loss of biopotency, owing to breakdown in the stomach. Several non-oral routes of administration have been explored, including transdermal, buccal, nasal, and inhaled delivery. Specifically, the lung provides an attractive alternative for systemic administration of therapeutic polypeptides given its accessibility and large alveolar-capillary network for drug absorption (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Delivery system",
"    </span>",
"    &nbsp;&mdash;&nbsp;For insulin to be delivered through the lungs, inhalation devices that provide dose accuracy and consistency are critical. Due to its inefficient absorption, higher doses of inhaled insulin compared to subcutaneous must be administered to achieve a therapeutic response. The formerly available inhaled insulin delivery system (Exubera) involved use of a bulky device to dispense human insulin as a dry-powdered formulation with little dosing flexibility. A different inhaled insulin formulation, which appears to have a more convenient delivery system and greater dosing flexibility, is in development [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/6-8,10\">",
"     6-8,10",
"    </a>",
"    ]. This new Technosphere formulation (Afrezza) contains recombinant human insulin dissolved with powder (fumaryl diketopiperazine). Once inhaled, Technosphere insulin is rapidly absorbed upon contact with the lung surface (half-life about one hour) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Both the insulin and the powder are nearly completely cleared from the lungs of healthy individuals within 12 hours of inhalation; only 0.3 percent of the insulin and 0.4 percent of the powder concentration remain after 12 hours. In contrast, with the Exubera formulation, about 8 to 9 percent of the inhaled dose remained in the lungs 12 hours later [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled insulin displays an onset of action similar (Exubera) to or faster (Technosphere) than rapid-acting insulin analogs (lispro, aspart or glulisine), reaching a maximum peak blood insulin concentration within 15 to 30 minutes (Technosphere). The duration of glucose-lowering activity of inhaled insulin is comparable to that of rapid-acting insulins administered subcutaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/8,13-20\">",
"     8,13-20",
"    </a>",
"    ]. Intrasubject variability of inhaled insulin under controlled conditions is comparable to subcutaneous insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/21\">",
"     21",
"    </a>",
"    ], but it may be higher in clinical practice due to inexperience with the device when first prescribed and due to fluctuating respiratory function because of intercurrent illness. Given its pharmacokinetic profile, inhaled insulin has been studied as a pre-meal non-invasive alternative to subcutaneous regular or rapid-acting insulin and needs to be administered with a long-acting insulin formulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since most of the publicly available data on inhaled insulin are for Exubera, the efficacy data primarily reflect the experience with this formulation. Inhaled insulin has been studied in randomized controlled trials in both type 1 and type 2 diabetes, involving more than 4000 participants with a baseline hemoglobin A1C of 7 to 9.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/8,9,22\">",
"     8,9,22",
"    </a>",
"    ]. All trials were open-label and no studies used the \"double-dummy\" technique, where all patients receive both an inhaler and injections (with only one of the two methods delivering active study drug or placebo). In general, trials comparing inhaled with subcutaneous insulin are designed for \"non-inferiority,\" while those comparing inhaled insulin to oral agents are designed to show \"superiority\" of inhaled insulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Type 1 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several trials in patients with type 1 diabetes in which inhaled insulin was found to have similar efficacy as subcutaneous regular or lispro insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/23-29\">",
"     23-29",
"    </a>",
"    ]. As an example, a six-month randomized trial in type 1 diabetic patients on basal twice daily NPH insulin compared premeal inhaled insulin (n = 163) with subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    (n = 165) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/28\">",
"     28",
"    </a>",
"    ]. Mean A1C levels were reduced to a similar degree in both arms and fasting glucose levels were lower with inhaled insulin.",
"   </p>",
"   <p>",
"    However, neither arm reached A1C levels (less than 7 percent) associated with reduced risk of diabetes-specific chronic complications; it is not clear if the results would have been the same if more aggressive treatment of blood glucose had been pursued. In addition, because of dosing inflexibility relative to subcutaneous insulin, it may be difficult to achieve tight glucose control with an acceptable rate of hypoglycemia with inhaled insulin preparations. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Dose and administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Type 2 diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are also several trials in patients with type 2 diabetes comparing inhaled insulin (alone or in combination with an intermediate or long-acting insulin or an oral agent) to a comparator group, either subcutaneous insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/8,30-33\">",
"     8,30-33",
"    </a>",
"    ] or oral hypoglycemic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The subcutaneous insulin regimens in the comparator arms included a combination of basal (NPH, ultralente, or glargine given once or twice daily) and bolus (regular or lispro given two or three times daily) insulin or premixed biphasic insulin formulations (eg,",
"    <span class=\"nowrap\">",
"     70/30",
"    </span>",
"    biaspart). Inhaled insulin was administered with meals and was titrated according to study-specific glucose goals as was the subcutaneous insulin used as control. These short-term studies (up to 26 weeks) reported similar improvements in A1C in the inhaled and subcutaneous insulin groups [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Trials of longer duration (52 to 104 weeks) also reported similar improvements in A1C in the inhaled plus basal versus subcutaneous insulin groups [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/8,36\">",
"     8,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the studies comparing inhaled insulin to oral hypoglycemic regimens, the oral agents (sulfonylureas,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    , thiazolidinediones) were taken either alone or in combination with one or two other oral medications. Reductions in A1C were greater with inhaled insulin. However, doses of oral hypoglycemic agents were not adjusted to glycemic targets [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of combination inhaled insulin and oral agent therapy has also been studied [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/6,35,37-39\">",
"     6,35,37-39",
"    </a>",
"    ]. In trials comparing the addition of inhaled insulin versus an inhaled powder placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/6\">",
"     6",
"    </a>",
"    ] or no inhaled placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/35,37\">",
"     35,37",
"    </a>",
"    ], reductions in A1C were greater in the inhaled insulin group. In trials comparing the addition of inhaled insulin versus another oral agent (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or sulfonylurea) in patients inadequately controlled with one oral agent, inhaled insulin and the second oral agent were similarly effective in improving glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Whether inhaled insulin is capable of achieving the tight control goal, ie, A1C &lt;7 percent, is not clear from the studies conducted to date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H673161\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one case report, inhaled insulin was used successfully to manage subcutaneous insulin resistance syndrome, an exceedingly rare condition thought to be due to rapid degradation of insulin in the subcutaneous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Inhaled versus subcutaneous insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of six randomized trials (three in type 1 and three in type 2 diabetes) comparing inhaled insulin with rapidly-acting insulin injections concluded that glycemic control was equivalent, but patient satisfaction and quality of life was greater with inhaled insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/41\">",
"     41",
"    </a>",
"    ]. A meta-analysis of 11 studies comparing inhaled to subcutaneous insulin in patients with type 1 or type 2 diabetes reported the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a small difference in hemoglobin A1C decline from baseline favoring subcutaneous insulin (weighted mean difference, 0.08 percent [95% CI 0.03-0.14]); this difference was statistically significant only in patients with type 1 diabetes.",
"     </li>",
"     <li>",
"      The advantage of subcutaneous over inhaled insulin was evident in the two studies of 104 weeks duration (weighted mean difference, 0.18 percent [95% CI 0.09-0.27]), while there was no difference between subcutaneous versus inhaled insulin in studies of less than 24 weeks duration [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/23,30\">",
"       23,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inhaled insulin significantly decreased fasting plasma glucose compared to subcutaneous insulin (weighted mean difference -25.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [95% CI -41.9 to -9.7] respectively), displaying a more prolonged action than its pharmacokinetic profile would suggest [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the clinical studies, there was no difference between inhaled and subcutaneous insulin groups in proportion of patients with type 1 or type 2 diabetes reaching the hemoglobin A1C goal &lt;7 percent (risk ratio 1.15 [95% CI 0.96-1.38]; 27.1 percent with inhaled insulin versus 24.6 percent with subcutaneous insulin) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/26,28,29,32,33\">",
"     26,28,29,32,33",
"    </a>",
"    ]. However, these proportions are much lower compared to what was achieved with intensive subcutaneous insulin therapy in the Diabetes Control and Complications Trial or the UK Prospective Diabetes Study more than a decade earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Therefore, it is important to avoid having patients replace their current effective subcutaneous therapy with inhaled insulin and expect the same degree of glycemic control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Inhaled insulin versus oral hypoglycemic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of six studies that compared inhaled insulin to oral hypoglycemic agents in patients with type 2 diabetes reported the following [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhaled insulin significantly lowered hemoglobin A1C compared to oral agents (weighted mean difference, -1.04 percent [95% CI -1.59 to -0.49]) but with large heterogeneity among the trials.",
"     </li>",
"     <li>",
"      Patients with type 2 diabetes on inhaled insulin were more likely to achieve hemoglobin A1C &lt;7 percent compared to those on oral agents (risk ratio 1.87 percent [95% CI 1.07-3.25]; 30.9 percent versus 16.9 percent, respectively).",
"     </li>",
"     <li>",
"      Inhaled insulin significantly decreased fasting plasma glucose compared to oral agents (weighted mean difference 22.1",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [95% CI -44.0 to -0.3], respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The finding that inhaled insulin improves glycemia more than fixed doses of oral agents is not surprising and is consistent with previous observations that have reported a higher efficacy of insulin versus oral therapy in achieving glycemic targets in the long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/44\">",
"     44",
"    </a>",
"    ]. However, the superior glycemic outcome of inhaled insulin was seen in trials that were 12 weeks long and that exclusively titrated inhaled insulin to a glucose target while oral medication doses were not adjusted [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/34,35,37\">",
"     34,35,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the two studies lasting 24 weeks where the dose of the oral agents was titrated to glucose goals, there was little difference between inhaled and oral agents in glycemic efficacy, even though the studies were designed to show superiority of inhaled insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PATIENT SATISFACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study where patients received educational information, the availability of inhaled insulin as a treatment option increased approximately threefold the proportion of patients who would theoretically choose insulin overall [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/45\">",
"     45",
"    </a>",
"    ]. In trials of patients with type 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/25,26,46,47\">",
"     25,26,46,47",
"    </a>",
"    ] or type 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/31,33\">",
"     31,33",
"    </a>",
"    ] diabetes (all less than 24 weeks duration) that reported such data, there was a statistically significant increase in overall patient satisfaction and quality of life with inhaled compared to subcutaneous insulin. Areas of improvement included ease of administration, social comfort, convenience, mealtime flexibility, and ease of taking insulin many times a day. However, in a later trial comparing inhaled insulin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    to biphasic insulin, there was no difference in quality of life or attitudes toward insulin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If translated into clinical practice, enhanced patient satisfaction and willingness to embrace inhaled insulin may improve adherence and glycemic control. However, the increased patient acceptability of inhaled insulin reported in trials may be related to the novelty of the new delivery method, and it remains to be seen whether patients will exhibit the same degree of preference and adherence in clinical practice and how rapidly health care providers will adopt this new technology.",
"   </p>",
"   <p>",
"    In general, adherence also depends on the characteristics of the delivery device (eg, size, simplicity of use) and cost. For example, Technosphere inhaled insulin, currently in phase III trials, uses a thumb-size device for delivery, which should increase acceptability. However, it is important to note that in most studies, inhaled insulin has been compared to subcutaneous insulin delivered with syringes. The widespread use of pen devices for subcutaneous insulin administration has significantly improved ease of administration and compliance with subcutaneous insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS AND PRECAUTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled insulin is contraindicated or used with caution in a number of clinical situations, such as in smokers and in those with underlying pulmonary disease. It has been estimated that inhaled insulin would be inappropriate in 40 percent of community-based patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/49\">",
"     49",
"    </a>",
"    ]. Because of the progressive decline in pulmonary function associated with diabetes, the proportion of ineligible patients increases to two-thirds after another seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical trials, there was no difference between inhaled versus subcutaneous insulin in the proportion of patients reporting at least one episode of severe hypoglycemia (risk ratio 1.00 [95% CI 0.95-1.04]) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/22\">",
"     22",
"    </a>",
"    ], although some studies have reported less hypoglycemia with inhaled insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/8\">",
"     8",
"    </a>",
"    ]. As expected, given the improved glycemic control and previous observations with subcutaneous insulin therapy, there was a threefold increased risk of severe hypoglycemia in the inhaled insulin group compared to oral agents [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/22,50\">",
"     22,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of severe hypoglycemia with inhaled insulin in clinical practice is difficult to predict. Initially, it may be high due to the novelty of using a new delivery device and lack of experience, but the risk should diminish with more training and practice. Furthermore, dose adjustments have yet to be perfected for finer small-increment dosing needed to avoid hypoglycemia, especially in insulin-sensitive patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of inhaled insulin in patients with type 1 or type 2 diabetes, there was no difference in weight gain (0.2 to 1.5 kg) seen in either the inhaled or subcutaneous insulin groups, except in two studies which reported a weight difference of 1.3 to 1.6 kg in the inhaled compared to subcutaneous insulin group in patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/8,22,33\">",
"     8,22,33",
"    </a>",
"    ]. A retrospective analysis of pooled six-month data from five phase III Exubera studies reported less weight gain with Exubera than subcutaneous insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/51\">",
"     51",
"    </a>",
"    ]. In contrast, Exubera resulted in more weight gain compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    or sulfonylureas (adjusted mean difference 1.85 kg [95% CI 0.98-2.73]) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/35,37,38\">",
"     35,37,38",
"    </a>",
"    ], but there was no difference when compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    (adjusted mean difference 0.95 kg [95% CI 0.18-2.09]) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pulmonary safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major concern with inhaled insulin is the potential for pulmonary toxicity because of the immunogenic and growth-promoting properties of insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/52\">",
"     52",
"    </a>",
"    ]. It is important to note that all clinical trials selected participants with no recent history of smoking (at least six months) or underlying pulmonary disease, such as asthma, interstitial lung disease or chronic obstructive pulmonary disease. All participants had a normal chest x-ray and pulmonary function tests (PFT) at baseline.",
"   </p>",
"   <p>",
"    Combining data from all trials with Exubera, approximately 2 percent of patients on inhaled insulin discontinued treatment due to respiratory events versus 0 and 0.1 percent, respectively, in the comparator groups (subcutaneous insulin or oral hypoglycemic agents). In a 52-week trial comparing Technosphere inhaled insulin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    to subcutaneous biphasic insulin, a greater proportion of patients in the inhaled insulin group discontinued therapy because of adverse events (9 versus 4 percent with subcutaneous insulin) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/8\">",
"     8",
"    </a>",
"    ]. The most common respiratory event leading to discontinuation in patients in the inhaled insulin group is cough.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Cough",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common pulmonary symptom associated with inhaled insulin is non-productive cough in patients with either type 1 or type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/22\">",
"     22",
"    </a>",
"    ]. As an example, in the 52-week trial comparing Technosphere inhaled insulin plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/30/34279?source=see_link\">",
"     insulin glargine",
"    </a>",
"    with premixed biphasic subcutaneous insulin, cough was reported by 32 and 4 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/8\">",
"     8",
"    </a>",
"    ]. Cough occurs within seconds to minutes of inhaled insulin administration. It is mild in severity and not associated with changes in pulmonary function tests. Cough is noted early in the treatment course (within the first month) and diminishes in frequency and severity over time. Given its timing immediately following the inhalation, the cough appears to be directly related to the delivery method including potential irritation from excipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Forced expiratory volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;In clinical studies, inhaled insulin was associated with a greater decline from baseline in forced expiratory volume at one minute (FEV1) than the comparator group (weighted mean difference -0.031 liters [95% CI -0.043 to -0.020]) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/22\">",
"     22",
"    </a>",
"    ]. The decline in FEV1 was slowly progressive over the first three to six months, but stabilized in studies of duration up to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/23,30,36\">",
"     23,30,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Carbon monoxide-diffusing capacity (DLCO)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with type 1 diabetes, inhaled insulin was associated with a greater decline from baseline in DLCO than subcutaneous insulin (weighted mean difference -0.902",
"    <span class=\"nowrap\">",
"     ml/min/mmHg",
"    </span>",
"    [95% CI -1.546 to -0.258]). The decline in DLCO was evident in studies with duration equal to or less than 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/25-29\">",
"     25-29",
"    </a>",
"    ], while there was no difference in the two-year study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/23\">",
"     23",
"    </a>",
"    ]. In a 12-week crossover trial, DLCO returned towards baseline after patients were crossed over to subcutaneous insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/29\">",
"     29",
"    </a>",
"    ]. Among patients with type 2 diabetes, there was no difference from baseline in DLCO between inhaled insulin versus the comparator group in studies up to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/30,36\">",
"     30,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Long-term safety monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although these small declines in FEV1 and DLCO occurred early in the treatment and were non-progressing over two years, given that patients with diabetes have reduced baseline pulmonary function and more rapid declines in pulmonary function over time compared to healthy controls, even small declines in FEV1 and DLCO induced by inhaled insulin may have potential clinical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/53-56\">",
"     53-56",
"    </a>",
"    ]. Because Technosphere insulin is rapidly cleared from the alveolar-capillary bed, it may theoretically be associated with less lung-related toxicity. However, studies of longer duration (greater than two years) are needed to fully evaluate the long-term effects of inhaled insulin on lung function.",
"   </p>",
"   <p>",
"    Because of the effect of inhaled insulin on pulmonary function seen in short-term trials and the lack of safety data from long term trials, all patients should have pulmonary function assessed prior to initiating therapy with inhaled insulin, which includes spirometry (FEV1) and assessment of DLCO. The efficacy and safety of inhaled insulin in patients with baseline FEV1 or DLCO &lt;70 percent predicted have not been established and its use in this population is not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In long-term surveillance of the pre-marketing clinical trials, 6 of 4740 Exubera-treated patients and 1 of 4292 comparator-treated patients developed lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/57\">",
"     57",
"    </a>",
"    ]. There has also been one post-marketing report of a primary lung malignancy in a patient treated with Exubera. All of the patients diagnosed with lung cancer had a prior history of cigarette smoking and there are too few cases to determine if these cancers are related to Exubera.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials excluded patients with recent history of tobacco use because active smoking increases the rate of absorption and bioavailability of inhaled insulin in healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/58\">",
"     58",
"    </a>",
"    ], and changes in smoking habits greatly and rapidly alter the pharmacokinetics of inhaled insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/59\">",
"     59",
"    </a>",
"    ]. The effects of smoking on inhaled insulin are not formulation or device specific; rather, they reflect an increase in the alveolar epithelial permeability associated with smoking [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/60\">",
"     60",
"    </a>",
"    ]. Given the unpredictable absorption with changes in smoking behavior, inhaled insulin is contraindicated in patients who smoke including those who have quit smoking less than six months prior [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/61\">",
"     61",
"    </a>",
"    ]. If a patient starts or resumes smoking, inhaled insulin must be discontinued immediately. Smokers may represent up to a quarter of the diabetes population in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/62\">",
"     62",
"    </a>",
"    ]. The use of inhaled insulin is also problematic in patients who are passive smokers as the absorption may be reduced up to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Asthma, chronic obstructive pulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;All trials included patients with normal baseline lung function and there is only limited data available for patients with asthma and chronic obstructive pulmonary disease (COPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/22,61,63\">",
"     22,61,63",
"    </a>",
"    ]. After a single dose of inhaled insulin, non-diabetic patients with asthma absorbed less insulin than healthy participants resulting in diminished glucose reduction without a change in airway reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/64\">",
"     64",
"    </a>",
"    ]. Non-diabetic ex-smokers with COPD absorbed more insulin compared to controls in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/61\">",
"     61",
"    </a>",
"    ] but less in another [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/65\">",
"     65",
"    </a>",
"    ]. The absorption and pharmacokinetic profile of Technosphere inhalation appears to be unaltered in mild to moderate COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/63\">",
"     63",
"    </a>",
"    ]. Long-term efficacy and safety of inhaled insulin in patients with diabetes and asthma or COPD needs to be established in long-term studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Upper respiratory infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetics of inhaled insulin did not differ during an acute upper respiratory infection in non-diabetics, but there are no data regarding infections of the lower respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/66\">",
"     66",
"    </a>",
"    ]. As patients with diabetes are at greater risk for both chronic lung conditions and acute respiratory infections, a better characterization of the efficacy and safety of inhaled insulin in patients with diabetes and pulmonary disease is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhaled insulin is not recommended in patients with asthma or COPD and is contraindicated in any patient with unstable or poorly controlled lung disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacokinetics of inhaled insulin appear to change slightly with exercise. In one study of 23 non-smoking patients with type 1 diabetes treated with AERx inhaled insulin, 30 minutes of moderate exercise beginning 30, 120, or 240 minutes after dosing changed the shapes of the insulin curve compared with no exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/68\">",
"     68",
"    </a>",
"    ]. Starting the exercise 30 minutes after dosing resulted in a shorter time to maximal insulin concentration, but after stopping exercise, the insulin concentration decreased below the level of the no exercise group. The area under the insulin curve over two hours was either the same (for dosing 30 and 240 min prior to exercise) or decreased (for dosing 120 min prior to exercise) compared with no exercise.",
"   </p>",
"   <p>",
"    There is likely individual variation in the response to inhaled insulin with exercise. Individuals planning to use inhaled insulin prior to exercise should be aware of the possible changes in pharmacokinetics and increase glucose monitoring accordingly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Insulin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Higher concentrations of insulin antibodies were seen after inhaled compared with subcutaneous insulin, especially among patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/8,26-29,32,33,35\">",
"     8,26-29,32,33,35",
"    </a>",
"    ]. Over the time period of these trials, the level of insulin antibodies was not associated with any measured clinical outcomes, including inhaled insulin dosing requirements, glycemic control or adverse outcomes (allergic events, pulmonary side effects or hypoglycemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/69\">",
"     69",
"    </a>",
"    ]. However, the long-term clinical significance of the increase in antibodies is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H674895\">",
"    <span class=\"h2\">",
"     Cardiovascular safety profile",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preliminary findings of two separate studies suggest that treatment with the investigational Technosphere inhaled insulin (insulin human [rDNA origin]) at mealtimes does not result in excess cardiovascular events in type 1 or type 2 diabetes patients [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In addition, Technosphere did not produce clinically significant effects on heart rate, PR and QRS interval duration, or cardiac morphology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     DOSE AND ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given its pharmacokinetic profile, inhaled insulin should be administered immediately prior to meals (no more than 10 minutes prior to each meal). In patients with type 1 diabetes, inhaled insulin should be used in regimens that include a longer-acting insulin. In patients with type 2 diabetes, inhaled insulin can be used as monotherapy or in combination with oral agents or longer-acting insulins [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15353/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Currently, there is no inhaled insulin available for clinical use. A formulation of inhaled insulin that is still in phase III clinical trials (Technosphere) contains insulin particles optimized for inhalation (2.5 micrometers in diameter), which dissolve rapidly after inhalation. The particles are delivered with a thumb-sized inhaler with increased dose-flexibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1 diabetes &mdash; Insulin therapy is essential in all patients with type 1 diabetes. We recommend subcutaneous rapid-acting insulin rather than inhaled insulin for the management of type 1 diabetes (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Inhaled versus subcutaneous insulin'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=see_link\">",
"       \"Insulin therapy in adults with type 1 diabetes mellitus\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Based on \"non-inferiority\" studies, inhaled insulin offers an alternative non-invasive option for premeal insulin administration with comparable glycemic efficacy to subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      . However, in these studies, neither the inhaled insulin nor the control arms achieved optimal glycemic efficacy that has been achieved with injection regimens in previous trials with insulin.",
"      <br/>",
"      <br/>",
"      In addition, dose adjustments with the formerly available inhaled insulin device were not perfected for finer small-increment dosing needed to avoid hypoglycemia, especially in insulin-sensitive patients.",
"     </li>",
"     <li>",
"      Type 2 diabetes &mdash; Initial treatment for type 2 diabetes should be diet modification and exercise with concurrent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      , followed by additional oral agents or subcutaneous insulin if normoglycemia is not achieved. Insulin therapy should not be delayed when it becomes necessary. For the majority of patients, we suggest intermediate or long-acting (\"basal\") insulin administration as the first step in insulin treatment. For type 2 diabetic patients who subsequently require premeal rapid-acting insulin, we suggest subcutaneous rapid-acting insulin rather than inhaled insulin (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"       \"Management of persistent hyperglycemia in type 2 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other &mdash; Inhaled insulin may represent an alternative therapeutic option in patients with documented subcutaneous insulin resistance syndrome.",
"     </li>",
"     <li>",
"      Smoking &mdash; We recommend subcutaneous rapid-acting insulin rather than inhaled insulin in smokers with diabetes who require insulin therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Smoking increases the rate of absorption and bioavailability of inhaled insulin in healthy volunteers, and changes in smoking habits greatly and rapidly alter the pharmacokinetics of inhaled insulin, increasing the risk of hypoglycemia. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Smoking'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Asthma/COPD/other",
"      </span>",
"      lung disease &mdash; The efficacy and safety of inhaled insulin in patients with baseline FEV1 or DLCO &lt;70 percent predicted have not been established, and its use in this population is not recommended. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Asthma, chronic obstructive pulmonary disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference between inhaled versus subcutaneous insulin in the proportion of patients reporting at least one episode of severe hypoglycemia. However, there was a threefold increased risk of severe hypoglycemia in the inhaled insulin group compared to oral agents. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhaled insulin is associated with a dry non-productive cough and mild non-progressive decline in pulmonary function testing. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pulmonary safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There was no difference in weight gain between the inhaled and subcutaneous insulin groups. However, there was an increase in weight with inhaled insulin compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"      or sulfonylurea use.",
"     </li>",
"     <li>",
"      Higher concentrations of insulin antibodies were seen after inhaled compared to subcutaneous insulin, which is of uncertain clinical significance. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Insulin antibodies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients being considered for inhaled insulin require assessment of pulmonary function at baseline, after six months of therapy, and annually thereafter, even in the absence of pulmonary symptoms.",
"      <br/>",
"      <br/>",
"      If patients on inhaled insulin have a confirmed decline of &ge;20 percent in FEV1 from baseline, inhaled insulin should be discontinued. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Long-term safety monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Pittas AG, Greenberg AS. Contemporary Diagnosis and Management of Diabetes, Handbooks in Health Care Co., Newtown, PA 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/2\">",
"      Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care 2005; 28:2673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/3\">",
"      Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997; 20:292.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Approves First Ever Inhaled Insulin Combination Product for Treatment of Diabetes, January 2006. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108585.htm (Accessed on June 26, 2006).",
"    </li>",
"    <li>",
"     Pharmaceutical Approvals Monthly 2008; 13:17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/6\">",
"      Rosenstock J, Bergenstal R, Defronzo RA, et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents. Diabetes Care 2008; 31:2177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/7\">",
"      Steiner S, Pf&uuml;tzner A, Wilson BR, et al. Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002; 110:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/8\">",
"      Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 2010; 375:2244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/9\">",
"      Agu RU, Ugwoke MI, Armand M, et al. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001; 2:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/10\">",
"      Tack CJ, Christov V, de Galan BE, et al. Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. J Diabetes Sci Technol 2008; 2:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/11\">",
"      Cassidy JP, Amin N, Marino M, et al. Insulin lung deposition and clearance following Technosphere&reg; insulin inhalation powder administration. Pharm Res 2011; 28:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/12\">",
"      Rave K, Heise T, Heinemann L, Boss AH. Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol 2008; 2:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/13\">",
"      Rave K, Bott S, Heinemann L, et al. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005; 28:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/14\">",
"      Rave KM, Nosek L, de la Pe&ntilde;a A, et al. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005; 28:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/15\">",
"      Rave K, Nosek L, Heinemann L, et al. Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles. Diabet Med 2004; 21:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/16\">",
"      Kapitza C, Heise T, Fishman RS, et al. Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol. Diabetes Technol Ther 2004; 6:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/17\">",
"      Kim D, Mudaliar S, Chinnapongse S, et al. Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes. Diabetes Care 2003; 26:2842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/18\">",
"      Perera AD, Kapitza C, Nosek L, et al. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes. Diabetes Care 2002; 25:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/19\">",
"      Brunner GA, Balent B, Ellmerer M, et al. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001; 44:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/20\">",
"      Rave K, Heise T, Pf&uuml;tzner A, Boss AH. Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care 2007; 30:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/21\">",
"      Kapitza C, Hompesch M, Scharling B, Heise T. Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol Ther 2004; 6:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/22\">",
"      Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med 2006; 145:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/23\">",
"      Skyler JS, Jovanovic L, Klioze S, et al. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Diabetes Care 2007; 30:579.",
"     </a>",
"    </li>",
"    <li>",
"     Exubera Study #1027. Advisory Committee Briefing Document: Exubera (insulin [rDNA origin] powder for oral inhalation). file://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4169B1_01_01-Pfizer-Exubera.pdf (Accessed on June 22, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/25\">",
"      Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/26\">",
"      Quattrin T, B&eacute;langer A, Bohannon NJ, et al. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/27\">",
"      Heise T, Bott S, Tusek C, et al. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care 2005; 28:2161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/28\">",
"      Skyler JS, Weinstock RS, Raskin P, et al. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005; 28:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/29\">",
"      Garg S, Rosenstock J, Silverman BL, et al. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes. Diabetologia 2006; 49:891.",
"     </a>",
"    </li>",
"    <li>",
"     Exubera Study #1029. Advisory Committee Briefing Document: Exubera (insulin [rDNA origin] powder for oral inhalation). file://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4169B1_01_01-Pfizer-Exubera.pdf (Accessed on June 22, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/31\">",
"      Cappelleri JC, Cefalu WT, Rosenstock J, et al. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002; 24:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/32\">",
"      Hermansen K, R&ouml;nnemaa T, Petersen AH, et al. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004; 27:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/33\">",
"      Hollander PA, Blonde L, Rowe R, et al. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27:2356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/34\">",
"      DeFronzo RA, Bergenstal RM, Cefalu WT, et al. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: a 12-week, randomized, comparative trial. Diabetes Care 2005; 28:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/35\">",
"      Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005; 143:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/36\">",
"      Rosenstock J, Cefalu WT, Hollander PA, et al. Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. Diabetes Care 2008; 31:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/37\">",
"      Weiss SR, Cheng SL, Kourides IA, et al. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 2003; 163:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/38\">",
"      Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care 2006; 29:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/39\">",
"      Barnett AH, Dreyer M, Lange P, Serdarevic-Pehar M. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care 2006; 29:1818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/40\">",
"      van Alfen-van der Velden AA, Noordam C, de Galan BE, et al. Successful treatment of severe subcutaneous insulin resistance with inhaled insulin therapy. Pediatr Diabetes 2010; 11:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/41\">",
"      Royle P, Waugh N, Deakin M, Philip S. WITHDRAWN: Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev 2009; :CD003890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/42\">",
"      Mikhail NE, Wali S, Cope D. Effect of inhaled insulin on fasting and postprandial plasma glucose. Ann Intern Med 2007; 146:821; author reply 821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/43\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/44\">",
"      Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281:2005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/45\">",
"      Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care 2005; 28:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/46\">",
"      Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001; 24:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/47\">",
"      Testa MA, Simonson DC. Satisfaction and quality of life with premeal inhaled versus injected insulin in adolescents and adults with type 1 diabetes. Diabetes Care 2007; 30:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/48\">",
"      Summers KH, Szeinbach SL, Lenox SM. Preference for insulin delivery systems among current insulin users and nonusers. Clin Ther 2004; 26:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/49\">",
"      Davis TM, Davis WA. An assessment of eligibility for inhaled insulin (Exubera): the Fremantle Diabetes Study. Diabetes Care 2007; 30:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/50\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/51\">",
"      Hollander PA, Krasner A, Klioze S, et al. Body weight changes associated with insulin therapy: a retrospective pooled analysis of inhaled human insulin (Exubera) versus subcutaneous insulin in five controlled Phase III trials. Diabetes Care 2007; 30:2508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/52\">",
"      Hsia CC, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med 2005; 118:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/53\">",
"      Sreeja CK, Samuel E, Kesavachandran C, Shashidhar S. Pulmonary function in patients with diabetes mellitus. Indian J Physiol Pharmacol 2003; 47:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/54\">",
"      Innocenti F, Fabbri A, Anichini R, et al. Indications of reduced pulmonary function in type 1 (insulin-dependent) diabetes mellitus. Diabetes Res Clin Pract 1994; 25:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/55\">",
"      Goldman MD. Lung dysfunction in diabetes. Diabetes Care 2003; 26:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/56\">",
"      Davis WA, Knuiman M, Kendall P, et al. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care 2004; 27:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/57\">",
"      The Pink Sheet. 2008; 70:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/58\">",
"      Himmelmann A, Jendle J, Mell&eacute;n A, et al. The impact of smoking on inhaled insulin. Diabetes Care 2003; 26:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/59\">",
"      Becker RH, Sha S, Frick AD, Fountaine RJ. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care 2006; 29:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/60\">",
"      Jones JG, Minty BD, Lawler P, et al. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1980; 1:66.",
"     </a>",
"    </li>",
"    <li>",
"     Exubera US Package Insert file://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021868lbl.pdf (Accessed on October 01, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/62\">",
"      Haire-Joshu D, Glasgow RE, Tibbs TL. Smoking and diabetes. Diabetes Care 1999; 22:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/63\">",
"      Potocka E, Amin N, Cassidy J, et al. Insulin pharmacokinetics following dosing with Technosphere insulin in subjects with chronic obstructive pulmonary disease. Curr Med Res Opin 2010; 26:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/64\">",
"      Henry RR, Mudaliar SR, Howland WC 3rd, et al. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care 2003; 26:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/65\">",
"      Rave K, de la Pe&ntilde;a A, Tibaldi FS, et al. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability. Diabetes Care 2007; 30:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/66\">",
"      McElduff A, Mather LE, Kam PC, Clauson P. Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin Diabetes Management System. Br J Clin Pharmacol 2005; 59:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/67\">",
"      Smith SA, Poland GA. Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care 2000; 23:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/68\">",
"      Petersen AH, K&ouml;hler G, Korsatko S, et al. The effect of exercise on the absorption of inhaled human insulin via the AERx insulin diabetes management system in people with type 1 diabetes. Diabetes Care 2007; 30:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/69\">",
"      Fineberg SE, Kawabata T, Finco-Kent D, et al. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005; 90:3287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/70\">",
"      Baughman RA, Haworth PC, Litwin JS, et al. No cardiac effects found with therapeutic and supratherapeutic doses of Technosphere inhalation powder:Results from a thorough QTc clinical study. Diabetes 2011; 60:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15353/abstract/71\">",
"      Bilheimer DW, Ren H, Boss AH. Analysis of cardiovascular adverse events in patients with type 1 or type 2 diabetes enrolled in selected therapeutic trials in the phase 2/3 Technosphere insulin development program. Diabetes 2011; 60:Supplement 1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1764 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15353=[""].join("\n");
var outline_f14_63_15353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Delivery system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Type 1 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Type 2 diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H673161\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Inhaled versus subcutaneous insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Inhaled insulin versus oral hypoglycemic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PATIENT SATISFACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SIDE EFFECTS AND PRECAUTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pulmonary safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Cough",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Forced expiratory volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Carbon monoxide-diffusing capacity (DLCO)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Long-term safety monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Asthma, chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Upper respiratory infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Insulin antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H674895\">",
"      Cardiovascular safety profile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      DOSE AND ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=related_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/55/15225?source=related_link\">",
"      General principles of insulin therapy in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24906?source=related_link\">",
"      Insulin therapy in adults with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=related_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=related_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_63_15354="Constipation in children: Etiology and diagnosis";
var content_f14_63_15354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Constipation in children: Etiology and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/63/15354/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15354/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/63/15354/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15354/contributors\">",
"     William J Klish, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?14/63/15354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?14/63/15354/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?14/63/15354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation is common among children, accounting for an estimated 3 to 5 percent of all visits to pediatricians. Estimates of the true prevalence of constipation vary between 1 and 30 percent, even when uniform criteria are used [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/1\">",
"     1",
"    </a>",
"    ]. The peak prevalence is during the pre-school years in most reports. There is no consistent effect of gender on the prevalence of childhood constipation.",
"   </p>",
"   <p>",
"    Complaints range from infrequent bowel evacuation, hard small feces, difficult or painful evacuation of large-diameter stools, and fecal incontinence (voluntary or involuntary evacuation of feces into the underwear, also known as encopresis) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44182?source=see_link\">",
"     \"Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although constipation is common and varies considerably in its severity, the complaint should not be ignored. The clinician has an important role in identifying the small fraction of children with organic causes of constipation. Moreover, children with functional constipation will benefit from prompt and thorough treatment interventions. Delayed or inadequate intervention may result in stool withholding behavior, with worsening constipation and psychosocial consequences.",
"   </p>",
"   <p>",
"    The diagnosis and etiology of constipation in children will be reviewed here. The prevention and treatment of constipation is described separately. The evaluation of children with fecal incontinence, which is often but not always associated with constipation, also is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2710?source=see_link\">",
"     \"Prevention and treatment of acute constipation in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36298?source=see_link\">",
"     \"Treatment of chronic functional constipation and fecal incontinence in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44182?source=see_link\">",
"     \"Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NORMAL STOOLING PATTERNS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation is generally understood as a delay or difficulty in defecation, but the interpretation of the term \"delay\" varies broadly with age. Because of changes with growth and development, the frequency and type of stools must be interpreted in the context of the child's age and stage of maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the full-term newborn infant, the first bowel movement usually occurs within 36 hours of birth, but may happen later in infants who are born prematurely; 90 percent of normal newborns pass meconium within the first 24 hours of life.",
"     </li>",
"     <li>",
"      During the first week of life, infants pass a mean of four stools per day, although this is variable depending upon whether infants are breastfed or receiving formula.",
"     </li>",
"     <li>",
"      During the first three months of life, breastfed infants pass a mean of three stools per day, whereas formula-fed infants pass a mean of two stools per day [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      By 2 years of age, the number of bowel movements has fallen to just under two per day.",
"     </li>",
"     <li>",
"      After 4 years of age, it is slightly more than one per day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The frequency of bowel movements is influenced by the mode of feeding and the type of formula [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Some normal breastfed newborns may stool with each feeding or may not have a bowel movement any more often than every 7 to 10 days. Formula-fed infants tend to have several each day, but there is variation between formulas. Some soy formulas tend to produce harder stools compared to milk-based formulas, while hydrolyzed casein formulas produce looser stools [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gradual decrease in bowel movement frequency with advancing age correlates with changes in transit time and varying patterns of colonic motility. The mean total gastrointestinal transit time is 8.5 hours at 1 to 3 months of age, 16 hours at 4 to 24 months, 26 hours at 3 to 13 years of age, and 30 to 48 hours after puberty [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic criteria have been established by the panel of the Multinational Working Teams to Develop Criteria for Functional Disorders (Rome III) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In contrast to the earlier Rome II criteria, fecal incontinence (now the preferred term over encopresis or soiling) was added as a diagnostic criterion for functional constipation, functional fecal retention was incorporated into the category of functional constipation, and the time requirement for chronicity was shortened to encourage earlier identification and treatment.",
"   </p>",
"   <p>",
"    The Rome III report defines diagnostic criteria for the following categories of functional disorders of defecation in children:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Functional constipation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In infants and preschool children",
"     </li>",
"     <li>",
"      In children 4 to 18 years old",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infant dyschezia",
"     </li>",
"     <li>",
"      Nonretentive fecal incontinence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The definition of functional constipation requires two of six criteria describing stool frequency, hardness, size, fecal incontinence, or volitional stool retention; the symptoms must be present for one month in infants and toddlers, and two months in older children (",
"    <a class=\"graphic graphic_table graphicRef57882 \" href=\"UTD.htm?23/14/23788\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infant dyschezia is defined as at least 10 minutes of straining and crying before successful passage of soft stool in an otherwise healthy infant younger than 6 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/9\">",
"     9",
"    </a>",
"    ]. The symptom is caused by failure to relax the pelvic floor during the defecation effort, and generally resolves spontaneously.",
"   </p>",
"   <p>",
"    Fecal incontinence can occur in the context of functional constipation (80 percent), or without constipation (\"nonretentive incontinence\", 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/10\">",
"     10",
"    </a>",
"    ]. Among children with constipation, there are no clear differences in pathophysiology or psychology between those with and without fecal incontinence. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44182?source=see_link\">",
"     \"Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Functional versus organic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major causes of constipation in children can be divided broadly into two categories: functional and organic. At any age, it is important to distinguish between functional constipation and serious organic causes such as intestinal obstruction.",
"   </p>",
"   <p>",
"    Functional constipation is an umbrella term describing persistent, difficult, infrequent, or seemingly incomplete defecation without evidence of a primary anatomic or biochemical cause [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/11\">",
"     11",
"    </a>",
"    ]. Functional constipation accounts for most constipation-related symptoms in children and infants, except those presenting during the neonatal period, when organic causes are more likely. However, infant dyschezia is a frequent cause of constipation-like symptoms in neonates and young infants. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Diagnostic criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Organic causes are responsible for fewer than 5 percent of children with constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/4,12\">",
"     4,12",
"    </a>",
"    ]. They include (",
"    <a class=\"graphic graphic_table graphicRef82181 graphicRef70206 graphicRef61392 \" href=\"UTD.htm?13/34/13869\">",
"     table 2A-C",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomic malformations such as anal stenosis, imperforate anus, anterior displaced anus, sacral teratoma (pelvic mass).",
"     </li>",
"     <li>",
"      Metabolic and gastrointestinal causes such as hypothyroidism, hypercalcemia, hypokalemia, cystic fibrosis, diabetes mellitus, multiple endocrine neoplasia type 2B, and gluten enteropathy (celiac disease).",
"     </li>",
"     <li>",
"      Neuropathic conditions such as spinal cord abnormalities or trauma, neurofibromatosis, static encephalopathy, or tethered cord.",
"     </li>",
"     <li>",
"      Intestinal nerve and muscle disorders such as Hirschsprung disease, intestinal neuronal dysplasia, visceral myopathies, or neuropathies.",
"     </li>",
"     <li>",
"      Abnormal abdominal musculature such as prune-belly, Down syndrome, and gastroschisis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44407?source=see_link\">",
"       \"Prune-belly syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"       \"Clinical features and diagnosis of Down syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Connective tissue disorders (eg, scleroderma).",
"     </li>",
"     <li>",
"      Certain drugs such as antacids, opiates, and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"       phenobarbital",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Miscellaneous other disorders such as cow's milk protein intolerance; heavy metal (lead) ingestion; vitamin D intoxication, and botulism [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF FUNCTIONAL CONSTIPATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three periods in which the infant and developing child are particularly prone to develop constipation. The first occurs after the introduction of cereals and solid food into the infant's diet, the second with toilet training, and the third during the start of school [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/4\">",
"     4",
"    </a>",
"    ]. Each of these milestones represents potential challenges and a sense of achievement; on the other hand, each has the potential to convert defecation into an unpleasant experience. That unhappy experience may prompt the child to consciously or subconsciously try to avoid repeating it.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Painful defecation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Painful defecation is a crucial but often silent clue as a potential trigger to long-term constipation that must be investigated with care (",
"    <a class=\"graphic graphic_table graphicRef55786 \" href=\"UTD.htm?16/49/17179\">",
"     table 2F",
"    </a>",
"    ). The frequency of painful defecation as a trigger for chronic constipation was estimated in a retrospective study of 227 children (35 percent of whom were younger than 3 years of age) who presented to a pediatric gastroenterologist with difficult defecation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/13\">",
"     13",
"    </a>",
"    ]. Of the younger children, 86 percent presented with pain, 71 percent with impaction, and 97 percent with severe withholding. The younger children had painful defecation for a mean of 14 &plusmn; 9 months before presentation. Of the older children, 85 percent presented with fecal soiling, 57 percent with pain, 73 percent with fecal impaction, and 96 percent exhibited withholding. Sixty-three percent of the children presenting with fecal soiling had a history of painful defecation beginning before 3 years of age.",
"   </p>",
"   <p>",
"    These observations suggest that painful defecation frequently precedes chronic fecal impaction and fecal soiling. As a result, early, effective treatment of painful defecation in infancy might lower the incidence of chronic fecal impaction and fecal soiling in children of school age.",
"   </p>",
"   <p>",
"    When the child avoids defecation because of pain, stool accumulates in the rectum and becomes hard, causing even more pain when they pass. With chronic rectal distention, the anal canal shortens, the internal anal sphincter dilates, and when the external anal sphincter relaxes, semisolid stool leaks onto the perianal skin and clothing. The initial problem must be addressed as soon as possible to avoid this ongoing spiral.",
"   </p>",
"   <p>",
"    Children who avoid defecation because of a negative experience have a form of functional or behavioral constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/14\">",
"     14",
"    </a>",
"    ]. The only abnormal motor activity in most children with chronic constipation is found in the rectum, which may dilate to such an extent that insufficient pressure is generated to push the stool into the anal canal. Although some manometric studies have suggested that some constipated children have \"anismus,\" (contraction of the external sphincter when they try to defecate) others have assessed this finding as merely the manometric equivalent of withholding [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/14\">",
"     14",
"    </a>",
"    ]. The child's response to ignore the urge to defecate (initially a conscious decision) becomes automatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Toilet training issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toilet training is a developmental milestone that affects self-esteem and independence. To master toileting, a toddler must develop the ability and interest in retaining a bowel movement until it can be released into the toilet. This behavior frequently leads to less frequent defecation, and sometimes to hard and painful stools. The problem may be exacerbated if toilet training is vigorously encouraged before the child is developmentally ready. Power struggles may develop if it is forced on a child by a parent, potentially leading to various problems, one of which is constipation.",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics emphasizes that parents should avoid pushing their children into toilet training, and instead, watch for signs that the child is developmentally ready [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Toilet training works best when it is aligned with the child's signs of readiness to progress past each phase. Visits to the healthcare provider can help parents anticipate the steps along the way in the process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37592?source=see_link\">",
"     \"Toilet training\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Dietary considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modern diet has been cited as the chief suspect in childhood constipation and related problems such as recurrent abdominal pain. Most studies indicate that fewer than 10 percent of children presenting with recurrent abdominal pain have an identifiable organic etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/12\">",
"     12",
"    </a>",
"    ]. Because constipation is a common complaint among children who present with chronic abdominal pain, the impact of diet should be thoroughly investigated.",
"   </p>",
"   <p>",
"    Unlike previous generations, children today consume large amounts of highly processed food items at the expense of fruit, vegetables, or fiber. Functional constipation can be improved by providing appropriate amounts of fiber and fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lack of fiber was revealed as a potential contributor to idiopathic chronic constipation in a large, case-control study in several counties in Greece, involving 291 children with constipation and 1602 controls ages 2 to 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/18\">",
"     18",
"    </a>",
"    ]. Nutritional data were obtained from a three-day dietary record and a dietary history. Constipated children had lower intake of calories and nutrients, lower body",
"    <span class=\"nowrap\">",
"     weight/height,",
"    </span>",
"    and higher prevalence of reported anorexia. Lack of dietary fiber was an independent predictor of chronic constipation. Nonetheless, chronic functional constipation frequently does not respond to treatment with added dietary fiber or fiber supplements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36298?source=see_link\">",
"     \"Treatment of chronic functional constipation and fecal incontinence in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While a balanced diet including fruits, vegetables, and fiber is recommended in all children and may be useful in preventing or treating mild constipation, there is little evidence that adding fiber to the diet is an effective treatment for severe constipation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36298?source=see_link\">",
"     \"Treatment of chronic functional constipation and fecal incontinence in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between cow&rsquo;s milk and constipation has been controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/19\">",
"     19",
"    </a>",
"    ]. Some children do seem to have less of a problem when switched from cow&rsquo;s milk to a soy formula [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/20\">",
"     20",
"    </a>",
"    ]. Initially this was thought to be caused by an allergic mechanism, but this also remains controversial. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Cow's milk intolerance'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Family history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children in some families may be predisposed to developing constipation. In one longitudinal study, a family history of constipation was observed in more than one-half of children with chronic constipation and soiling seen over a seven-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/21\">",
"     21",
"    </a>",
"    ]. The reasons for this familial tendency are not clear, and may include shared genetic, environmental, or dietary factors [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ORGANIC CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, there are multiple organic causes of constipation. Their relative frequency among constipated infants and children is not well defined. The following sections will focus on relatively frequent considerations in clinical practice and miscellaneous less common disorders that may be easy to miss (",
"    <a class=\"graphic graphic_table graphicRef57393 graphicRef64759 graphicRef82181 graphicRef61392 graphicRef55786 graphicRef70206 \" href=\"UTD.htm?16/25/16798\">",
"     table 2A-F",
"    </a>",
"    ). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cow's milk intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumption of cow's milk has been associated with a variety of gastrointestinal disturbances including gastroesophageal reflux disease, enterocolitis, and constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the most detailed studies to evaluate the association with constipation focused on 65 children (ages 11 to 72 months) with chronic constipation who had been referred to a pediatric gastroenterology clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients were given cow or soy milk for two weeks; feedings were reversed after a one-week washout period. A response was defined as eight or more bowel movements during the treatment period. A response was observed in 68 percent of children when fed with soy milk compared with none of the children with cow's milk. Responding children were more likely to have coexistent rhinitis, dermatitis, or bronchospasm, suggesting an allergic basis for symptoms. They were also more likely to have anal fissures and erythema or edema at baseline, evidence of inflammation of the rectal mucosa and signs of hypersensitivity (such as specific IgE antibodies to cow's milk antigens). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hirschsprung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hirschsprung disease (HD) is a motor disorder of the colon caused by the failure of neural crest cells (precursors of colonic ganglion cells) to migrate completely during colonic development. As a result, the affected segment of the colon fails to relax, causing a functional obstruction. Hirschsprung disease is associated with several congenital abnormalities and syndromes including Down syndrome, and cardiac disease (especially septal defects). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hirschsprung disease should be considered in the following circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset of symptoms in the first week of life",
"     </li>",
"     <li>",
"      Delayed passage of meconium (after 48 hours of life)",
"     </li>",
"     <li>",
"      Abdominal distension",
"     </li>",
"     <li>",
"      Vomiting",
"     </li>",
"     <li>",
"      A transition zone on a contrast enema",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While HD is usually diagnosed in newborns or within the first few months of life, patients with less severe disease may not be diagnosed until later in childhood. Such patients typically have a history of chronic constipation and failure to thrive. The physical examination may reveal a tight anal canal and empty ampulla.",
"   </p>",
"   <p>",
"    Hirschsprung disease also may present initially as enterocolitis, a potentially life-threatening illness in which patients have a sepsis-like picture with fever, vomiting, and diarrhea that can progress to toxic megacolon, a potentially life-threatening complication. Delay in diagnosis increases the risk for enterocolitis. This disorder arises most commonly between the second and third months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/6\">",
"     6",
"    </a>",
"    ]. Although uncommon, HD can be newly diagnosed in adults. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34950?source=see_link\">",
"     \"Emergency complications of Hirschsprung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cystic fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystic fibrosis (CF) is the most common fatal autosomal recessive disease among Caucasian populations, with a frequency of 1 in 2000 to 3000 live births. The usual presenting symptoms and signs include persistent pulmonary infection, pancreatic insufficiency, and elevated sweat chloride levels. However, many patients demonstrate mild or atypical symptoms, including constipation, and clinicians should remain alert to the possibility of CF even when only a few of the usual features are present.",
"   </p>",
"   <p>",
"    Meconium ileus is the presenting problem in 10 to 20 percent of newborns with CF, and is virtually pathognomonic of the diagnosis. Episodes of small bowel obstruction also may occur in older children and adults, and have been variously termed \"meconium ileus equivalent\" or \"distal ileal obstructive syndrome\". Surgical intervention may be required to alleviate the obstruction, and may lead to recurrent problems from adhesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34369370\">",
"    <span class=\"h2\">",
"     Anorectal anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abnormalities of anorectal development represent a spectrum from high imperforate anus to anteriorly displaced anus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/28\">",
"     28",
"    </a>",
"    ]. In the majority of cases of imperforate anus, a fistula is present, and the anomaly may be overlooked initially because some meconium may be passed through the fistula or vaginal opening (",
"    <a class=\"graphic graphic_figure graphicRef78404 \" href=\"UTD.htm?36/1/36883\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An anteriorly displaced anus (\"ectopic anus\") probably causes constipation only when the anus is substantially displaced [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. There is little evidence that mild or moderate anterior displacement of the anus contributes to constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The abnormality is suggested by noting that the anal opening is not located in the center of the pigmented area of the perineum (",
"    <a class=\"graphic graphic_picture graphicRef62573 graphicRef65755 \" href=\"UTD.htm?16/8/16519\">",
"     picture 1A-B",
"    </a>",
"    ). The diagnosis is supported by measuring the Anal Position Index (API), also known as the anogenital index. The API is defined by the following ratios [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; Girls:",
"    <span class=\"nowrap\">",
"     Anus-fourchette/coccyx-fourchette",
"    </span>",
"   </p>",
"   <p>",
"    mean &plusmn; SD for API is 0.45 &plusmn; 0.08",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; Boys:",
"    <span class=\"nowrap\">",
"     Anus-scrotum/coccyx-scrotum",
"    </span>",
"   </p>",
"   <p>",
"    mean &plusmn; SD for API is 0.54 &plusmn; 0.07",
"   </p>",
"   <p>",
"    Some studies define anteriorly displaced anus as an API &lt;2 SD from the mean (eg, &lt;0.29 in girls and &lt;0.40 in boys) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/33\">",
"     33",
"    </a>",
"    ]. By definition, these cutoffs identify approximately 4 percent of infants with the most anteriorly located anuses. If intractable constipation is present, these children should be evaluated by an expert for consideration of anorectal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies use cutoffs of &lt;0.34 for girls and &lt;0.46 for boys, definitions that lead to very high rates of anteriorly displaced anus (43 percent of girls and 25 percent of boys) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/31\">",
"     31",
"    </a>",
"    ]. These cutoffs do not appear to be useful in identifying clinically relevant anterior displacement, as there is no correlation with constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Because of these variable findings, we suggest using the API only as a guide; decisions about surgery should not be based purely on the basis of the API.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other causes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infantile botulism &mdash; Botulism is a rare but potentially life-threatening neuroparalytic syndrome resulting from the action of a neurotoxin elaborated by the spore-forming microorganism Clostridium botulinum. Infantile botulism is the most frequent form of the disease, with a mean of 71 cases annually in the United States and a mortality rate up to 5 percent. Honey has been directly linked to infant botulism. Corn syrup, although implicated, has never been directly linked with botulism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16426?source=see_link&amp;anchor=H19#H19\">",
"       \"Food poisoning in children\", section on 'Botulism'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Disease presentation and severity are quite variable in infant botulism, most likely as a result of size of the bacterial inoculum and host susceptibility. The initial presentation may simply involve constipation, shortly followed by weakness, feeding difficulties, descending or global hypotonia, drooling, anorexia, irritability, and weak cry. The autonomic nervous system is usually affected first with findings of dry mucous membranes, blood pressure instability, arrhythmias, as well as fecal and urinary retention. This is generally followed by descending motor weakness beginning with the cranial nerves, followed by trunk and then limb involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=see_link\">",
"       \"Botulism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lead poisoning &mdash; The clinical manifestations of lead poisoning vary depending upon the lead level and the age of the exposed individual. Lead colic, which includes sporadic vomiting, intermittent abdominal pain, and constipation, may occur with a lead level as low as 60",
"      <span class=\"nowrap\">",
"       microgram/dL",
"      </span>",
"      (2.90",
"      <span class=\"nowrap\">",
"       micromol/L).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"       \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypothyroidism &mdash; Constipation may be seen in children with congenital or acquired hypothyroidism. Symptoms and signs that may be present in the neonatal period include lethargy, slow movement, hoarse cry, feeding problems, constipation, macroglossia, umbilical hernia, large fontanels, hypotonia, dry skin, hypothermia, and prolonged jaundice. A few newborn infants with thyroid dyshormonogenesis have a palpable goiter, but it usually appears later. More than 95 percent of newborn infants with congenital hypothyroidism have few if any clinical manifestations of hypothyroidism because some T4 crosses the placenta. The most common manifestation of hypothyroidism in children with acquired hypothyroidism is short stature. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"       \"Clinical features and detection of congenital hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link\">",
"       \"Acquired hypothyroidism in childhood and adolescence\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link\">",
"       \"Diagnostic approach to short stature\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"       \"Clinical manifestations of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intestinal pseudo-obstruction &mdash; Chronic intestinal pseudo-obstruction is a rare, congenital, or acquired condition caused by a group of various types of nerve and muscle disorders that result in obstructive intestinal symptoms without any mechanical obstruction. Presenting symptoms depend upon the area of the gastrointestinal tract that is affected, and may include nausea, vomiting, abdominal pain, constipation,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      other manifestations [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/34-36\">",
"       34-36",
"      </a>",
"      ]. The primary forms are mostly congenital; secondary disorders are uncommon in children. Normal antroduodenal manometry rules out pseudo-obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/37\">",
"       37",
"      </a>",
"      ]. Colonic transit time (CTT) is typically very prolonged (all patients had CTT &gt;96 hours in one study) [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/34\">",
"       34",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=see_link\">",
"       \"Chronic intestinal pseudo-obstruction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neurologic handicaps &mdash; Children with neurologic impairments, particularly cerebral palsy and spinal dysraphism, often have problems related to defecation. Constipation is found in the majority of children with cerebral palsy, resulting from intestinal hypotonia and motor paralysis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/4,35\">",
"       4,35",
"      </a>",
"      ]. Children with neurologic handicaps often are fed through gastrostomy tubes with formulas containing inadequate fiber, further contributing to constipation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"       \"Clinical features of cerebral palsy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=see_link&amp;anchor=H17#H17\">",
"       \"Overview of the management of myelomeningocele (spina bifida)\", section on 'Bowel management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extremely low birth weight &mdash; Extremely low birth weight infants with neurodevelopmental impairment appear to be at increased risk of constipation at school age. This was illustrated by one report, in which one-third of children who had birth weight less than 750 g had constipation lasting at least until adolescence [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/38\">",
"       38",
"      </a>",
"      ]. These patients had significantly higher rates of neurosensory impairment and lower mean IQ scores on the Wechsler Intelligence Scale for Children III (WISC III) compared with birth weight-matched controls without constipation. They also appeared to have significantly higher rates of associated toileting problems, including encopresis and stool withholding.",
"     </li>",
"     <li>",
"      Multiple endocrine neoplasia type 2 &mdash; Constipation may be one of a number of gastrointestinal symptoms appearing very early in life in patients with multiple endocrine neoplasia type 2 (MEN2) syndromes [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/39\">",
"       39",
"      </a>",
"      ]. &nbsp;In one review, all patients with MEN2A-HD were operated on for presumed Hirschsprung disease 2 to 63 years before being diagnosed with MEN2. All patients responding were underweight as infants and had symptoms of abdominal pain, distention, and constipation. Some also manifested hematochezia, emesis, or intermittent diarrhea before surgery. The majority of patients with MEN2B also had gastrointestinal symptoms 1 to 24 years before being diagnosed with MEN2, including flatulence (86 percent), abdominal distention or being underweight as a child (64 percent), abdominal pain (54 percent), constipation or diarrhea (43 percent), difficulty swallowing (39 percent), and vomiting (14 percent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"       \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intestinal neuronal dysplasia &mdash; Intestinal neuronal dysplasia (IND) is diagnosed based on histologic abnormalities in rectal suction biopsies among infants or older children with chronic constipation. Features include hyperganglionosis, in which the ganglia are giant or ectopic, and increased acetylcholinesterase staining [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/39\">",
"       39",
"      </a>",
"      ]. Similar changes may be seen proximal to the aganglionic segment in Hirschsprung disease. There is some controversy whether this histological appearance is a developmental abnormality of the intestinal submucosal and myenteric parasympathetic nervous system, a consequence of chronic constipation, or a variant of normal intestinal development [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/40\">",
"       40",
"      </a>",
"      ]. Considerable inter-observer variation in interpreting the histologic findings further complicates the diagnosis.",
"      <br/>",
"      <br/>",
"      One study examined long-term outcomes in 105 patients presenting with constipation and histologic abnormalities consistent with IND type B, and managed conservatively with diet, laxatives, and sometimes anal dilatations [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/39\">",
"       39",
"      </a>",
"      ]. Most of the patients presented during the first year of life. Ninety-four percent of patients had normal or near-normal defecation at 5 to 10 years of follow-up, suggesting gradual improvement over time.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of a child with constipation relies primarily on a focused history and physical examination (",
"    <a class=\"graphic graphic_table graphicRef79830 \" href=\"UTD.htm?3/11/3260\">",
"     table 3",
"    </a>",
"    ), with particular attention to common causes of constipation and to exclude the rare but most serious organic causes of the symptom (",
"    <a class=\"graphic graphic_table graphicRef57393 \" href=\"UTD.htm?12/46/13035\">",
"     table 2D",
"    </a>",
"    ). The history should be obtained from the parents and the child, if appropriate. The partnership established with the family should continue until the constipation is resolved, to ensure that symptoms do not progress into a worse problem [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Constipation and enuresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorectal and lower urinary tract function are interrelated. As a result, constipation is often associated with voiding dysfunction and enuresis. This relationship between abnormal bowel and bladder function is referred to as the dysfunctional elimination syndrome (DES). Enuresis is commonly associated with functional constipation, but neurogenic disorders must also be excluded. Successful treatment of the constipation is an important component of treating the voiding dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28793?source=see_link&amp;anchor=H17#H17\">",
"     \"Etiology and clinical features of bladder dysfunction in children\", section on 'Constipation and dysfunctional elimination syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Distinguishing functional from organic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the initial assessment, particular attention should be given to features that raise suspicion for an organic cause, listed here. Specific signs and symptoms of the diseases causing constipation are discussed by disease state. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Organic causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Warning signs suggesting the possibility of organic causes include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/6,43\">",
"     6,43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Weight loss or poor weight gain",
"     </li>",
"     <li>",
"      Anorexia",
"     </li>",
"     <li>",
"      Delayed growth",
"     </li>",
"     <li>",
"      Delayed passage of meconium (after 48 hours of life) (",
"      <a class=\"graphic graphic_table graphicRef82181 \" href=\"UTD.htm?40/31/41467\">",
"       table 2A",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Urinary incontinence or bladder disease",
"     </li>",
"     <li>",
"      Passage of blood (unless attributable to an anal fissure)",
"     </li>",
"     <li>",
"      Constipation present from birth or early infancy",
"     </li>",
"     <li>",
"      Acute constipation",
"     </li>",
"     <li>",
"      Fever, vomiting, or diarrhea",
"     </li>",
"     <li>",
"      Extraintestinal symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical findings suggesting an organic etiology include [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Failure to thrive",
"     </li>",
"     <li>",
"      Abdominal distention",
"     </li>",
"     <li>",
"      Lower spine abnormalities",
"     </li>",
"     <li>",
"      Anteriorly displaced anus",
"     </li>",
"     <li>",
"      Patulous anus",
"     </li>",
"     <li>",
"      Tight, empty rectum in presence of palpable fecal mass",
"     </li>",
"     <li>",
"      Absent anal wink",
"     </li>",
"     <li>",
"      Absent cremasteric reflex",
"     </li>",
"     <li>",
"      Decreased lower extremity tone or strength",
"     </li>",
"     <li>",
"      Absence of delay in relaxation phase of lower extremity deep-tendon reflexes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Findings supporting a functional etiology include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Onset of constipation coincides with dietary change (eg, introduction of cow's milk), toilet training, or painful bowel movement",
"     </li>",
"     <li>",
"      Stool withholding behavior (",
"      <a class=\"graphic graphic_table graphicRef55786 \" href=\"UTD.htm?16/49/17179\">",
"       table 2F",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Good response to conventional laxatives",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Assessment of environmental factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;When functional constipation is suspected, particular attention should be given to environmental factors that may have influenced the child's bowel activities. These factors include a history of painful evacuation, stool withholding, introduction of cow's milk, and poor diet (",
"    <a class=\"graphic graphic_table graphicRef64759 \" href=\"UTD.htm?7/41/7835\">",
"     table 2E",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Etiology of functional constipation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If practicable, parents should prepare a five- to seven-day symptom and dietary history before bringing the child to see the pediatrician [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/44\">",
"     44",
"    </a>",
"    ], taking care to record stool frequency, appearance, and any pain involved. The point at which the constipation was first noted, and any potential relationship with a coinciding event, should be sought.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apparent straining during defecation in an infant does not necessarily indicate constipation; if accompanied by the passage of soft stools in an otherwise healthy infant, this symptom is known as \"infant dyschezia\". The symptom is caused by failure to relax the pelvic floor during the defecation effort. In addition, infants also have inadequate abdominal muscles to fix the abdominal wall to produce a valsalva maneuver. Reassurance of the parents is appropriate; rectal stimulation may be counterproductive and laxatives are generally unnecessary. The problem usually resolves spontaneously. Infants also can learn withholding behavior and stiffen their body and turn red in the face as they hold back. This withholding behavior may be triggered by painful bowel movements from formed stools or anal fissures. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Diagnostic criteria'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Organic causes of constipation should be considered if the straining behavior is accompanied by hard stools or warning signs are present; the most important etiologies to consider in this age group are Hirschsprung disease and cystic fibrosis. In particular, a history of delayed passage of meconium should raise concerns about the possibility of Hirschsprung disease; more than 90 percent of normal newborns, but only 10 percent of infants with Hirschsprung disease, pass meconium within the first 24 hours of life. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Distinguishing functional from organic causes'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Organic causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include an evaluation of the perianal area, including the appearance and location of the anus, sensory and motor function, and digital rectal examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     External examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings suggestive of spinal dysraphism include sensory and motor deficits, a patulous anus, urinary incontinence, an absent cremasteric reflex, increased pigmentation, vascular nevi, or hair tufts in the sacrococcygeal area [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Other causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The abnormalities of anorectal development represent a spectrum from high imperforate anus to anteriorly displaced anus [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/28\">",
"     28",
"    </a>",
"    ]. The rectum may communicate with the vagina (high imperforate anus), or at any place along the midline between the",
"    <span class=\"nowrap\">",
"     fourchette/scrotum",
"    </span>",
"    and the normal anal location (",
"    <a class=\"graphic graphic_figure graphicRef78404 \" href=\"UTD.htm?36/1/36883\">",
"     figure 1",
"    </a>",
"    ). When the communication is abnormally close to the fourchette or scrotum, the anus is considered \"anteriorly displaced\" or \"ectopic\" (",
"    <a class=\"graphic graphic_picture graphicRef62573 graphicRef65755 \" href=\"UTD.htm?16/8/16519\">",
"     picture 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An anteriorly displaced anus is easily overlooked. The abnormality is suggested by noting that the anal opening is not located in the center of the pigmented area of the perineum. The diagnosis is supported by measuring the Anal Position Index (API), which is defined as the ratio of the",
"    <span class=\"nowrap\">",
"     anus-fourchette/scrotum",
"    </span>",
"    distance to the",
"    <span class=\"nowrap\">",
"     coccyx-fourchette/scrotum",
"    </span>",
"    distance. Measurements are most easily made by placing a strip of clear tape on the longitudinal axis of the perineum, marking the positions of the coccyx, anus, and",
"    <span class=\"nowrap\">",
"     fourchette/scrotum,",
"    </span>",
"    then removing the tape for measurement against a standard ruler. Normal ratios are discussed above. (See",
"    <a class=\"local\" href=\"#H34369370\">",
"     'Anorectal anomalies'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Digital examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The digital rectal examination should not be overlooked [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/45\">",
"     45",
"    </a>",
"    ]. In functional constipation, the examination usually reveals a distended rectum that is full of stool.",
"   </p>",
"   <p>",
"    Findings suggestive of Hirschsprung disease include a tight anal canal with an empty ampulla. In addition, infants often have gross distention of the abdomen and failure to thrive. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Hirschsprung disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemoccult testing of the stool should be performed in most cases, particularly in infants with constipation, in whom subclinical milk protein intolerance may present as constipation. In infants and children with marked abdominal distension or who are ill-appearing, hemoccult positive stools may indicate enterocolitis, and the patient requires prompt further evaluation. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Cow's milk intolerance'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13\">",
"     'Hirschsprung disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, organic causes of constipation can be excluded on the basis of a careful history and physical examination. If warning signs of possible organic constipation are present, focused laboratory and radiographic testing should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory and radiographic testing should be selected based upon the history and physical examination. For the majority of children whose presentation is typical of functional constipation, laboratory testing is pursued only if the patient fails to respond to a well-conceived and carefully administered intervention program, including disimpaction, frequent and effective use of laxatives, and behavioral management. In contrast, laboratory testing is performed early in patients with signs or symptoms suggestive of an organic cause of constipation, such as the following clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with significant constipation from the neonatal period, especially those with delayed passage of meconium &mdash; Perform a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema (\"unprepped\", ie, without measures to remove stool from the rectum) to investigate the possibility of Hirschsprung disease (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59877 graphicRef58657 \" href=\"UTD.htm?27/52/28481\">",
"       image 1A-B",
"      </a>",
"      ). Some providers use anorectal manometry as the initial investigation. In very young infants, the barium enema may be normal and the diagnosis must be established by rectal biopsy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hirschsprung disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"       \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with a history of rectosigmoid impaction, especially in association with encopresis [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/46-48\">",
"       46-48",
"      </a>",
"      ] &mdash; Perform urine analysis and urine culture. Fecal impaction may predispose to urinary tract infections due to the mechanical effects of the distended rectum compressing the bladder.",
"     </li>",
"     <li>",
"      Children with failure to thrive or recurrent abdominal pain &mdash; Perform a complete blood count and serologic screening for celiac disease (usually IgA antibodies to tissue transglutaminase). Celiac disease is common in most populations and may present with minimal symptoms, including constipation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link\">",
"       \"Clinical manifestations and diagnosis of celiac disease in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with evidence of spinal dysraphism or neurological impairment of the perianal area or lower extremities &mdash; Perform plain films of the lumbosacral spine, and consider magnetic resonance imaging to investigate the possibility of tethered cord and spinal cord tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children with impaired linear growth and depressed reflexes &mdash; Obtain serum levels of thyroid stimulating hormone to exclude hypothyroidism.",
"     </li>",
"     <li>",
"      Children at risk for electrolyte disturbances (eg, those with metabolic abnormalities or inability to tolerate adequate fluids) &mdash; Check serum calcium and electrolytes.",
"     </li>",
"     <li>",
"      Children at risk for lead toxicity &mdash; Screen for lead toxicity with a blood lead level. Screening recommendations vary by community. Children at particular risk include those with pica, developmental disabilities, living in housing built before 1950 or housing that recently has been renovated, or with a family history of lead poisoning in a sibling. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"       \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=see_link&amp;anchor=H17#H17\">",
"       \"Screening tests in children and adolescents\", section on 'Lead poisoning'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children in whom the diagnosis of constipation remains equivocal &mdash; A plain abdominal film can be helpful to document retained stool when there is inadequate historical information or the physical examination is limited by patient cooperation, obesity, or when it is deferred for psychological considerations. However, it should be recognized that plain films are not particularly specific for constipation, are inconsistently interpreted by different observers, and rarely add to the diagnosis if the rectal examination reveals a large amount of retained stool [",
"      <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/50,51\">",
"       50,51",
"      </a>",
"      ]. Thus, they should not be used as a substitute for a thorough history and physical examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This list is not exhaustive and specific laboratory testing may be considered in any patient with an atypical presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Motility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Motility testing is typically considered in patients who have no obvious organic cause of constipation and who fail to respond to aggressive treatment of functional constipation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Colon transit studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic transit studies (using ingested markers) can help distinguish motility disorders from outlet obstruction. A subset of children with intractable constipation has abnormally slow movement of food residue through the colon, a condition generically referred to as \"slow-transit\" constipation. However, it remains unclear whether this group of children is distinct from those with functional constipation, many of whom have relatively delayed colonic transit. Therefore, slow transit constipation is a clinical description rather than a disease. Typical features of children with slow transit constipation are delayed passage of the first meconium stool beyond 24 hours of age, symptoms of severe constipation within a year, or treatment-resistant encopresis at 2 to 3 years of age, and soft stools despite infrequent bowel actions [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colonic transit time (CTT) can be measured using colon transit studies, which permit determination of segmental and total colon transit while providing an objective measure of the severity of constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/54\">",
"     54",
"    </a>",
"    ]. Simple transit studies can be done using a variety of radiopaque markers. One of the easiest techniques is to have the child swallow a capsule containing 24 radiopaque markers (Sitzmark capsules) once a day for three days. Plain radiographs are taken on the fourth day (and sometimes also on the seventh day), and analyzed for the number and location of retained markers [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/55\">",
"     55",
"    </a>",
"    ]. Ideally, any fecal impaction should be relieved, and laxatives should be discontinued several days prior to performing the study.",
"   </p>",
"   <p>",
"    The colonic transit time using this technique is calculated with the following formula:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the day 4 films",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Colonic transit time (hours) = # markers remaining x 1.0",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(where 1.0 = 72",
"    <span class=\"nowrap\">",
"     hours/72",
"    </span>",
"    markers ingested)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the day 7 films",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Colonic transit time (hours) = # markers remaining x 2.3",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(where 2.3 = 168",
"    <span class=\"nowrap\">",
"     hours/72",
"    </span>",
"    markers ingested)",
"   </p>",
"   <p>",
"    If capsules containing 20 (rather than 24) radioopaque markers are used, the constant 1.2 is used for the day 4 calculation, and 2.8 for the day 7 calculation.",
"   </p>",
"   <p>",
"    In one study of adolescents, CTT was 58.3 for those with constipation, and 30.2 hours for those without constipation [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/55\">",
"     55",
"    </a>",
"    ]. CTT &gt;100 hours is considered to be a significantly delayed, termed \"Pediatric slow transit constipation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transit time also may be analyzed by colonic segment, using similar calculations. If capsules containing radiopaque markers are not available, the test can be performed using segments of number 10 radiopaque nasogastric tube cut into 1 cm lengths.",
"   </p>",
"   <p>",
"    Most children with slow transit constipation have no identifiable underlying disease. They are managed in the same way as other children with functional constipation, but they have a worse prognosis for prompt recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/56\">",
"     56",
"    </a>",
"    ]. Such children may require further evaluation and may respond to stimulant laxatives. A few have disorders associated with colonic dysmotility, which include intestinal neuronal dysplasia and intestinal neuronal dysplasia type B. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Other causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This study also may help to identify patients with outlet obstruction, manifested by accumulation of markers in the rectosigmoid area. Patients with outlet obstruction may require a biopsy to evaluate for Hirschsprung disease or other neuromuscular disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/4\">",
"     4",
"    </a>",
"    ]. However, this pattern also may be seen in patients with fecal impaction, and in those with abnormal responses of the pelvic floor muscles during defecation. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Organic causes'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13673?source=see_link&amp;anchor=H9#H9\">",
"     \"Etiology and evaluation of chronic constipation in adults\", section on 'Outlet delay'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Anorectal manometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorectal manometry involves placement of a catheter containing pressure-transducing sensors into the rectum, thereby permitting measurement of neuromuscular function of the anorectum. The procedure includes measurements of the rectoanal inhibitory reflex (which is absent in Hirschsprung disease), rectal sensation and compliance, and squeeze pressures. The test is performed mainly in children with intractable constipation that restricts their lifestyle, or when there is suspicion of intestinal pseudo-obstruction or Hirschsprung disease [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/4,35,46,57,58\">",
"     4,35,46,57,58",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Organic causes'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/2/43041?source=see_link\">",
"       \"Patient information: Constipation in children (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/18/20770?source=see_link\">",
"       \"Patient information: Hirschsprung disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/7/15477?source=see_link\">",
"       \"Patient information: Constipation in infants and children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are consistent with guidelines developed by the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and endorsed by the American Academy of Pediatrics (available at:",
"    <a class=\"external\" href=\"file://www.naspghan.org/\">",
"     www.naspghan.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?14/63/15354/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Constipation is generally understood as a delay or difficulty in defecation, but in children, the interpretation of the term \"delay\" varies broadly with age. Because children are growing and developing, the frequency and type of stools must be interpreted in the context of the child's age and stage of maturation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Normal stooling patterns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Functional constipation is defined by the presence of at least two of six criteria describing stool frequency, hardness, size, fecal incontinence, or volitional stool retention; the symptoms must be present for one month in infants and toddlers, and two months in older children (",
"      <a class=\"graphic graphic_table graphicRef57882 \" href=\"UTD.htm?23/14/23788\">",
"       table 1",
"      </a>",
"      ). The diagnosis also requires exclusion of organic causes of the symptoms. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic criteria'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Functional versus organic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infant dyschezia refers to the symptom straining and crying before successful passage of soft stool in an otherwise healthy infant younger than 6 months of age. Reassurance of the parents is appropriate; rectal stimulation may be counterproductive and laxatives are generally unnecessary. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Infants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fecal incontinence (encopresis) is usually a consequence of underlying constipation. Less commonly, fecal incontinence may occur in the absence of constipation, in which case it is termed \"nonretentive\" fecal incontinence. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Diagnostic criteria'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44182?source=see_link\">",
"       \"Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Functional constipation accounts for most constipation-related symptoms in children past the neonatal period. It can often be traced to a painful, frightening, or otherwise distressing experience associated with defecation that the child wants to avoid repeating and, therefore, refrains from evacuation. Functional constipation can generally be diagnosed based upon the history and physical examination, both of which should be normal except for stool retention (",
"      <a class=\"graphic graphic_table graphicRef79830 \" href=\"UTD.htm?3/11/3260\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Distinguishing functional from organic causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Organic causes are responsible for fewer than 5 percent of children with constipation but include multiple diagnostic considerations (",
"      <a class=\"graphic graphic_table graphicRef57393 graphicRef64759 graphicRef82181 graphicRef61392 graphicRef55786 graphicRef70206 \" href=\"UTD.htm?16/25/16798\">",
"       table 2A-F",
"      </a>",
"      ). Particular attention should be given to features of the history and physical examination that should raise suspicion for an organic cause. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Distinguishing functional from organic causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory and radiographic testing should be selected based upon the history and physical examination. For the majority of children whose presentation is typical of functional constipation, laboratory testing is pursued only if the patient fails to respond to a well-conceived and carefully administered intervention program, including disimpaction, frequent and effective use of laxatives, and behavioral management. In contrast, laboratory testing is performed early in patients with signs or symptoms suggestive of an organic cause of constipation. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs and symptoms suggestive of Hirschsprung disease include delayed passage of meconium (after 48 hours of life), failure to thrive or delayed growth, vomiting, abdominal distension, and a tight anal canal with an empty ampulla. Affected children may also present initially with enterocolitis, in which patients have a sepsis-like picture with fever, vomiting, and diarrhea which can progress to toxic megacolon. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hirschsprung disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cow's milk may be a cause of constipation in infants and young children. The diagnosis is suggested by onset of symptoms coinciding with an increase in cow's milk in the diet, and is generally confirmed and treated by substitution of soy or hydrolyzed protein in the formula. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Cow's milk intolerance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/1\">",
"      van den Berg MM, Benninga MA, Di Lorenzo C. Epidemiology of childhood constipation: a systematic review. Am J Gastroenterol 2006; 101:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/2\">",
"      Rubin GP. Childhood constipation. Am Fam Physician 2003; 67:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/3\">",
"      Loening-Baucke V. Chronic constipation in children. Gastroenterology 1993; 105:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/4\">",
"      Di Lorenzo C. Pediatric anorectal disorders. Gastroenterol Clin North Am 2001; 30:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/5\">",
"      Fontana M, Bianchi C, Cataldo F, et al. Bowel frequency in healthy children. Acta Paediatr Scand 1989; 78:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/6\">",
"      Constipation Guideline Committee of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. Evaluation and treatment of constipation in infants and children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2006; 43:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/7\">",
"      Hyams JS, Treem WR, Etienne NL, et al. Effect of infant formula on stool characteristics of young infants. Pediatrics 1995; 95:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/8\">",
"      Rasquin A, Di Lorenzo C, Forbes D, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006; 130:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/9\">",
"      Hyman PE, Milla PJ, Benninga MA, et al. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology 2006; 130:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/10\">",
"      Benninga MA, B&uuml;ller HA, Heymans HS, et al. Is encopresis always the result of constipation? Arch Dis Child 1994; 71:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/11\">",
"      Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 Suppl 2:II43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/12\">",
"      Thiessen PN. Recurrent abdominal pain. Pediatr Rev 2002; 23:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/13\">",
"      Partin JC, Hamill SK, Fischel JE, Partin JS. Painful defecation and fecal soiling in children. Pediatrics 1992; 89:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/14\">",
"      Di Lorenzo C. Childhood constipation: finally some hard data about hard stools! J Pediatr 2000; 136:4.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Guide to Toilet Training, Elk Grove Village, IL 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/16\">",
"      Stadtler AC, Gorski PA, Brazelton TB. Toilet training methods, clinical interventions, and recommendations. American Academy of Pediatrics. Pediatrics 1999; 103:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/17\">",
"      Hyams JS. Diet and gastrointestinal disease. Curr Opin Pediatr 2002; 14:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/18\">",
"      Roma E, Adamidis D, Nikolara R, et al. Diet and chronic constipation in children: the role of fiber. J Pediatr Gastroenterol Nutr 1999; 28:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/19\">",
"      Heine RG, Elsayed S, Hosking CS, Hill DJ. Cow's milk allergy in infancy. Curr Opin Allergy Clin Immunol 2002; 2:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/20\">",
"      Irastorza I, Iba&ntilde;ez B, Delgado-Sanzonetti L, et al. Cow's-milk-free diet as a therapeutic option in childhood chronic constipation. J Pediatr Gastroenterol Nutr 2010; 51:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/21\">",
"      Abrahamian FP, Lloyd-Still JD. Chronic constipation in childhood: a longitudinal study of 186 patients. J Pediatr Gastroenterol Nutr 1984; 3:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/22\">",
"      Chan AO, Hui WM, Lam KF, et al. Familial aggregation in constipated subjects in a tertiary referral center. Am J Gastroenterol 2007; 102:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/23\">",
"      Ostwani W, Dolan J, Elitsur Y. Familial clustering of habitual constipation: a prospective study in children from West Virginia. J Pediatr Gastroenterol Nutr 2010; 50:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/24\">",
"      Magazz&ugrave; G, Scoglio R. Gastrointestinal manifestations of cow's milk allergy. Ann Allergy Asthma Immunol 2002; 89:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/25\">",
"      Turunen S, Karttunen TJ, Kokkonen J. Lymphoid nodular hyperplasia and cow's milk hypersensitivity in children with chronic constipation. J Pediatr 2004; 145:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/26\">",
"      Iacono G, Cavataio F, Montalto G, et al. Intolerance of cow's milk and chronic constipation in children. N Engl J Med 1998; 339:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/27\">",
"      Lewis NA, Levitt MA, Zallen GS, et al. Diagnosing Hirschsprung's disease: increasing the odds of a positive rectal biopsy result. J Pediatr Surg 2003; 38:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/28\">",
"      Hendren WH. Pediatric rectal and perineal problems. Pediatr Clin North Am 1998; 45:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/29\">",
"      Hendren WH. Constipation caused by anterior location of the anus and its surgical correction. J Pediatr Surg 1978; 13:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/30\">",
"      Leape LL, Ramenofsky ML. Anterior ectopic anus: a common cause of constipation in children. J Pediatr Surg 1978; 13:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/31\">",
"      Herek O, Polat A. Incidence of anterior displacement of the anus and its relationship to constipation in children. Surg Today 2004; 34:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/32\">",
"      Gen&ccedil; A, Taneli C, Tansu�� N, et al. Evaluation of the location of the anus by a modified technique in the neonate. J Pediatr Surg 2002; 37:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/33\">",
"      Davari HA, Hosseinpour M. The anal position index: a simple method to define the normal position of the anus in neonate. Acta Paediatr 2006; 95:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/34\">",
"      Heneyke S, Smith VV, Spitz L, Milla PJ. Chronic intestinal pseudo-obstruction: treatment and long term follow up of 44 patients. Arch Dis Child 1999; 81:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/35\">",
"      Hussain SZ, Di Lorenzo C. Motility disorders. Diagnosis and treatment for the pediatric patient. Pediatr Clin North Am 2002; 49:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/36\">",
"      Mousa H, Hyman PE, Cocjin J, et al. Long-term outcome of congenital intestinal pseudoobstruction. Dig Dis Sci 2002; 47:2298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/37\">",
"      Cucchiara S, Borrelli O, Salvia G, et al. A normal gastrointestinal motility excludes chronic intestinal pseudoobstruction in children. Dig Dis Sci 2000; 45:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/38\">",
"      Cunningham C, Taylor HG, Minich NM, Hack M. Constipation in very-low-birth-weight children at 10 to 14 years of age. J Pediatr Gastroenterol Nutr 2001; 33:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/39\">",
"      Schimpl G, Uray E, Ratschek M, H&ouml;llwarth ME. Constipation and intestinal neuronal dysplasia type B: a clinical follow-up study. J Pediatr Gastroenterol Nutr 2004; 38:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/40\">",
"      Koletzko S, Jesch I, Faus-Kebetaler T, et al. Rectal biopsy for diagnosis of intestinal neuronal dysplasia in children: a prospective multicentre study on interobserver variation and clinical outcome. Gut 1999; 44:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/41\">",
"      Procter E, Loader P. A 6-year follow-up study of chronic constipation and soiling in a specialist paediatric service. Child Care Health Dev 2003; 29:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/42\">",
"      Feng WC, Churchill BM. Dysfunctional elimination syndrome in children without obvious spinal cord diseases. Pediatr Clin North Am 2001; 48:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/43\">",
"      Leung AK, Chan PY, Cho HY. Constipation in children. Am Fam Physician 1996; 54:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/44\">",
"      Arce DA, Ermocilla CA, Costa H. Evaluation of constipation. Am Fam Physician 2002; 65:2283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/45\">",
"      Gold DM, Levine J, Weinstein TA, et al. Frequency of digital rectal examination in children with chronic constipation. Arch Pediatr Adolesc Med 1999; 153:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/46\">",
"      Abi-Hanna A, Lake AM. Constipation and encopresis in childhood. Pediatr Rev 1998; 19:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/47\">",
"      Hellerstein S, Linebarger JS. Voiding dysfunction in pediatric patients. Clin Pediatr (Phila) 2003; 42:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/48\">",
"      Loening-Baucke V. Urinary incontinence and urinary tract infection and their resolution with treatment of chronic constipation of childhood. Pediatrics 1997; 100:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/49\">",
"      Rosen R, Buonomo C, Andrade R, Nurko S. Incidence of spinal cord lesions in patients with intractable constipation. J Pediatr 2004; 145:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/50\">",
"      Pensabene L, Buonomo C, Fishman L, et al. Lack of utility of abdominal x-rays in the evaluation of children with constipation: comparison of different scoring methods. J Pediatr Gastroenterol Nutr 2010; 51:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/51\">",
"      Berger MY, Tabbers MM, Kurver MJ, et al. Value of abdominal radiography, colonic transit time, and rectal ultrasound scanning in the diagnosis of idiopathic constipation in children: a systematic review. J Pediatr 2012; 161:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/52\">",
"      Hutson JM, McNamara J, Gibb S, Shin YM. Slow transit constipation in children. J Paediatr Child Health 2001; 37:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/53\">",
"      Benninga MA, B&uuml;ller HA, Tytgat GN, et al. Colonic transit time in constipated children: does pediatric slow-transit constipation exist? J Pediatr Gastroenterol Nutr 1996; 23:241.",
"     </a>",
"    </li>",
"    <li>",
"     Loening-Baucke, V. Constipation and encopresis. In: Pediatric Gastroenterology and Nutrition in Clinical Practice. Lifschitz CH (Ed), Marcel Dekker, New York 2001. p.551.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/55\">",
"      Zaslavsky C, da Silveira TR, Maguilnik I. Total and segmental colonic transit time with radio-opaque markers in adolescents with functional constipation. J Pediatr Gastroenterol Nutr 1998; 27:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/56\">",
"      de Lorijn F, van Wijk MP, Reitsma JB, et al. Prognosis of constipation: clinical factors and colonic transit time. Arch Dis Child 2004; 89:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/57\">",
"      Osatakul S, Patrapinyokul S, Osatakul N. The diagnostic value of anorectal manometry as a screening test for Hirschsprung's disease. J Med Assoc Thai 1999; 82:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?14/63/15354/abstract/58\">",
"      Pensabene L, Youssef NN, Griffiths JM, Di Lorenzo C. Colonic manometry in children with defecatory disorders. role in diagnosis and management. Am J Gastroenterol 2003; 98:1052.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5906 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15354=[""].join("\n");
var outline_f14_63_15354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NORMAL STOOLING PATTERNS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Functional versus organic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY OF FUNCTIONAL CONSTIPATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Painful defecation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Toilet training issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Dietary considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ORGANIC CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cow's milk intolerance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hirschsprung disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cystic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34369370\">",
"      Anorectal anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Constipation and enuresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Distinguishing functional from organic causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Assessment of environmental factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      External examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Digital examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Motility testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Colon transit studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Anorectal manometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5906\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5906|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/31/29183\" title=\"diagnostic image 1A\">",
"      Hirschsprung dz barium enema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/48/17166\" title=\"diagnostic image 1B\">",
"      Functional constipation barium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5906|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/1/36883\" title=\"figure 1\">",
"      Spectrum of anorectal anatomy in the female",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5906|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/40/10882\" title=\"picture 1A\">",
"      Intermediate anorectal malformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/17/40209\" title=\"picture 1B\">",
"      Anteriorly displaced anus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5906|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/14/23788\" title=\"table 1\">",
"      Rome III constipation child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/31/41467\" title=\"table 2A\">",
"      Causes of delayed passage of meconium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/32/5643\" title=\"table 2B\">",
"      Endocrine and metabolic causes of constipation in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/63/21499\" title=\"table 2C\">",
"      Neurogenic causes of constipation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/46/13035\" title=\"table 2D\">",
"      Causes constipation children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/41/7835\" title=\"table 2E\">",
"      Physiologic causes of constipation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/49/17179\" title=\"table 2F\">",
"      Causes of stool withholding children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/11/3260\" title=\"table 3\">",
"      Evaluation of an infant or child with constipation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/26/2474?source=related_link\">",
"      Chronic intestinal pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44182?source=related_link\">",
"      Definition, clinical manifestations, and evaluation of functional fecal incontinence in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34950?source=related_link\">",
"      Emergency complications of Hirschsprung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/7/28793?source=related_link\">",
"      Etiology and clinical features of bladder dysfunction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/22/13673?source=related_link\">",
"      Etiology and evaluation of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16426?source=related_link\">",
"      Food poisoning in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26344?source=related_link\">",
"      Overview of the management of myelomeningocele (spina bifida)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/2/43041?source=related_link\">",
"      Patient information: Constipation in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/7/15477?source=related_link\">",
"      Patient information: Constipation in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/18/20770?source=related_link\">",
"      Patient information: Hirschsprung disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2710?source=related_link\">",
"      Prevention and treatment of acute constipation in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44407?source=related_link\">",
"      Prune-belly syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/13/43225?source=related_link\">",
"      Screening tests in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/45/37592?source=related_link\">",
"      Toilet training",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36298?source=related_link\">",
"      Treatment of chronic functional constipation and fecal incontinence in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f14_63_15355="Total fetal loss rate1";
var content_f14_63_15355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Total fetal loss rate: CVS compared with amniocentesis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Study, year",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"2\">",
"       Total loss rate, percent",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Difference percentage",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Relative risk, 95 percent CI",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       CVS",
"      </td>",
"      <td class=\"subtitle2\">",
"       Amniocentesis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       MRC (1991)",
"      </td>",
"      <td>",
"       13.7 (220/1609)",
"      </td>",
"      <td>",
"       9.0 (144/1592)",
"      </td>",
"      <td>",
"       4.6",
"      </td>",
"      <td>",
"       1.5 (1.2-1.8)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Smidt-Jensen (1992)",
"      </td>",
"      <td>",
"       9.1 (195/2144)",
"      </td>",
"      <td>",
"       7.0 (81/1158)",
"      </td>",
"      <td>",
"       2.1",
"      </td>",
"      <td>",
"       1.3 (1.1-1.7)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Overall",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       2.9",
"      </td>",
"      <td>",
"       1.4 (1.2-1.6)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MRC: Medical Research Council.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15355=[""].join("\n");
var outline_f14_63_15355=null;
var title_f14_63_15356="Liver injury scale";
var content_f14_63_15356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53232&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Liver injury scale (1994 revision)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Grade*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Injury type",
"       </td>",
"       <td class=\"subtitle1\">",
"        Injury description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        I",
"       </td>",
"       <td>",
"        Hematoma",
"       </td>",
"       <td>",
"        Subcapsular, &lt;10 percent surface area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        Capsular tear, &lt;1 cm parenchymal depth",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        II",
"       </td>",
"       <td rowspan=\"2\">",
"        Hematoma",
"       </td>",
"       <td>",
"        Subcapsular, 10-50 percent surface area",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intraparenchymal, &lt;10 cm in diameter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        1-3 cm parenchymal depth, &lt;10 cm in length",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        III",
"       </td>",
"       <td>",
"        Hematoma",
"       </td>",
"       <td>",
"        Subcapsular, &gt;50 percent surface area or expanding; ruptured subcapsular or parenchymal hematoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Laceration",
"       </td>",
"       <td>",
"        Intraparenchymal hematoma &gt;10 cm or expanding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;3 cm parenchymal depth",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        Parenchymal disruption involving 25-75 percent of hepatic lobe or 1-3 Couinaud's segments within a single lobe",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        V",
"       </td>",
"       <td>",
"        Laceration",
"       </td>",
"       <td>",
"        Parenchymal disruption involving &gt;75 percent of hepatic lobe or &gt;3 Couinaud's segments within a single lobe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular",
"       </td>",
"       <td>",
"        Juxtahepatic venous injuries; ie, retrohepatic vena cava/central major hepatic veins",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        VI",
"       </td>",
"       <td>",
"        Vascular",
"       </td>",
"       <td>",
"        Hepatic avulsion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Advance one grade for multiple injuries, up to grade III.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Moore, EE, Cogbill, TH, Jurkovich, GJ, et al. Organ injury scaling: spleen and liver (1994 revision). J Trauma 1995; 38:323.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15356=[""].join("\n");
var outline_f14_63_15356=null;
var title_f14_63_15357="Microcephaly deletion and duplication syndromes";
var content_f14_63_15357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected microdeletion and microduplication syndromes that can feature microcephaly*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Chromosomal location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Selected reference(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1q21.1 deletion",
"       </td>",
"       <td>",
"        Moderate/mild learning difficulties, heart defects, cataract (1q21.1 duplications associated with macrocephaly)",
"       </td>",
"       <td>",
"        1,2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2q23.1 deletion",
"       </td>",
"       <td>",
"        Severe learning and communication problems, seizures, stereotypies, disturbed sleep",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2q31.1 deletion",
"       </td>",
"       <td>",
"        Learning difficulties, growth retardation, seizures, microcephaly in 50 percent, short palpebral fissures, broad eyebrows",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5q35 microduplication (reciprocal to the Sotos syndrome/NSD1 common deletion)",
"       </td>",
"       <td>",
"        Short stature, delayed bone age, speech delay, and mild or no dysmorphism (opposite of Sotos syndrome?)",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6q25 deletion",
"       </td>",
"       <td>",
"        Callosal agenesis, facial dysmorphisms, hearing loss",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9q34 deletion",
"       </td>",
"       <td>",
"        Mental retardation, minor facial dysmorphisms, epilepsy; EHMT1 haploinsufficiency implicated",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16p11.2 deletion and duplication",
"       </td>",
"       <td>",
"        Autism and macrocephaly with deletion 16p11.2;&nbsp;attention deficit hyperactivity&nbsp;and microcephaly with duplication 16p11.2; epilepsy",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        17q23.1q23.2 microdeletion",
"       </td>",
"       <td>",
"        Speech delay, microcephaly, growth retardation, dysmorphisms (heart, hands, limbs), abnormalities",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        22q13.3 deletion",
"       </td>",
"       <td>",
"        Severe mental retardation and speech deficits, minimal dysmorphism (SHANK3 and other genes implicated)",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Note that the clinical findings other than microcephaly often are unremarkable, so array CGH is usually required for diagnosis. Additional information on emerging genomic disorders is available at:",
"     <a href=\"https://decipher.sanger.ac.uk/application/syndrome\">",
"      https://decipher.sanger.ac.uk/application/syndrome",
"     </a>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Mefford HC, Sharp AJ, Baker C, et al. Recurrent rearrangements of chromosome 1q21.1 and variable pediatric phenotypes. N Engl J Med 2008; 359:1685.",
"       </li>",
"       <li>",
"        Brunetti-Pierri N, Berg JS, Scaglia F, et al. Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities. Nat Genet 2008; 40:1466.",
"       </li>",
"       <li>",
"        van Bon BW, Koolen DA, Brueton L, et al. The 2q23.1 microdeletion syndrome: clinical and behavioural phenotype. Eur J Hum Genet 2010; 18:163.",
"       </li>",
"       <li>",
"        Mitter D, Chiaie BD, L&uuml;decke HJ, et al. Genotype-phenotype correlation in eight new patients with a deletion encompassing 2q31.1. Am J Med Genet A 2010; 152A:1213.",
"       </li>",
"       <li>",
"        Franco LM, de Ravel T, Graham BH, et al. A syndrome of short stature, microcephaly and speech delay is associated with duplications reciprocal to the common Sotos syndrome deletion. Eur J Hum Genet 2010; 18:258.",
"       </li>",
"       <li>",
"        Kleefstra T, van Zelst-Stams WA, Nillesen WM, et al. Further clinical and molecular delineation of the 9q subtelomeric deletion syndrome supports a major contribution of EHMT1 haploinsufficiency to the core phenotype. J Med Genet 2009; 46:598.",
"       </li>",
"       <li>",
"        Nagamani SC, Erez A, Eng C, et al. Interstitial deletion of 6q25.2-q25.3: a novel microdeletion syndrome associated with microcephaly, developmental delay, dysmorphic features and hearing loss. Eur J Hum Genet 2009; 17:573.",
"       </li>",
"       <li>",
"        Shinawi M, Liu P, Kang SH, et al. Recurrent reciprocal 16p11.2 rearrangements associated with global developmental delay, behavioral problems, dysmorphism, epilepsy, and abnormal head size. J Med Genet 2010; 47:332.",
"       </li>",
"       <li>",
"        Ballif BC, Theisen A, Rosenfeld JA, et al. Identification of a recurrent microdeletion at 17q23.1q23.2 flanked by segmental duplications associated with heart defects and limb abnormalities. Am J Hum Genet 2010; 86:454.",
"       </li>",
"       <li>",
"        Wilson HL, Crolla JA, Walker D, et al. Interstitial 22q13 deletions: genes other than SHANK3 have major effects on cognitive and language development. Eur J Hum Genet 2008; 16:1301.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15357=[""].join("\n");
var outline_f14_63_15357=null;
var title_f14_63_15358="Early surgery and native valve endocarditis mortality";
var content_f14_63_15358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Early surgery and native valve endocarditis mortality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 262px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * p&lt;0.05 for difference between early surgery versus medical therapy for native valve endocarditis.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Lalani, T, Cabell, CH, Benjamin, DK, et al. Analysis of the impact of early surgery on in-hospital mortality of native valve endocarditis: use of propensity score and instrumental variable methods to adjust for treatment-selection bias. Circulation 2010; 121:1005.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15358=[""].join("\n");
var outline_f14_63_15358=null;
var title_f14_63_15359="Ultrasound of omphalocele and cystic hygroma";
var content_f14_63_15359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77707&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of omphalocele and cystic hygroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 278px; height: 186px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal view of a fetus with trisomy 18 at 12 weeks of gestation with an omphalocele and cystic hygroma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f14_63_15359=[""].join("\n");
var outline_f14_63_15359=null;
